| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Peptides | Dermatologic System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Peptides | Dermatologic System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Peptides | Dermatologic System |
Recent Updates
Recently added Catalysts
Johnson & Johnson$256.98
-1.94 (-0.75%)
A 95Pipeline Score Fair Value Pharma · Commercial
Market Cap
564.11 B
EPS
8.74
P/E Ratio
27.1 $
Value Trade
1.46 B
SEC Financials
Q1 2026Dilution Risk
Revenue
24.06 B
R&D Expenses
3.53 B
Operating CF
2.51 B
Total Assets
200.89 B
Total Liabilities
119.71 B
Equity
81.19 B
D/E Ratio
12,345
1.55 %
Week
3.61 %
1 Month
-4.92 %
3 Month
14.9 %
6 Month
36.78 %
5 Year
37,394.82 %
All Time
Cash Data
Cash Position
22.05 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 22, 2026
Overview
Volume
6.54 M
52 Week Range
149.04 - 251.71
% held by Insiders
0.14 %
% held by Institutions
77.33 %
Enterprise Value
597.04 B
Total Shares
2.41 B
Short %
1.1 %
Float Shares
2.41 B
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Johnson & Johnson
1955Total events
20Upcoming
1004Tier-1 (high impact)
2010 – 2026Coverage
Upcoming catalysts 20
TBD
T2Trial Initiation
Ongoing Phase 3 OrigAMI-5 study evaluating subcutaneous amivantamab in combination with pembrolizumab and carboplatin vs 5FU plus pembrolizumab and platinum-based chemotherapy as first-line treatment in HPV-unrelated R/M HNSCC
TBD
T1Full Results
Full results of Phase 3 MajesTEC-9 study to be presented at a future major medical meeting
TBD
T1FDA Filing Accepted
Results to be shared with global health authorities (potential regulatory submissions)
TBD
T2Trial Initiation
Phase 3 OrigAMI-3 study underway evaluating subcutaneous amivantamab with FOLFIRI in first- and second-line colorectal cancer
TBD
T2Other Regulator Milestone
Marketing authorization applications under review in multiple countries
Event history 1935
Jul 6, 2026
▲CHMP Positive OpinionTECVAYLIApprovedEx-US Regulatory
CHMP positive opinion for TECVAYLI in combination with daratumumab for RRMM after at least one prior therapy
relapsed or refractory multiple myelomasource ↗
Jul 6, 2026
▲Full ResultsTECVAYLIApprovedClinical Data
Phase 3 MajesTEC-3 results: PFS and OS benefit with teclistamab + daratumumab vs standard of care
relapsed or refractory multiple myelomasource ↗
Jun 26, 2026
▲CHMP Positive OpinionTeclistamabEx-US Regulatory
CHMP recommends approval of teclistamab plus daratumumab for RRMM after at least one prior therapy
relapsed or refractory multiple myelomasource ↗
Jun 26, 2026
▲Oral PresentationNipocalimabApprovedPresentation
New data from Vivacity-MG3 presented at EAN 2026 Congress
generalised myasthenia gravissource ↗
Jun 26, 2026
●Trial InitiationNipocalimabApprovedTrial
PETUNIA study design presented at EAN 2026
generalised myasthenia gravissource ↗
Jun 26, 2026
▲CHMP Positive OpinionTECVAYLIApprovedEx-US Regulatory
CHMP recommends approval of TECVAYLI plus daratumumab for RRMM after at least one prior therapy
relapsed or refractory multiple myelomasource ↗
Jun 26, 2026
▲FDA ApprovalNipocalimabApprovedFDA Decision
EMA approval for gMG in adults and adolescents (12+) anti-AChR or anti-MuSK positive
generalised myasthenia gravissource ↗
Jun 13, 2026
▲Full ResultsTALVEYApprovedClinical Data
MonumenTAL-3 results presented at EHA 2026 and published in NEJM
relapsed/refractory multiple myelomasource ↗
Jun 13, 2026
▲Oral PresentationTALVEYApprovedPresentation
MonumenTAL-3 results presented at EHA 2026
relapsed/refractory multiple myelomasource ↗
Jun 13, 2026
▲PublicationTALVEYApprovedPresentation
MonumenTAL-3 results published in The New England Journal of Medicine
relapsed/refractory multiple myelomasource ↗
Jun 13, 2026
●sNDA SubmissionTALVEYApprovedRegulatory Filing
sBLA submitted to FDA for TALVEY + DARZALEX FASPRO ± pomalidomide
relapsed/refractory multiple myelomasource ↗
Jun 13, 2026
●EU MAA SubmissionTALVEYApprovedEx-US Regulatory
Type II variation application submitted to EMA for TALVEY + DARZALEX FASPRO ± pomalidomide
relapsed/refractory multiple myelomasource ↗
Drug Pipeline Intelligence
A95
Pipeline Score $133.2B
Pipeline ValueFair Value
Valuation Signal455
Drugs Scored0.8x
rNPV / MCap Top 100%
Large Pharma (rank 1 of 911)
Percentile RankJohnson & Johnson earns an A-grade pipeline score (95/100), with $133.2B risk-adjusted pipeline value, led by Tapentadol in Tumor (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tapentadol Small molecule | Osteoarthritis, Hip | Phase 3 | NCT00361504 | 58% | $23.6B | COMPLETED | 1,123 | - | - | Jul 1, 2008 | - | Apr 29, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
nipocalimab BreakthroughPriorityFast Track+1 | generalised myasthenia gravis | Phase 3 | 2026-06-26 | -4.9 [2.88] vs. -2.7 [2.46]; difference: -2.22 [standard error (SE)]: 0.76; p=0.005; -5.2 [4.45] vs -1.9 [3.69]; difference: -3.38 [SE:0.986]; p=0.001; -4.5 [2.64] vs. -2.3 [2.37]; difference: -2.23 [SE: 0.588]; p<0.001 Read More | Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis Read More | |
nipocalimab BreakthroughPriorityFast Track+1 | generalised myasthenia gravis | Phase 3 | 2026-06-26 | -4.9 [2.88] vs. -2.7 [2.46]; difference: -2.22 [standard error (SE)]: 0.76; p=0.005; -5.2 [4.45] vs -1.9 [3.69]; difference: -3.38 [SE:0.986]; p=0.001; -4.5 [2.64] vs. -2.3 [2.37]; difference: -2.23 [SE: 0.588]; p<0.001 Read More | Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis Read More | |
nipocalimab BreakthroughPriorityFast Track+1 | generalised myasthenia gravis | Phase 3 | 2026-06-26 | -4.9 [2.88] vs. -2.7 [2.46]; difference: -2.22 [standard error (SE)]: 0.76; p=0.005; -5.2 [4.45] vs -1.9 [3.69]; difference: -3.38 [SE:0.986]; p=0.001; -4.5 [2.64] vs. -2.3 [2.37]; difference: -2.23 [SE: 0.588]; p<0.001 Read More | Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in JNJ
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
JNJ Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
JNJEmpfehlung des CHMP bringt TECVAYLI®▼ (teclistamab) von Johnson & Johnson in Kombination mit daratumumab als potenziellen Behandlungsstandard für das rezidivierte/refraktäre multiple Myelom einen Schritt weiter
Johnson & Johnson's TECVAYLI (teclistamab) in combination with daratumumab has received a positive recommendation from the CHMP for treating relapsed or refractory multiple myeloma. This recommendation is based on Phase III study data showing significant improvements in progression-free and overall survival compared to standard therapies. The combination therapy could delay disease progression in patients who have received prior treatments.
Read more →JNJJohnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis
Johnson & Johnson presented new data on nipocalimab at the EAN 2026 Congress, highlighting its effectiveness in treating generalized myasthenia gravis (gMG). The Phase 3 Vivacity-MG3 study showed improved outcomes for patients early in their disease and those with lower symptom burdens. Additionally, the PETUNIA study aims to collect pregnancy outcome data related to nipocalimab treatment.
Read more →JNJCHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma
Johnson & Johnson announced that the CHMP has recommended the approval of TECVAYLI (teclistamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma. This recommendation is based on Phase 3 data showing significant improvements in patient survival rates. The combination therapy could potentially establish a new standard of care for patients who have received at least one prior therapy.
Read more →JNJJohnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia...
Johnson & Johnson presented new data on IMAAVY (nipocalimab-aahu) at the EAN 2026 Congress, highlighting its effectiveness in treating generalized myasthenia gravis (gMG). The Phase 3 Vivacity-MG3 study showed improved outcomes for patients early in their disease and those with lower symptom burden. Additionally, IMAAVY maintained control after common infections, and a new study will address pregnancy outcomes.
Read more →JNJJohnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
Johnson & Johnson has announced a substantial investment exceeding $1 billion to enhance its vision manufacturing operations in Jacksonville, Florida. This initiative aims to bolster local manufacturing capabilities and contribute positively to the regional economy. The investment reflects the company's commitment to advancing its production facilities in the U.S.
Read more →JNJNew TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24...
Johnson & Johnson announced promising results from the Phase 3 MonumenTAL-3 study, showcasing the efficacy of TALVEY® (talquetamab-tgvs) combined with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in treating relapsed or refractory multiple myeloma. The data revealed significant improvements in progression-free survival (81.3%) and overall survival (89.2%) compared to standard treatment. These findings position TALVEY® as a leading bispecific combination therapy, emphasizing Johnson & Johnson's commitment to advancing treatments in earlier lines of therapy. The results are being discussed for regulatory approval to expedite patient access to this treatment option.
Read more →JNJJohnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
Johnson & Johnson has announced the expansion of the TECNIS PureSee intraocular lens (IOL) in the U.S. market. This advanced lens option aims to provide cataract surgeons and their patients with improved visual outcomes. The move is expected to enhance the treatment landscape for cataract surgery in the country.
Read more →JNJIMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY®...
Johnson & Johnson (NYSE: JNJ) announced promising results from the Phase 2/3 ENERGY study of IMAAVY® (nipocalimab-aahu), which showed significant and durable improvements in hemoglobin levels for patients with warm autoimmune hemolytic anemia (wAIHA). The trial revealed that patients on the treatment experienced rapid onset of effect, demonstrating a mean hemoglobin increase within the first week. These findings provide hope for patients suffering from wAIHA, a condition with no FDA-approved treatment options, as IMAAVY aims to target autoantibody-driven red blood cell destruction. The results have been submitted for FDA Priority Review to support the supplemental Biologics License Application for IMAAVY.
Read more →JNJJohnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
Johnson & Johnson has announced its acquisition of Firefly Bio, Inc., aiming to enhance its oncology pipeline. This strategic move focuses on integrating Firefly's novel degrader antibody conjugate platform, which is expected to provide innovative treatment options for cancer patients. The acquisition reflects JNJ's commitment to advancing its biopharmaceutical capabilities.
Read more →JNJJohnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Johnson & Johnson presented new biomarker analyses from the Phase 2 DAHLIAS study, highlighting the efficacy of nipocalimab in treating moderate-to-severe Sjögren's disease. The data indicates that patients with elevated autoantibody levels showed improved clinical responses. These findings will be shared at the 2026 EULAR Congress, supporting further investigation in the ongoing Phase 3 DAFFODIL study.
Read more →JNJJohnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce ...
Johnson & Johnson announced that nipocalimab, a neonatal Fc receptor blocker, significantly reduced disease activity in patients with systemic lupus erythematosus (SLE) in a Phase 2 study. The results showed sustained improvements through Week 52, particularly in autoantibody-positive patients. The ongoing Phase 3 study is currently recruiting participants, and nipocalimab has received Fast Track Designation from the FDA.
Read more →JNJJohnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Johnson & Johnson announced that nipocalimab, an FcRn blocker, met its primary endpoint in reducing systemic lupus erythematosus (SLE) disease activity in a Phase 2 study. The results showed significant and sustained improvements in disease activity through 52 weeks, particularly in autoantibody-positive patients. The findings will be presented at the EULAR 2026 Congress.
Read more →JNJL’étude de la Phase 3 menée par Johnson & Johnson sur le cancer de la prostate montre qu’ERLEADA® (apalutamide), administré avant et après la chirurgie, réduit considérablement le risque de métastases ou de décès par rapport à l’hormonothérapie seule, ce qui pourrait bouleverser un paradigme thérapeutique en vigueur depuis des décennies
Johnson & Johnson's Phase 3 PROTEUS study demonstrated that ERLEADA® (apalutamide) combined with hormone therapy significantly reduces the risk of metastases and improves surgical outcomes in high-risk localized prostate cancer patients. The study found that patients receiving the combination therapy had a ninefold increase in the likelihood of having minimal residual cancer after surgery. These findings suggest a potential shift in treatment paradigms for prostate cancer.
Read more →JNJEl estudio de Fase 3 de Johnson & Johnson sobre el cáncer de próstata demuestra que ERLEADA® (apalutamida), administrada antes y después de la cirugía, reduce significativamente el riesgo de metástasis o fallecimiento en comparación con la terapia hormonal por sí sola, lo que podría suponer un cambio en el paradigma terapéutico vigente desde hace décadas
Johnson & Johnson's Phase 3 PROTEUS study indicates that ERLEADA® (apalutamida) combined with hormonal therapy before and after prostate cancer surgery significantly reduces the risk of metastasis and mortality compared to hormonal therapy alone. The findings suggest a potential shift in treatment paradigms for high-risk localized prostate cancer. Results will be presented at ASCO 2026 and published in The New England Journal of Medicine.
Read more →JNJRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
Johnson & Johnson reported positive results from the Phase 1b/2 OrigAMI-4 study, showing that subcutaneous amivantamab and hyaluronidase-lpuj produced a 42% overall response rate in patients with advanced head and neck squamous cell carcinoma. The study highlighted that over one-third of responders achieved complete responses, with a median follow-up of 11.8 months indicating durable responses. A supplemental Biologics License Application has been submitted to the FDA for approval.
Read more →JNJJohnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Johnson & Johnson's Phase 3 PROTEUS study results reveal that apalutamide combined with hormone therapy significantly improves clinical outcomes for high-risk localized prostate cancer patients. The treatment reduced the risk of metastasis or death by 20% and increased the likelihood of minimal cancer remaining at surgery. These findings suggest a shift in treatment strategies for prostate cancer.
Read more →JNJJohnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm
Johnson & Johnson's Phase 3 PROTEUS study results show that ERLEADA® (apalutamide) combined with hormone therapy significantly reduces the risk of metastasis or death in high-risk localized prostate cancer patients. The study found that patients receiving this combination therapy were nine times more likely to have minimal cancer remaining post-surgery. These findings suggest a potential shift in treatment approaches for aggressive prostate cancer, emphasizing earlier intervention.
Read more →JNJRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
Johnson & Johnson announced updated results from the Phase 1/1b CHRYSALIS-2 study, showing that the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) provides significant clinical benefits for patients with atypical EGFR-mutated non-small cell lung cancer (NSCLC). The median overall survival was nearly 3.5 years, indicating a durable response in this challenging patient population. The findings were presented at the 2026 ASCO Annual Meeting.
Read more →JNJNew TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
Johnson & Johnson announced positive data from the Phase 3 MajesTEC-9 study, showing that TECVAYLI (teclistamab-cqyv) significantly improves progression-free and overall survival in patients with relapsed or refractory multiple myeloma. The study demonstrated a 71% reduction in disease progression or death and a 40% reduction in mortality risk compared to standard therapies. These findings support TECVAYLI's role as a potential new standard of care.
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results 2026
Johnson & Johnson will conduct an investor conference call on July 15th to discuss its second-quarter results. The call will feature key executives, including CEO Joaquin Duato and CFO Joseph J. Wolk. This event aims to provide investors with insights into the company's performance and future outlook.
Read more →JNJFDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
Johnson & Johnson announced that the FDA has approved a label expansion for TREMFYA (guselkumab), confirming its efficacy in inhibiting structural joint damage in adults with active psoriatic arthritis (PsA). This makes TREMFYA the only IL-23 inhibitor with such evidence, offering a vital treatment option for patients at risk of irreversible joint damage. The approval is based on positive results from the Phase 3b APEX study.
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Johnson & Johnson is set to host an investor conference call to discuss its second-quarter results. This event aims to provide insights into the company's financial performance and strategic direction. Details regarding the timing and access to the call will be shared with stakeholders.
Read more →JNJJohnson & Johnson Launches 'Gut Tunnel' Experience in Singapore to Highlight the Importance of Endoscopic Remission in IBD Ahead of World IBD Day, Johnson & Johnson today launched the interactive 'Gut Tunnel' experience in Singapore, alongside educational programs across...
Johnson & Johnson has launched the 'Gut Tunnel' experience in Singapore to promote awareness of endoscopic remission for inflammatory bowel disease (IBD). This initiative coincides with World IBD Day and aims to educate patients on the importance of achieving this treatment goal. The installation will be available from May 18 to May 21, 2026.
Read more →JNJGroundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation A new global survey of patient and urologist perception and experience—conducted in collaboration with leading bladder cancer professional and...
A new global survey conducted by The Harris Poll on behalf of Johnson & Johnson reveals the significant physical, mental, and emotional toll experienced by patients undergoing standard-of-care treatments for bladder cancer. The survey included responses from 817 patients and 802 urologists across six countries, shedding light on patient experiences that are frequently overlooked during treatment discussions. Released ahead of the American Urological Association Annual Meeting, the findings emphasize the need for enhanced support and continued innovation in bladder cancer treatments.
Read more →JNJJohnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Johnson & Johnson will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9th, 2026. The event will feature a Fireside Chat with management at 10:00 a.m. ET. Investors can access the live audio webcast on the company's website, with a replay available 48 hours later.
Read more →JNJJohnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
Johnson & Johnson is set to present 18 abstracts at the upcoming APA and ASCP meetings, showcasing its advancements in neuropsychiatry. The presentations will cover key disorders, including major depressive disorder and schizophrenia, emphasizing the company's commitment to developing effective treatments. Notable data includes long-term results for CAPLYTA and analyses of seltorexant for MDD with insomnia symptoms.
Read more →JNJJohnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Johnson & Johnson is set to participate in the Goldman Sachs 47th Annual Global Healthcare Conference. This event highlights the company's ongoing engagement with investors and stakeholders in the healthcare sector. Further details about the conference and J&J's specific agenda have not been disclosed.
Read more →JNJJohnson & Johnson launches Generation Fine, a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission Johnson & Johnson (NYSE: JNJ) today announced the launch of Generation Fine, a global campaign designed to challenge what it means to feel fine in...
Johnson & Johnson has launched the Generation Fine campaign aimed at transforming perceptions around depression treatment, encouraging patients to move beyond merely feeling 'fine.' The initiative responds to survey findings indicating that a large proportion of individuals with major depressive disorder do not find traditional antidepressants effective for achieving remission. By collaborating with mental health advocates, the campaign seeks to empower patients with resources and support for discussing treatment options with healthcare providers. Generation Fine highlights the unique challenges faced by those with depression through authentic patient narratives, stressing that individuals should not settle for inadequate treatment outcomes.
Read more →JNJJohnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
Johnson & Johnson's Phase 3 FUZION study reveals that TREMFYA (guselkumab) significantly improves combined fistula remission rates in adults with perianal fistulizing Crohn's disease. The study, presented at Digestive Disease Week 2026, marks the first randomized trial in two decades to show efficacy in this challenging condition. Results indicate that 28.3% of patients achieved remission with TREMFYA, compared to 10.3% with placebo.
Read more →JNJJohnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
Johnson & Johnson's investigational therapy JNJ-4804 has shown promising results in Phase 2b studies for treating refractory ulcerative colitis and Crohn's disease. The therapy demonstrated superior clinical and endoscopic outcomes compared to existing treatments like golimumab and guselkumab. The findings highlight its potential to address significant unmet needs in patients who have not responded to multiple therapies. JNJ plans to advance to Phase 3 trials based on these encouraging results.
Read more →JNJCAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
Johnson & Johnson announced that CAPLYTA (lumateperone) ranked highest in a network meta-analysis comparing adjunctive treatments for major depressive disorder (MDD). The analysis, presented at the 2026 NEI Spring Congress, showed CAPLYTA's superiority in efficacy without causing weight gain. This indirect comparison aids treatment decisions in the absence of direct clinical trials.
Read more →JNJJohnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
Johnson & Johnson has appointed Ryan Koors as Vice President of Investor Relations, effective May 7, 2026. Koors, who has over 20 years of experience within the company, succeeds Darren Snellgrove, who is leaving for a CFO position at Halozyme. His extensive background in finance and leadership roles positions him well to support the company's strategic goals.
Read more →JNJJohnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference
Johnson & Johnson will participate in the Bernstein’s 42nd Annual Strategic Decisions Conference on May 27th, 2026. The management will engage in a Fireside Chat at 11:00 a.m. ET. A live audio webcast will be available on their Investor Relations website, with an archived session accessible later.
Read more →JNJFDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)
The FDA has granted Priority Review for IMAAVY (nipocalimab-aahu), marking it as a potential first approved treatment for warm autoimmune hemolytic anemia (wAIHA). This designation highlights the urgent need for effective therapies for this life-threatening condition. The pivotal Phase 2/3 ENERGY study demonstrated significant improvements in hemoglobin levels and fatigue in patients treated with IMAAVY compared to placebo.
Read more →JNJJohnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference
Johnson & Johnson will participate in the Bernstein’s 42nd Annual Strategic Decisions Conference. The event aims to discuss strategic decisions within the biopharma industry. Further details about the topics to be covered or key speakers have not been provided.
Read more →JNJFDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) based on...
Johnson & Johnson announced that the FDA has approved a supplemental New Drug Application for CAPLYTA (lumateperone), based on new long-term data demonstrating significant efficacy in reducing relapse risk in schizophrenia. Clinical trials indicated a 63% reduction in relapse and 84% of patients remained relapse-free over six months. The results reinforce the medication's safety profile and highlight its role in providing long-term stability for patients. This approval marks an important milestone for the management of schizophrenia, a condition affecting approximately 2.8 million adults in the U.S.
Read more →JNJIMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG) Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients...
Johnson & Johnson reported promising results for IMAAVY (nipocalimab-aahu) following a Phase 3 study demonstrating sustained disease control in generalized myasthenia gravis (gMG) patients. Over a follow-up period of 120 weeks, IMAAVY showed significant clinical improvements and reductions in total IgG levels among antibody-positive adults. A post-hoc analysis revealed that patients with sustained minimal symptom expression experienced enhanced quality of life. The company is also enrolling participants for the EPIC study, comparing IMAAVY to another FcRn blocker, indicating a focus on further validating the treatment's efficacy.
Read more →JNJJohnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Johnson & Johnson will participate in the 2026 RBC Capital Markets Global Healthcare Conference on May 19th. Management will engage in a Fireside Chat at 11:30 a.m. ET, which will be accessible via a live audio webcast. A replay of the webcast will be available approximately 48 hours after the event.
Read more →JNJJohnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
Johnson & Johnson will participate in the Bank of America 2026 Healthcare Conference on May 12, 2026. The management team will engage in a Fireside Chat at 2:20 p.m. Eastern Time. A live audio webcast will be available on the company's Investor Relations website, with an archived session accessible later.
Read more →JNJJohnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
Johnson & Johnson is set to participate in the Bank of America 2026 Healthcare Conference. This event will provide an opportunity for the company to engage with investors and discuss its strategic initiatives. Further details about the conference and J&J's agenda are yet to be disclosed.
Read more →JNJJohnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
Johnson & Johnson has announced a 3.1% increase in its quarterly dividend, marking the 64th consecutive year of dividend growth. This decision reflects the company's ongoing commitment to returning value to its shareholders and showcases its financial stability. The increase is a positive indicator of the company's performance and future outlook.
Read more →JNJJohnson & Johnson reports Q1 2026 results, raises 2026 outlook
Johnson & Johnson has reported its Q1 2026 financial results and has raised its outlook for the year. The details of the results and the specific reasons for the revised outlook were not provided in the article. This update reflects the company's ongoing performance and strategic adjustments in the biopharma sector.
Read more →JNJmedia-relations its.jnj.com Investor contact investor-relations its.jnj.com For immediate release Johnson Johnson reports Q1 2026 results, raises 2026 outlook 2026 First-Quarter reported sales growth of 9.9
Johnson & Johnson (NYSE JNJ) reported a strong first quarter for 2026 with a 9.9% growth in sales, reaching $24.1 billion. The company raised its full-year guidance, forecasting $100.8 billion in reported sales and an adjusted EPS of $11.55. Despite the positive sales growth and new product approvals, the company faced challenges, with net earnings falling dramatically by 52.4% compared to the previous year. However, optimistic projections indicate a potential for double-digit growth in the future.
Read more →JNJICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
Johnson & Johnson announced positive one-year results from its Phase 3 studies of ICOTYDE (icotrokinra) for treating moderate-to-severe plaque psoriasis. The data show high rates of complete skin clearance in adolescents and adults, with no new safety concerns. This once-daily oral treatment represents a significant advancement in psoriasis care.
Read more →JNJJohnson & Johnson’s DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers
Johnson & Johnson's DARZALEX (daratumumab) has received approval from the CHMP for self-administration by patients or caregivers, marking a significant milestone in multiple myeloma treatment. This update allows patients to administer the drug from the fifth dose, enhancing flexibility in their care. The decision is based on ten years of innovation and aims to ease the burden of frequent hospital visits.
Read more →JNJFDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 ...
Johnson & Johnson has received FDA approval for ICOTYDE™ (icotrokinra), an innovative oral peptide for moderate-to-severe plaque psoriasis. This treatment uniquely targets the IL-23 receptor, offering patients a convenient once-daily pill with demonstrated high efficacy and a favorable safety profile based on extensive Phase 3 clinical trials. The approval is expected to significantly impact treatment strategies for both adult and adolescent patients suffering from plaque psoriasis.
Read more →JNJJohnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical...
Johnson & Johnson announced successful results from a Phase 1 study of the investigational intravesical drug-releasing system, Erda-iDRS, for treating non-muscle-invasive bladder cancer. The study showed a high complete response rate in patients with recurrent intermediate-risk disease and promising recurrence-free outcomes in high-risk patients. The findings support the ongoing development of Erda-iDRS, which aims to provide effective localized treatment while minimizing systemic side effects. Further studies are planned to evaluate Erda-iDRS in various risk settings.
Read more →JNJJohnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
Johnson & Johnson announced FDA approval for TECVAYLI® plus DARZALEX FASPRO® as a treatment for adults with relapsed or refractory multiple myeloma. This approval is based on the Phase 3 MajesTEC-3 study, which demonstrated significant improvements in progression-free survival and overall survival. The combination therapy is expected to establish a new standard of care for patients who have undergone at least one prior treatment.
Read more →JNJJohnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
Johnson & Johnson's nipocalimab has received FDA Fast Track designation for treating systemic lupus erythematosus (SLE). This designation is based on positive Phase 2 study results showing reduced disease activity. The company is now enrolling patients for a Phase 3 study, aiming to address the significant unmet needs in SLE treatment.
Read more →JNJJohnson & Johnson to Host Investor Conference Call on First-Quarter Results - March 2, 2026
Johnson & Johnson will hold an investor conference call on April 14th to discuss its first-quarter results. The call will feature key executives, including CEO Joaquin Duato and CFO Joseph J. Wolk. This initiative reflects the company's commitment to transparency and investor engagement.
Read more →JNJEarly study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
Johnson & Johnson announced promising preliminary results from a Phase 1b study of pasritamig combined with docetaxel for advanced prostate cancer. The combination showed a favorable safety profile and significant prostate-specific antigen (PSA) response rates, leading to plans for Phase 3 studies. The innovative T-cell engager pasritamig targets prostate cancer cells specifically, enhancing treatment efficacy.
Read more →JNJJohnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for IMAAVY® (nipocalimab-aahu) as the first treatment for warm autoimmune hemolytic anemia (wAIHA). The pivotal ENERGY trial showed that IMAAVY® produced a rapid and durable hemoglobin response, addressing a significant unmet need in this rare disease. The submission marks a milestone for patients suffering from wAIHA, which currently has no approved therapies.
Read more →JNJTREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
Johnson & Johnson's TREMFYA (guselkumab) has shown promising long-term results in the QUASAR study for treating ulcerative colitis, with over 80% of patients in clinical remission at Week 140. The study also reported significant histo-endoscopic mucosal improvement and maintained efficacy regardless of prior treatments. No new safety issues were identified, reinforcing confidence in TREMFYA's long-term use.
Read more →JNJRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational...
Johnson & Johnson announced promising results from the Phase 1b/2 OrigAMI-4 study, showing that the combination of RYBREVANT FASPRO™ and immunotherapy achieved a 56% overall response rate in patients with recurrent or metastatic head and neck squamous cell carcinoma. The treatment demonstrated rapid and durable antitumor activity, with a 10% complete response rate. These findings suggest a significant improvement over existing therapies, highlighting the potential of this approach in addressing unmet medical needs in this patient population.
Read more →JNJRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
Johnson & Johnson announced that the FDA has granted Breakthrough Therapy Designation for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) to treat adults with recurrent or metastatic head and neck squamous cell carcinoma. This designation is based on clinical data showing rapid and durable responses in patients who have limited treatment options after prior therapies. The therapy aims to target specific pathways associated with the cancer, potentially improving patient outcomes.
Read more →JNJRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for ...
Johnson & Johnson announced that the FDA has granted Breakthrough Therapy Designation for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) for adults with recurrent or metastatic head and neck squamous cell carcinoma. This designation is based on promising clinical data showing rapid and durable responses in patients who have limited treatment options. The therapy targets EGFR and MET pathways and is currently being evaluated in ongoing clinical trials.
Read more →JNJFDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
Johnson & Johnson announced that the FDA has approved a new monthly dosing schedule for RYBREVANTFASPRO™ (amivantamab and hyaluronidase-lpuj), the only EGFR-targeted therapy available for once-a-month administration. This change aims to reduce treatment visits while maintaining the drug's safety and efficacy. The approval builds on previous advancements that simplified the administration process and improved patient outcomes in treating EGFR-mutated non-small cell lung cancer.
Read more →JNJFDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for ...
Johnson & Johnson announced that the FDA has approved a new monthly dosing schedule for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) for treating EGFR-mutated advanced non-small cell lung cancer. This new regimen simplifies treatment, reducing clinic visits while maintaining safety and efficacy. The approval builds on previous successes and aims to improve patient outcomes and convenience.
Read more →JNJJohnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference
Johnson & Johnson will present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026. The management will engage in a Fireside Chat at 11:30 a.m. Eastern Time. A live audio webcast will be available on their Investor Relations website, with an archived version accessible later.
Read more →JNJJohnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens[1] for Astigmatic Adults living with Presbyopia Today, Johnson & Johnson announced the launch of two new contact lenses in Singapore – ACUVUE® OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM – the first ...
Johnson & Johnson has launched two new contact lenses in Singapore: the ACUVUE® OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM and the ACUVUE® OASYS MAX 1-Day for ASTIGMATISM. These lenses are designed for astigmatic adults experiencing presbyopia, offering improved comfort and clarity. The multifocal toric lens is the first of its kind, addressing a significant gap in the market.
Read more →JNJJohnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference
Johnson & Johnson will participate in the TD Cowen 46th Annual Health Care Conference on March 3rd, 2026. The management team will engage in a Fireside Chat at 11:10 a.m. Eastern Time. A live audio webcast of the presentation will be available on the company's Investor Relations website, with an archived version accessible later.
Read more →JNJReal-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate...
Johnson & Johnson announced results from a real-world head-to-head analysis showing that patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with ERLEADA® achieved a statistically significant 51% decrease in the risk of death compared to those treated with darolutamide over a follow-up period of 24 months. These findings were revealed at the 36th Annual International Prostate Cancer Update and highlight the drug's real-world efficacy, aligning with earlier trial data. The study utilized sound methodological practices, emphasizing the importance of effective treatment options for advanced prostate cancer patients.
Read more →JNJDARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
Johnson & Johnson's DARZALEX FASPRO has received FDA approval for a new quadruplet regimen (D-VRd) to treat adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This regimen demonstrated superior efficacy compared to the standard VRd, showing deeper responses and improved MRD negativity rates. The approval underscores DARZALEX FASPRO's role as a foundational therapy in multiple myeloma treatment.
Read more →JNJJohnson & Johnson reports Q4 and Full-Year 2025 results
Johnson & Johnson reported strong financial results for Q4 and full-year 2025, highlighting significant growth in its Innovative Medicine and MedTech segments. The company emphasized its robust pipeline and portfolio, which are expected to drive continued growth. However, challenges such as the impact of STELARA in Immunology and uncertainties in future financial predictions were noted.
Read more →JNJmedia-relations its.jnj.com Investor contact investor-relations its.jnj.com For immediate release Johnson Johnson reports Q4 and Full-Year 2025 results 2025 Fourth-Quarter reported sales growth of 9.1% to $
Johnson & Johnson (NYSE: JNJ) reported a strong performance for Q4 and the full year of 2025, characterized by a significant sales increase of 9.1% in Q4, totaling $24.6 billion, and a full-year sales growth of 6.0%, amounting to $94.2 billion. The company highlighted substantial earnings per share, both on a reported and adjusted basis, and noted critical innovations in its product pipeline, including recent FDA approvals. Looking ahead, J&J anticipates continued growth with guidance for 2026 indicating reported sales of approximately $100.5 billion. The overall performance reflects a successful period marked by advancements across multiple therapeutic areas.
Read more →JNJNew clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder CAPLYTA® nearly doubled the likelihood of remission at six weeks compared to placebo as an adjunctive therapy to an antidepressant based on pooled...
Johnson & Johnson has released new analysis indicating that CAPLYTA® (lumateperone) nearly doubles the likelihood of remission in adults with major depressive disorder (MDD) when used as an adjunctive therapy to antidepressants. In a six-week study, 65% of patients achieved remission, and further long-term data demonstrated sustained benefits over six months. The findings were presented at the 64th Annual Meeting of the American College of Neuropsychopharmacology and reflect both immediate and sustained treatment benefits. CAPLYTA® was recently approved as a treatment for MDD and is also indicated for schizophrenia and bipolar disorder.
Read more →JNJTECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
Johnson & Johnson announced positive results from the Phase 3 MajesTEC-9 study, showing that TECVAYLI monotherapy significantly reduces the risk of disease progression or death by 71% in patients with relapsed/refractory multiple myeloma. The study confirms superior progression-free survival and overall survival compared to standard treatments. These findings support TECVAYLI as a potential new standard of care for patients early in their treatment journey.
Read more →JNJJohnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
Johnson & Johnson announced the presentation of 11 abstracts at the 2026 American College of Neuropsychopharmacology Annual Meeting, showcasing new Phase 3 data on treatments for major depressive disorder and treatment-resistant depression. Key findings include analyses of CAPLYTA, SPRAVATO, and seltorexant, highlighting advancements in neuropsychiatry aimed at improving patient outcomes. The company emphasizes its commitment to addressing significant unmet needs in mental health care.
Read more →JNJRYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating...
Johnson & Johnson presented promising longer-term results from the Phase 1b/2 OrigAMI-1 study of amivantamab-vmjw for treating RAS/BRAF wild-type metastatic colorectal cancer. The study reported a 73% overall response rate in the first-line subgroup, with significant durability of responses noted in many patients, including those with liver metastases. The results support further investigation in ongoing Phase 3 studies. The safety profile of amivantamab combined with chemotherapy remained consistent with prior findings, with few treatment-related discontinuations.
Read more →JNJJohnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments
Johnson & Johnson has reached a voluntary agreement with the U.S. government aimed at improving access to medicines and reducing costs for American patients. This agreement includes an exemption from tariffs for the company's pharmaceutical products. Additionally, Johnson & Johnson is investing $55 billion in U.S. manufacturing, with plans to build new facilities in North Carolina and Pennsylvania, creating thousands of jobs.
Read more →JNJJohnson & Johnson celebrates innovation in cancer research with 2025 Dr. Paul Janssen Award Johnson & Johnson today announced Tony Hunter, Ph.D., of the Salk Institute as the recipient of the 2025 Dr. Paul Janssen Award for Biomedical...
Johnson & Johnson has announced Tony Hunter, Ph.D., of the Salk Institute, as the recipient of the 2025 Dr. Paul Janssen Award for Biomedical Research. He is recognized for his pioneering discoveries related to tyrosine kinases and their role in cancer progression. His foundational research has influenced the development of over 80 cancer therapies and continues to inspire new innovations. The award will be formally presented during a virtual symposium on March 2, 2026.
Read more →JNJJohnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic...
Johnson & Johnson has announced positive topline results from its Phase 2b JASMINE study involving nipocalimab, the first investigational FcRn blocker for systemic lupus erythematosus (SLE). The study met its primary endpoint, demonstrating the potential for reducing disease activity and steroid use among patients. Based on these promising findings, the company intends to move forward with a Phase 3 study. This breakthrough treatment could significantly impact the lives of those suffering from SLE, a chronic condition affecting millions worldwide.
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for First Quarter 2026
Johnson & Johnson has declared a cash dividend of $1.30 per share for the first quarter of 2026. This dividend is payable on March 10, 2026, to shareholders recorded by February 24, 2026. The announcement highlights the company's ongoing commitment to returning value to its shareholders.
Read more →JNJJohnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
Johnson & Johnson has completed its acquisition of Halda Therapeutics for $3.05 billion, aiming to enhance its oncology portfolio with Halda's proprietary RIPTAC™ platform. This platform is designed for developing oral, targeted therapies for solid tumors, including prostate cancer. The acquisition is expected to lead to a dilution in earnings per share in 2025 and 2026, alongside potential risks related to integration and product development.
Read more →JNJU.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
The U.S. FDA has approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first subcutaneous therapy for EGFR-mutated non-small cell lung cancer (NSCLC). This approval allows for a significantly reduced administration time, enhancing patient convenience. Clinical data indicates a projected overall survival benefit exceeding four years when combined with LAZCLUZE (lazertinib). The therapy aims to improve patient experience by minimizing treatment burden.
Read more →JNJU.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
The U.S. FDA has approved AKEEGA® (niraparib and abiraterone acetate) for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). This marks a significant advancement as it is the first precision medicine combination therapy for this patient group. Clinical trials demonstrated a 54% reduction in disease progression compared to standard treatments, addressing a critical unmet need in this aggressive cancer type.
Read more →JNJUnprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
Johnson & Johnson announced promising results from the Phase 3 MajesTEC-3 study, showing that the combination of TECVAYLI and DARZALEX FASPRO significantly improves progression-free and overall survival in patients with relapsed/refractory multiple myeloma. The combination has been granted Breakthrough Therapy Designation by the FDA, indicating its potential to become a new standard of care. The study demonstrated an 83% reduction in the risk of disease progression or death compared to standard treatments.
Read more →JNJJohnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
Johnson & Johnson's INLEXZO™ showed promising results in a Phase 2b study for patients with BCG-unresponsive, high-risk, papillary-only non-muscle invasive bladder cancer (NMIBC). The study reported a 74% disease-free survival rate at one year, with 95% of patients remaining progression-free. The treatment was well-tolerated, with most side effects being low grade. These findings highlight the potential of INLEXZO™ as a viable alternative to radical cystectomy.
Read more →JNJRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison...
Johnson & Johnson announced that the combination of amivantamab and lazertinib significantly improves overall survival in Asian patients with EGFR-mutated non-small cell lung cancer, as shown in the Phase 3 MARIPOSA study. The median overall survival is projected to exceed four years, surpassing the existing treatment with osimertinib. This combination therapy demonstrates a 26% reduction in the risk of death compared to osimertinib, establishing it as a new standard of care.
Read more →JNJEarlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
Johnson & Johnson announced positive follow-up results from the Phase 3 CARTITUDE-4 study, indicating that 80% of patients with relapsed or refractory multiple myeloma achieved treatment-free remission at 2.5 years after receiving CARVYKTI. The study suggests that earlier treatment may enhance immune fitness and prolong progression-free survival. However, there are concerns regarding increased early mortality and adverse effects such as cytokine release syndrome and neurologic toxicities.
Read more →JNJJohnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
Johnson & Johnson's gemcitabine intravesical system shows promising results in treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Data from the Phase 2b SunRISe-1 study reveal a 74.3% disease-free survival rate at one year, with 95.6% of patients remaining progression-free. The treatment is generally well-tolerated, with most side effects being low-grade.
Read more →JNJNew long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
Johnson & Johnson announced new long-term data from the Phase 3b APEX study, demonstrating that TREMFYA (guselkumab) significantly inhibits structural joint damage in patients with active psoriatic arthritis (PsA). The study showed sustained improvements in symptoms and joint health over 48 weeks, with a notable percentage of patients achieving significant clinical responses. The findings reinforce TREMFYA's position as a leading treatment option for PsA.
Read more →JNJFDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
Johnson & Johnson announced FDA approval for CAPLYTA® (lumateperone) as an adjunctive therapy for major depressive disorder (MDD) in adults. This approval follows positive results from Phase 3 trials, showing significant improvement in depression symptoms without increasing weight gain or other metabolic side effects. CAPLYTA® offers hope for the two-thirds of MDD patients who experience residual symptoms despite current treatments.
Read more →JNJDARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and...
Johnson & Johnson's DARZALEX FASPRO has received FDA approval as the first and only treatment for high-risk smoldering multiple myeloma. The approval follows positive results from the Phase 3 AQUILA study, which demonstrated a 51% reduction in the risk of disease progression compared to active monitoring. This landmark decision enables earlier intervention for patients before the disease advances to active multiple myeloma. The pivotal study presented significant improvement in progression-free survival and overall response rates for patients receiving DARZALEX FASPRO.
Read more →JNJJohnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
Johnson & Johnson has announced the launch of the EPIC study, the first head-to-head trial comparing IMAAVY™ with efgartigimod in adults with generalized myasthenia gravis (gMG). The study aims to establish IMAAVY™ as the preferred FcRn blocker for gMG patients. Additionally, new data from the Vibrance-MG study indicates that pediatric patients receiving IMAAVY™ showed sustained reductions in immunoglobulin G levels and improved disease control over 72 weeks.
Read more →JNJNew study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
Johnson & Johnson's recent ENCOMPASS study reveals significant unmet needs in psoriasis treatment, with over 90% of patients on injectables willing to switch to effective oral therapies. The study, presented at the 2025 Fall Clinical Dermatology Conference, highlights a strong preference for oral treatments among both patients and dermatology providers. Findings emphasize the need for patient-centered approaches to improve treatment outcomes and quality of life.
Read more →JNJIcotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
Johnson & Johnson announced positive Week 28 results from the Phase 2b ANTHEM-UC study of icotrokinra, a novel oral peptide targeting the IL-23 receptor for ulcerative colitis. The study demonstrated that 31.7% of patients achieved clinical remission and 38.1% showed endoscopic improvement compared to placebo. These results support the initiation of Phase 3 trials for icotrokinra in both ulcerative colitis and Crohn's disease.
Read more →JNJTREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
Johnson & Johnson announced positive results for TREMFYA (guselkumab) in treating moderately to severely active Crohn's disease, showing over 85% clinical remission rates at 96 weeks in Phase 3 studies. This makes TREMFYA the first IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrating durable remission. The findings highlight the drug's potential to improve patient quality of life.
Read more →JNJPublished in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
Johnson & Johnson announced that nipocalimab, an investigational treatment for Sjögren's disease, met its primary endpoint in the Phase 2 DAHLIAS study, showing significant improvement in disease activity at Week 24. The treatment demonstrated a reduction in key biomarkers and improved patient-reported symptoms. Nipocalimab is the only investigational therapy with Breakthrough Therapy Designation for SjD, with a Phase 3 study currently enrolling patients.
Read more →JNJIcotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
Johnson & Johnson announced promising long-term results from the Phase 3 ICONIC-TOTAL study of icotrokinra, a targeted oral peptide for plaque psoriasis. At Week 52, 72% of scalp and 85% of genital psoriasis patients achieved significant skin clearance. The treatment demonstrated a favorable safety profile and maintained effectiveness over the study period, indicating its potential as a new treatment option.
Read more →JNJSubcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
Johnson & Johnson announced promising results from the Phase 1b/2 OrigAMI-4 study of subcutaneous amivantamab for recurrent or metastatic head and neck cancer. The study showed a 45% overall response rate and a median duration of response of 7.2 months. This new formulation allows for a quick injection, enhancing patient convenience. The findings suggest significant potential for amivantamab in treating patients with limited options.
Read more →JNJTECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as...
Johnson & Johnson announced the positive topline results of the Phase 3 MajesTEC-3 study, showcasing the combination of TECVAYLI and DARZALEX FASPRO significantly improves progression-free survival and overall survival compared to standard treatment options for relapsed/refractory multiple myeloma. The study was unblinded following a recommendation from the Independent Data Monitoring Committee (IDMC) due to the statistically significant results. This combination therapy may establish a new standard of care options for patients who have undergone one to three prior lines of therapy.
Read more →JNJmedia-relations its.jnj.com Investor contact investor-relations its.jnj.com For immediate release Johnson Johnson reports Q3 2025 results raises 2025 sales outlook 2025 Third-Quarter reported sales growth o
Johnson & Johnson announced strong Q3 2025 results, with reported sales growth of 6.8%, reaching $24.0 billion. The company reported earnings per share of $2.12, with adjusted EPS at $2.80. They have raised their full-year sales outlook to $93.7 billion, supported by significant innovations, including new approvals for cancer treatments and progress across their pipeline. Additionally, the company is focusing on six priority areas to accelerate growth and innovation.
Read more →JNJJohnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress 17 abstracts from across the Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and...
Johnson & Johnson is set to present 17 abstracts on major depressive disorder (MDD) at the upcoming ECNP Congress in Amsterdam. The data focuses on new clinical insights from their portfolio, including treatments like CAPLYTA and SPRAVATO. Highlights include analyses of treatment options that address both MDD and treatment-resistant depression. The company's commitment to innovative therapies aims to improve patient outcomes amidst the complexities of managing MDD.
Read more →JNJIcotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated with the highest dose achieving...
Johnson & Johnson announced positive results from the Phase 2b ANTHEM-UC study of icotrokinra, an investigational oral peptide targeting the IL-23 receptor for ulcerative colitis. The study met its primary endpoint at Week 12, with 63.5% of patients in the highest dosing group achieving clinical response compared to 27% in the placebo group. Icotrokinra demonstrated meaningful improvements in secondary endpoints, including clinical and symptomatic remission. The positive outcomes have prompted further Phase 3 studies for icotrokinra in ulcerative colitis and Crohn's disease.
Read more →JNJTREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis Patients treated with subcutaneous TREMFYA® achieved clinically meaningful results in both clinical remission (36.7%) and endoscopic remission...
Johnson & Johnson announced that its drug TREMFYA® (guselkumab) achieved clinically significant results in a Phase 3 ASTRO study after 48 weeks of treatment in patients with moderately to severely active ulcerative colitis. The study showed that TREMFYA successfully induced clinical remission in 36.7% and endoscopic remission in 25.9% of patients. Importantly, TREMFYA is the first IL-23 inhibitor to offer a fully subcutaneous administration option approved by the FDA for ulcerative colitis, marking a significant development in treatment flexibility for patients. Safety results were consistent with the established profile of TREMFYA.
Read more →JNJU.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or...
Johnson & Johnson's TREMFYA (guselkumab) has received FDA approval for treating pediatric patients aged six years and older with moderate to severe plaque psoriasis and active psoriatic arthritis. This approval represents a notable advancement as TREMFYA becomes the first IL-23 inhibitor approved for pediatric use. The decision, based on the PROTOSTAR study's results, indicates that a significant percentage of pediatric patients experienced high levels of skin clearance. This milestone addresses a considerable gap in effective therapies for children suffering from these conditions.
Read more →JNJTECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma Johnson & Johnson (NYSE:JNJ) today announced that an investigational immune-based induction regimen with TECVAYLI® (teclistamab-cqyv) and DARZALEX...
Johnson & Johnson (NYSE: JNJ) announced promising results from the Phase 2 MajesTEC-5 study, where its investigational immune-based induction regimen combining TECVAYLI (teclistamab-cqyv) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) demonstrated high efficacy in transplant-eligible patients with newly diagnosed multiple myeloma. In the study, 100% of evaluable patients achieved minimal residual disease negativity after induction therapy. The complete response rate was reported at 85.7%. Though the treatment had some reported adverse events, it maintained a manageable safety profile.
Read more →JNJTREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in...
Johnson & Johnson has received FDA approval for TREMFYA (guselkumab) as the first fully human IL-23 inhibitor with a subcutaneous (SC) induction regimen for adults with moderately to severely active ulcerative colitis (UC). This approval allows patients the flexibility of self-administration from the start of treatment, a notable advantage over traditional intravenous options. The efficacy and safety of TREMFYA were demonstrated in the Phase 3 ASTRO trial, showing significant clinical and endoscopic improvements. Additionally, the company is launching a head-to-head study against Skyrizi in Crohn's disease to further validate TREMFYA's clinical profile.
Read more →JNJIcotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ...
Johnson & Johnson announced encouraging results from Phase 3 trials for icotrokinra, a new oral peptide treatment for moderate-to-severe plaque psoriasis. The data indicate superior skin clearance in patients compared to deucravacitinib, with similar adverse event rates to placebo. Long-term studies showed sustained efficacy and a favorable safety profile through 52 weeks. This could represent a significant advancement in psoriasis treatment options.
Read more →JNJJohnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting Johnson & Johnson (NYSE: JNJ) announced today that 21 abstracts featuring new real-world and clinical trial data will be presented at the annual U.S. ...
Johnson & Johnson (JNJ) announced that it will present 21 abstracts at the upcoming Psych Congress, showcasing new clinical and real-world data related to major depressive disorder, treatment-resistant depression, and schizophrenia. Key presentations include Phase 3 data on seltorexant, highlighting its efficacy compared to traditional treatments. The company aims to demonstrate its leadership in neuropsychiatry and its commitment to improving treatment outcomes for patients. The conference will take place from September 17 to 21 in San Diego, California.
Read more →JNJAsia cohort of Phase 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) achieved statistically significant and clinically meaningful improvement in overall survival versus osimertinib in EGFR-mutated non-small cell lung cancer Johnson & Johnson today announced positive topline results for overall survival (OS) from the Asia cohort of the Phase 3 MARIPOSA study, evaluating...
Johnson & Johnson announced positive topline results from the Asia cohort of the Phase 3 MARIPOSA study, showing that the combination of amivantamab and lazertinib significantly improves overall survival in patients with EGFR-mutated non-small cell lung cancer compared to osimertinib. The median overall survival is projected to exceed four years, marking a notable advancement in treatment options for this patient population. This combination is the first chemotherapy-free option to demonstrate such a survival benefit in this setting.
Read more →JNJU.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved INLEXZO™ (gemcitabine intravesical system), a new,...
Johnson & Johnson announced that the U.S. FDA has approved INLEXZO™ (gemcitabine intravesical system), a revolutionary treatment aimed at addressing BCG-unresponsive non-muscle invasive bladder cancer. The system allows for extended local delivery of the medication into the bladder, achieving a complete response in 82% of treated patients. This approval represents a critical advancement for patients who have limited treatment options and often face radical cystectomy. The therapy is designed to be administered in an outpatient setting, enhancing its accessibility for patients.
Read more →JNJmedia-relations its.jnj.com Investor contact investor-relations its.jnj.com FOR IMMEDIATE RELEASE Johnson Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-
Johnson & Johnson has elected John Morikis, retired CEO of The Sherwin-Williams Company, to its Board of Directors. Morikis is recognized for his leadership experience and understanding of global markets. He has expressed admiration for Johnson & Johnson's innovation in healthcare and is committed to supporting the company's long-term strategy for breakthrough treatments. His past roles included significant transformations at Sherwin-Williams, enhancing its market leadership and global presence.
Read more →JNJData published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing...
Johnson & Johnson announced that data published in The New England Journal of Medicine from the Phase 3 MARIPOSA study demonstrate that RYBREVANT (amivantamab-vmjw) in combination with LAZCLUZE (lazertinib) significantly improves overall survival for patients with first-line EGFR-mutated non-small cell lung cancer compared to osimertinib. At a median follow-up of 37.8 months, the combination is projected to offer a median overall survival exceeding four years, representing an increase of over one year. The study highlights a shift in treatment paradigms, emphasizing the potential for improved outcomes and reduced resistance to treatments.
Read more →JNJRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer Johnson & Johnson (NYSE:JNJ) today announced new analyses from the Phase 3 MARIPOSA study showing that first-line treatment with RYBREVANT®...
Johnson & Johnson (NYSE: JNJ) announced new findings from the Phase 3 MARIPOSA study detailing the effectiveness of RYBREVANT (amivantamab-vmjw) combined with LAZCLUZE (lazertinib) in preventing resistance mutations in EGFR-mutated non-small cell lung cancer. The combination therapy demonstrated a substantial overall survival benefit and significantly reduced the likelihood of developing MET amplification and EGFR mutations compared to osimertinib treatments. These updates were presented at the IASLC 2025 World Congress on Lung Cancer, underscoring its potential to improve treatment outcomes for patients with this type of lung cancer.
Read more →JNJJohnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA to include new evidence in the TREMFYA® label. This evidence is based on the Phase 3b APEX study, which demonstrated TREMFYA®'s significant efficacy in inhibiting joint damage in patients with active psoriatic arthritis. If approved, TREMFYA® will be recognized as the first IL-23 inhibitor to show such benefits, further solidifying its role in treating this chronic condition. The submission follows recent presentations at the EULAR 2025 Congress.
Read more →JNJJohnson & Johnson showcases latest advancements in Alzheimer's research at AAIC 2025 Johnson & Johnson (NYSE: JNJ) today announced promising new data from its Alzheimer's disease (AD) research program will be presented at the...
Johnson & Johnson (JNJ) announced that new data from its Alzheimer's research program will be presented at the Alzheimer's Association International Conference (AAIC) 2025. The findings will highlight the significance of tau in disease progression and the predictive strength of plasma biomarker pTau217. The company's collaboration with Gates Ventures aims to enhance research through the Global Neurodegeneration Proteomics Consortium, addressing challenges in understanding neurodegenerative diseases. The upcoming presentations will feature multiple abstracts discussing various aspects of Alzheimer's disease and potential biomarkers.
Read more →JNJJohnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data...
Johnson & Johnson has submitted a New Drug Application (NDA) to the U.S. FDA for icotrokinra, a novel oral peptide designed to treat moderate to severe plaque psoriasis in patients aged 12 and older. The submission includes data from four Phase 3 studies demonstrating its efficacy and safety, with significant skin clearance and a favorable safety profile. The drug is positioned to shift the treatment paradigm in psoriasis care, offering a simple daily pill as a potentially superior alternative to existing treatments. Future studies will further explore icotrokinra's efficacy compared to an injectable biologic.
Read more →JNJJohnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application...
Johnson & Johnson has announced that the FDA granted Priority Review for its New Drug Application for TAR-200, aimed at treating high-risk non-muscle invasive bladder cancer. This decision was based on promising results from the Phase 2b SunRISe-1 study, which showed an 82.4% complete response rate in patients. TAR-200 is designed as an innovative intravesical gemcitabine releasing system, marking a significant advancement in bladder cancer treatment options. The approval process is expected to accelerate, potentially enhancing available therapies for patients with limited treatment options.
Read more →JNJ▲ +6.2%on this newsshared move
media-relations its.jnj.com Investor contact investor-relations its.jnj.com For immediate release Johnson Johnson reports Q2 2025 results raises 2025 outlook 2025 Second-Quarter reported sales growth of 5.8
Johnson & Johnson reported its Q2 2025 results, highlighting a 5.8% increase in reported sales to $23.7 billion. The company raised its full-year sales guidance and adjusted EPS expectations due to strong operational performance across its MedTech and Innovative Medicine segments. The quarter also showcased significant advancements in its product pipeline, including approvals for new treatments in various fields. However, adjusted net earnings saw a slight decline compared to the same quarter last year.
Read more →JNJSupplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo Johnson & Johnson (NYSE:JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration...
Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) for CAPLYTA® (lumateperone) to the U.S. FDA, based on Phase 3 trial data showing a 63% reduction in relapse risk for schizophrenia patients compared to placebo. The data highlights CAPLYTA’s efficacy in preventing relapses, thereby enhancing treatment options for adults with schizophrenia. This submission aims to support long-term management and stability for patients experiencing this debilitating disorder, while also maintaining a favorable safety profile.
Read more →JNJJohnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM Today, Johnson & Johnson,† a global leader in eye health, announced the launch of ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM, the first and...
Johnson & Johnson has officially launched the ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM, the first daily disposable contact lens designed for people with both astigmatism and presbyopia. This new product aims to provide patients with improved visual clarity and comfort throughout the day. The company emphasizes innovative technologies that stabilize the lens and enhance hydration. Following this introduction, the ACUVUE OASYS MAX range will expand to additional markets outside of North America in the coming years.
Read more →JNJIMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC) Johnson & Johnson (NYSE: JNJ) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease...
Johnson & Johnson has announced results from an indirect treatment comparison showing that IMAAVY™ (nipocalimab-aahu) provides greater and sustained disease control in adults with generalized myasthenia gravis (gMG) compared to other approved FcRn blockers. The findings, presented at the European Academy of Neurology Congress, are based on robust Phase 3 data, highlighting the importance of consistent management of this chronic condition. IMAAVY was approved by the FDA earlier this year for a wide range of patients, and Johnson & Johnson is advancing its regulatory approvals internationally.
Read more →JNJInvestigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease Johnson & Johnson (NYSE: JNJ) announced today new results from the Phase 2 RedirecTT-1 study evaluating the investigational combination of TALVEY®...
Johnson & Johnson has announced promising results from the Phase 2 RedirecTT-1 study for their investigational combination of TALVEY and TECVAYLI in treating heavily pretreated multiple myeloma patients with extramedullary disease. The trial demonstrated a high overall response rate of 78.9% along with durable responses. This study represents the largest dedicated research into extramedullary disease, emphasizing the urgent need for more effective treatments for these patients. The results were presented at the 2025 European Hematology Association Congress and highlight the potential of dual-targeting approaches.
Read more →JNJJohnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational...
Johnson & Johnson (JNJ) announced promising results from its Phase 1b study of JNJ-90014496, a dual-targeting CAR T-cell therapy for relapsed or refractory large B-cell lymphoma. The therapy demonstrated a complete response rate of 75-80% among evaluable patients, indicating its potential effectiveness. Results shared at the 2025 European Hematology Association Congress highlighted JNJ-4496's ability to target both CD19 and CD20 antigens, enhancing treatment efficacy. Despite promising findings, the study also noted serious adverse events, including neurotoxicity and infections in some patients.
Read more →JNJNew results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia Johnson & Johnson (NYSE: JNJ) today announced new Phase 1b data showing encouraging antileukemic activity and a promising safety profile for...
Johnson & Johnson announced promising Phase 1b clinical trial results for bleximenib, a selective menin inhibitor, in combination with venetoclax and azacitidine for the treatment of acute myeloid leukemia (AML). The study revealed an overall response rate of 82% in relapsed or refractory patients and a 90% rate in newly diagnosed, chemo-ineligible patients. The treatment exhibited a favorable safety profile, with low rates of differentiation syndrome and no instances of QTc prolongation. This combination therapy aims to address significant unmet needs in AML, particularly for patients with certain genetic mutations.
Read more →JNJNew data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 3b APEX study showing that TREMFYA® (guselkumab) significantly reduced both...
Johnson & Johnson announced that TREMFYA (guselkumab) demonstrated significant efficacy in inhibiting joint structural damage in a Phase 3b APEX study for active psoriatic arthritis. Compared to placebo, TREMFYA showed a marked decrease in both joint and skin symptoms after 24 weeks, including a two and a half times greater ability to inhibit joint damage. With over 40% of patients achieving significant improvement, this establishes TREMFYA as a potential first-line treatment option for this condition. The study results were presented at the EULAR 2025 Congress.
Read more →JNJmedia-relations its.jnj.com Investor contact investor-relations its.jnj.com FOR IMMEDIATE RELEASE Johnson Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors New Brunswick, New J
Johnson & Johnson has elected Daniel Pinto, President of JPMorganChase, to its Board of Directors. Pinto's extensive experience in financial leadership and global capital markets is expected to add significant value to the board. He expressed admiration for J&J's commitment to healthcare innovation and improving patient outcomes. This strategic appointment may enhance J&J's initiatives in advancing healthcare solutions.
Read more →JNJSingle infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma Johnson & Johnson (NYSE:JNJ) announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of...
Johnson & Johnson announced that 33% of patients treated with CARVYKTI® achieved five or more years of progression-free survival following a single infusion, according to new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study. Notably, all patients evaluated at one site were found to be free of minimal residual disease throughout the follow-up period. The study also reported findings associated with safety and efficacy amidst a heavily pre-treated population. While the safety profile was consistent, concerns about second primary malignancies were noted.
Read more →JNJDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity Johnson & Johnson (NYSE: JNJ) today announced data from two studies highlighting that a DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based...
Johnson & Johnson announced promising data from two Phase 3 studies demonstrating that the DARZALEX FASPRO regimen significantly improves progression-free survival and minimal residual disease (MRD) rates in newly diagnosed multiple myeloma patients. Specifically, the studies showed a remarkable 95.3% progression-free survival rate at four years for transplant-eligible patients and high MRD negativity rates in both transplant-eligible and transplant-ineligible groups. These findings were presented at the 2025 ASCO Annual Meeting, highlighting DARZALEX FASPRO's potential as a key treatment option.
Read more →JNJJohnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the...
Johnson & Johnson announced promising results from the Phase 3 AMPLITUDE study, evaluating the efficacy of the combination therapy AKEEGA (niraparib and abiraterone acetate) in patients with HRR-altered metastatic castration-sensitive prostate cancer (mCSPC). The study indicated a nearly 50% reduction in disease progression and significant improvements in radiographic progression-free survival. This represents a major advancement as it is the first Phase 3 data showing clinical efficacy for a PARP inhibitor in this context. Although adverse events were more frequent with the combination treatment, the results underscore the potential of this therapy in offering improved outcomes for patients with specific genetic alterations.
Read more →JNJEarly results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients ...
Johnson & Johnson announced promising Phase 1 results for JNJ-79635322, a novel trispecific antibody in patients with relapsed or refractory multiple myeloma. The investigational therapy demonstrated an overall response rate of 86.1% among 36 patients, and a 100% response rate in those naive to BCMA and GPRC5D directed therapies. While showing optimistic efficacy, the trial reported common adverse events such as cytokine release syndrome and infections, alongside four treatment emergent patient deaths. The findings from this study highlight the potential for JNJ-5322 in future oncology treatments.
Read more →JNJJohnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that...
Johnson & Johnson has presented promising first-in-human results for pasritamig, a bispecific antibody showing anti-tumor activity in metastatic castration-resistant prostate cancer (mCRPC). The Phase 1 study indicated that pasritamig is well-tolerated, with low rates of adverse events. Notably, 42.4% of patients experienced over a 50% reduction in prostate-specific antigen levels, suggesting its potential as a targeted therapy for this challenging condition. Given the limited treatment options available for mCRPC, these findings support further investigation of pasritamig.
Read more →JNJU.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted (6-2) in...
The U.S. FDA's Oncologic Drugs Advisory Committee has voted in favor of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating high-risk smoldering multiple myeloma. The favorable 6-2 vote is based on encouraging data from the Phase 3 AQUILA study, which demonstrated potential improvements in progression-free survival. If approved, DARZALEX FASPRO may become the first treatment specifically targeting this patient group, paving the way for earlier intervention in managing the disease.
Read more →JNJIcotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class...
Johnson & Johnson announced positive results from its Phase 3 ICONIC-TOTAL study of icotrokinra (JNJ-2113), revealing significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis. At Week 16, 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved clear or almost clear skin. The treatment also showed a favorable safety profile, with no new safety concerns identified. These findings suggest that icotrokinra may provide a promising option for patients facing challenges in treating their psoriasis.
Read more →JNJTREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction...
Johnson & Johnson announced promising new data from the Phase 3 ASTRO study of TREMFYA (guselkumab) which demonstrated significant clinical remission and endoscopic improvement in patients with moderately to severely active ulcerative colitis at Week 24. As the first IL-23 inhibitor available for subcutaneous induction therapy, TREMFYA offers patients and physicians enhanced treatment flexibility. The data complements earlier positive findings from the QUASAR study and supports the recent FDA approvals for both subcutaneous and intravenous administration routes.
Read more →JNJTREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with...
Johnson & Johnson has announced new data from the Phase 3 QUASAR long-term extension study on TREMFYA (guselkumab) for adults with moderately-to-severely active ulcerative colitis. The results indicate that over 70% of patients maintained clinical remission and over 40% achieved endoscopic remission by Week 92. These findings highlight the drug's effectiveness and sustained efficacy, regardless of patients' prior biologic and JAK inhibitor treatments. Additionally, the safety profile remains consistent with previous data, showing no new safety concerns.
Read more →JNJJohnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG) Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY™ (nipocalimab-aahu), a human...
Johnson & Johnson has received FDA approval for IMAAVY™ (nipocalimab-aahu), the first FcRn blocker for the treatment of generalized myasthenia gravis (gMG) in both adults and pediatric patients aged 12 and older. This new therapy promises rapid reduction of immunoglobulin G (IgG) levels, contributing to substantial symptom relief and disease control for up to 20 months, as demonstrated in pivotal studies. The approval expands treatment options for a large population affected by gMG, with continuing regulatory submissions in progress worldwide.
Read more →JNJJohnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC Johnson & Johnson (NYSE: JNJ) today announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical...
Johnson & Johnson announced promising results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200 for high-risk non-muscle-invasive bladder cancer. The study showed a disease-free survival rate exceeding 80%, with 94% of participants able to preserve their bladders instead of undergoing radical cystectomy. Safety evaluations indicated a tolerable profile with no new adverse effects reported. The results highlight TAR-200's potential as a groundbreaking alternative treatment in this challenging patient population.
Read more →JNJJohnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer Johnson & Johnson (NYSE: JNJ) today announced new data from Cohort 2 of the pivotal Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical...
Johnson & Johnson announced promising data from the Phase 2b SunRISe-1 study for TAR-200, a new treatment for high-risk non-muscle invasive bladder cancer. The results showed an over 82% complete response rate, with more than half of patients remaining cancer-free for at least one year. The treatment has a favorable safety profile, primarily resulting in mild adverse events. TAR-200 represents a significant advancement for patients suffering from BCG-unresponsive bladder cancer, offering hope in a field with limited options.
Read more →JNJJohnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA Johnson & Johnson (NYSE: JNJ) announced today that new data from its leading oncology pipeline will be presented at the American Urological...
Johnson & Johnson (JNJ) has announced promising results from its TAR-200 therapy in treating high-risk non-muscle invasive bladder cancer. The data, which will be presented at the AUA 2025 Annual Meeting, highlights sustained response rates from the Phase 2b SunRISe-1 study. This innovative therapy is designed to provide localized treatment directly into the bladder, potentially allowing patients to avoid radical surgery. The findings aim to address the longstanding challenges in treating bladder cancer, where existing options have remained static for decades.
Read more →JNJmedia-relations its.jnj.com Investor contact investor-relations its.jnj.com For immediate release Johnson Johnson reports Q1 2025 results 2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion wi
Johnson & Johnson reported a 2.4% growth in Q1 2025 sales, totaling $21.9 billion, driven by operational growth in key segments. The company highlighted advancements in its product pipeline, including approvals for TREMFYA in Crohn's disease and significant data for RYBREVANT in non-small cell lung cancer. Earnings per share also saw a significant increase, marking a positive trend for the year. Additionally, the company has adjusted its full-year operational sales guidance following its acquisition of Intra-Cellular Therapies, suggesting strong confidence in its future performance.
Read more →JNJIcotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from a subgroup analysis of ICONIC-LEADa, the first ever Phase 3...
Johnson & Johnson announced promising results from the ICONIC-LEAD Phase 3 study for icotrokinra, a new treatment for moderate-to-severe plaque psoriasis in adolescents. The results indicate that 84.1% of participants experienced clear or almost clear skin after 16 weeks, with 75% achieving completely clear skin by week 24. The treatment also demonstrated a favorable safety profile, with adverse events recorded less frequently than in the placebo group. This could offer a vital new option for adolescents suffering from this condition.
Read more →JNJJohnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG) New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in...
Johnson & Johnson announced positive results from the Phase 3 Vivacity-MG3 study, indicating that nipocalimab effectively improves symptoms in adults with generalized myasthenia gravis over 18 months. The investigational treatment demonstrated sustained reductions in immunoglobulin G antibodies and a substantial improvement in muscle function and strength. Additionally, 45% of participants on steroids decreased or discontinued use during the open-label extension phase. These findings will be presented at the upcoming American Academy of Neurology Meeting, showcasing the commitment to developing innovative therapies for autoantibody diseases.
Read more →JNJTREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis Johnson & Johnson (NYSE: JNJ) today announced that the TREMFYA® (guselkumab) Phase 3b APEX study achieved both its primary endpoint (ACR20a) of...
Johnson & Johnson announced that TREMFYA (guselkumab) achieved its primary endpoint in the Phase 3b APEX study for treating adults with active psoriatic arthritis. The study demonstrated significant reductions in both symptoms and the progression of structural damage compared to placebo at Week 24. As the only IL-23 inhibitor to show this level of efficacy, TREMFYA reinforces its position as a critical treatment option for patients at risk of joint damage. The company plans to present further results at upcoming medical congresses.
Read more →JNJRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer Johnson & Johnson (NYSE:JNJ) today announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3...
Johnson & Johnson announced that RYBREVANT (amivantamab-vmjw) combined with LAZCLUZE (lazertinib) significantly improves overall survival in patients with EGFR-mutated non-small cell lung cancer compared to osimertinib. The Phase 3 MARIPOSA study revealed that the median overall survival has not yet been reached, with projections suggesting an extension of more than one year beyond osimertinib's median of three years. This is the first study to show a statistically significant survival benefit over osimertinib. The results were presented at the 2025 European Lung Cancer Congress.
Read more →JNJNew nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG) Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with...
Johnson & Johnson recently reported positive data from the Phase 3 Vivacity-MG3 study for nipocalimab, showing sustained disease control in generalized myasthenia gravis (gMG) patients. The findings will be presented at the upcoming AAN Annual Meeting, emphasizing the company's dedication to tackling the unmet needs of gMG patients. Additionally, the U.S. FDA has granted Priority Review for the Biologics License Application (BLA) for nipocalimab, suggesting that it could be available to patients in the near future. The research aims to improve outcomes for patients living with this challenging condition.
Read more →JNJU.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab), the first and only ...
The U.S. FDA has approved TREMFYA (guselkumab), the first IL-23 inhibitor that provides both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn's disease. This approval is based on supportive data from multiple Phase 3 trials demonstrating its efficacy in achieving clinical and endoscopic remission. TREMFYA's unique dual-acting mechanism and approved usage in other inflammatory bowel diseases highlight its significance in expanding treatment options available for impacted patients. The approval marks the fourth indication for TREMFYA in the U.S.
Read more →JNJRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025 Johnson & Johnson (NYSE:JNJ) announced today that new data from its industry-leading oncology pipeline will be presented at the 2025 European Lung...
Johnson & Johnson announced promising results from a Phase 3 study showcasing the efficacy of RYBREVANT (amivantamab-vmjw) combined with LAZCLUZE (lazertinib) in treating first-line EGFR-mutated non-small cell lung cancer (NSCLC). The analysis indicates a median overall survival improvement projected to surpass one year compared to standard treatment with osimertinib. This data will be presented at the upcoming 2025 European Lung Cancer Congress, signaling a shift in treatment paradigms for patients with specific EGFR mutations. The combination aims to enhance patient outcomes and experiences, establishing a benchmark for future therapies.
Read more →JNJNipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track...
Johnson & Johnson's investigational drug Nipocalimab has received Fast Track designation from the U.S. FDA for the treatment of adults with moderate-to-severe Sjögren's disease. This designation follows the previous Breakthrough Therapy designation and emphasizes the pressing need for effective treatments for the condition, which currently lacks FDA-approved therapies. The company is actively enrolling participants in the Phase 3 DAFFODIL study, building upon promising results from earlier studies showing the drug's potential benefits. Nipocalimab aims to offer crucial therapeutic options for patients suffering from this debilitating autoimmune disease.
Read more →JNJIcotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra (JNJ-2113), the first...
Johnson & Johnson reported positive topline results from its Phase 2b ANTHEM-UC study of icotrokinra (JNJ-2113), demonstrating significant clinical response and remission rates in patients with moderately to severely active ulcerative colitis. All evaluated dose groups met the primary endpoint, and the highest dose achieved a response rate of 63.5% compared to 27% for placebo. The drug showed a favorable safety profile, indicating its potential to be a transformative treatment option for ulcerative colitis.
Read more →JNJIcotrokinra results show potential to set a new standard of treatment in plaque psoriasis Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of...
Johnson & Johnson announced promising Phase 3 results for icotrokinra, an investigational oral treatment for moderate-to-severe plaque psoriasis. In the ICONIC-LEAD study, nearly half of the participants achieved complete skin clearance by Week 24, indicating strong efficacy. The results showed a favorable safety profile, as adverse events were similar between icotrokinra and placebo groups. Johnson & Johnson will initiate the first head-to-head trial to compare icotrokinra with an injectable biologic, which may reshape treatment paradigms in psoriasis care.
Read more →JNJTREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis Johnson & Johnson (NYSE: JNJ) today announced data from the Phase 3 ASTRO study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in...
Johnson & Johnson announced positive results from the Phase 3 ASTRO study of TREMFYA (guselkumab) for ulcerative colitis at the ECCO congress. The study demonstrated significant improvements in clinical and endoscopic measures compared to placebo. With this data, TREMFYA may soon offer the first fully subcutaneous induction therapy for patients, enhancing treatment options. The drug's safety profile remains consistent with previous data, and applications for regulatory approval have been submitted in Europe and the U.S.
Read more →JNJNew nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases Johnson & Johnson (NYSE: JNJ) today announced the publication of data detailing the differentiated molecular properties of nipocalimab, an...
Johnson & Johnson has published new data on nipocalimab, highlighting its unique molecular properties and strong potential as a treatment for IgG-driven alloantibody and autoantibody diseases. The investigational drug, which functions as a neonatal Fc receptor blocker, can reduce IgG levels significantly without adversely affecting immune function. The findings support nipocalimab's promise, noting its ability to specifically bind to FcRn and inhibit IgG recycling, thereby demonstrating potential clinical significance. Further investigation through various clinical phases continues to assess its efficacy and safety profile.
Read more →JNJFindings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology Johnson & Johnson (NYSE: JNJ) today announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an...
Johnson & Johnson announced the publication of pivotal Phase 3 study results for nipocalimab in treating generalized myasthenia gravis (gMG) in The Lancet Neurology. The study demonstrated a significant reduction in autoantibody levels and improvement in patient outcomes. Nipocalimab had a similar safety profile to placebo and has been granted FDA Priority Review. The findings suggest potential benefits for a broad population of antibody positive patients living with gMG.
Read more →JNJmedia-relations its.jnj.com Investor contact investor-relations its.jnj.com For immediate release Johnson Johnson reports Q4 and Full-Year 2024 results 2024 Fourth-Quarter reported sales growth of 5.3% to $
Johnson & Johnson (NYSE: JNJ) announced its financial results for Q4 and the full year 2024, highlighting a reported sales growth of 5.3% in Q4 and 4.3% for the full year, totaling $22.5 billion and $88.8 billion, respectively. Despite strong sales growth, net earnings showed a decline of 17% in Q4. The company highlighted significant advancements in its pipeline, including upcoming submissions and approvals. Looking ahead, Johnson & Johnson provided guidance for 2025, expecting operational sales growth between 2.5% to 3.5% and adjusted operational EPS of $10.75 to $10.95.
Read more →JNJSPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and...
Johnson & Johnson's SPRAVATO® (esketamine) has received FDA approval as the first and only monotherapy treatment for adults with treatment-resistant depression. The approval follows a Priority Review supported by clinical data showing significant efficacy at four weeks and rapid symptom relief within 24 hours. The treatment demonstrated a superior response compared to placebo, making it a noteworthy advancement for patients failing to respond to traditional antidepressants. However, its use is accompanied by risks, including sedation and potential for abuse, necessitating a controlled delivery through the SPRAVATO® Risk Evaluation and Mitigation Strategy Program.
Read more →JNJNew Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer Johnson & Johnson (NYSE: JNJ) announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug...
Johnson & Johnson has submitted a New Drug Application for TAR-200, intended for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer. This application is under review by the FDA through its Real-Time Oncology Review program, aimed at expediting treatment availability. TAR-200 has shown a promising complete response rate of 83.5% in Phase 2b clinical trials, potentially offering a significant new treatment option for patients with limited alternatives. The innovative system allows for outpatient administration without anesthesia, marking a notable advancement in bladder cancer treatment.
Read more →JNJNipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S...
Johnson & Johnson's nipocalimab has been granted a Priority Review by the U.S. FDA for the treatment of antibody-positive generalized myasthenia gravis (gMG). This designation follows promising results from the Phase 3 Vivacity-MG3 study, indicating a substantial reduction in disease symptoms among patients. Approximately 700,000 individuals globally are affected by gMG, and this treatment could offer new hope where no cure currently exists. The company is also pursuing approval in Europe for nipocalimab.
Read more →JNJJohnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a...
Johnson & Johnson has received Fast Track designation from the U.S. FDA for posdinemab, a monoclonal antibody targeting phosphorylated tau in early Alzheimer's disease patients. This therapy aims to slow the progression of tau pathology, potentially aiding cognitive function. Additionally, J&J's anti-tau immunotherapy, JNJ-2056, has also attained Fast Track status, underlining the company's commitment to innovative Alzheimer's treatments amid a significant unmet medical need.
Read more →JNJRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS)...
Johnson & Johnson (NYSE: JNJ) reported positive topline results from the Phase 3 MARIPOSA study, showing that RYBREVANT® plus LAZCLUZE™ significantly improved overall survival in patients with EGFR-mutated non-small cell lung cancer compared to the standard care drug osimertinib. The combination therapy is the first to demonstrate such a survival benefit in this patient population, with expectations of exceeding one year in median overall survival. The data underscores the potential for better patient outcomes and paves the way for important discussion at medical conferences and with health authorities.
Read more →JNJWarm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options Abstracts presented at ASH 2024 provide insight into the patient experience given the unpredictable nature of wAIHA, a rare autoantibody disease, and ...
Johnson & Johnson recently presented research at ASH 2024 on warm autoimmune hemolytic anemia (wAIHA), emphasizing the disease's significant burden and the lack of FDA-approved treatments. The company is investigating nipocalimab in a Phase 2/3 study, expected to yield results in 2025. Insights from patient perspectives reinforce the urgent need for targeted therapies and effective management strategies. Current treatments are associated with dissatisfaction and adverse side effects, underscoring the critical need for innovation in this area.
Read more →JNJCARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study Johnson & Johnson (NYSE:JNJ) announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene...
Johnson & Johnson announced promising results from the Phase 3 CARTITUDE-4 study, revealing that CARVYKTI (ciltacabtagene autoleucel) significantly outperformed standard therapies in achieving minimal residual disease (MRD) negativity in patients with relapsed or refractory multiple myeloma. An impressive 89% of evaluable patients achieved MRD negativity within two months of a single infusion. These findings enhance CARVYKTI's profile as a groundbreaking cell therapy that extends overall survival outcomes. Additionally, long-term remission rates, including progression-free survival, were notably higher in patients receiving CARVYKTI, indicating its strong potential for improved patient care.
Read more →JNJDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma Johnson & Johnson (NYSE: JNJ) today announced data from the Phase 3 AQUILA study showing that DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)...
Johnson & Johnson announced promising results from the Phase 3 AQUILA study, showing that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) significantly reduces the risk of progression from high-risk smoldering multiple myeloma to active multiple myeloma. The study demonstrated a 51% reduction in progression risk and extended overall survival rates compared to standard active monitoring. These findings highlight the potential of early intervention in improving patient outcomes.
Read more →JNJTECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients...
Johnson & Johnson announced promising frontline data for TECVAYLI (teclistamab-cqyv) in newly diagnosed multiple myeloma patients from two studies presented at the ASH Annual Meeting. The MajesTEC-5 study showed that all evaluable patients achieved minimal residual disease (MRD) negativity after three cycles of induction therapy. Additionally, TECVAYLI demonstrated a manageable safety profile and potential efficacy in combination therapies as both induction and maintenance treatment for multiple myeloma patients. Further evaluation of combination therapies is ongoing in the MajesTEC-7 study.
Read more →JNJDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma Johnson & Johnson (NYSE: JNJ) today announced data highlighting that DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens improve...
Johnson & Johnson announced that DARZALEX FASPRO-based regimens improve rates of minimal residual disease (MRD) negativity and progression-free survival in newly diagnosed multiple myeloma patients. Data from the Phase 3 CEPHEUS and AURIGA studies indicate that the addition of DARZALEX FASPRO to standard treatments significantly enhances treatment response. Findings were presented at the 2024 American Society of Hematology Annual Meeting, showcasing the medication's efficacy across diverse patient demographics. The studies also confirm that common safety profiles align with existing data on DARZALEX FASPRO.
Read more →JNJJohnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab) Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration...
Johnson & Johnson has submitted two supplemental Biologics License Applications to the FDA for TREMFYA® (guselkumab) to treat pediatric patients. The applications seek approval for children aged 6 and older with moderate to severe plaque psoriasis and those aged 5 and older with active juvenile psoriatic arthritis. This move highlights Johnson & Johnson's commitment to addressing a critical treatment gap in pediatric dermatology and rheumatology, backed by data from multiple studies. If approved, TREMFYA would be the first monoclonal antibody treatment for these conditions in children.
Read more →JNJJohnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
Johnson & Johnson has submitted a supplemental Biologics License Application to the U.S. FDA for its drug TREMFYA (guselkumab), seeking approval for a subcutaneous induction regimen specifically for adults with moderately to severely active ulcerative colitis. This move comes on the heels of recent FDA approval for TREMFYA in treating ulcerative colitis via an intravenous regimen. The submission is bolstered by positive results from the Phase 3 ASTRO study, which demonstrated significant outcomes for clinical remission. If approved, TREMFYA will become the first IL-23 inhibitor to offer a subcutaneous administration option for ulcerative colitis.
Read more →JNJJohnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting Johnson & Johnson (NYSE:JNJ) announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and...
Johnson & Johnson (JNJ) announced it will present more than 90 abstracts at the upcoming 2024 American Society of Hematology Annual Meeting, showcasing its robust hematology portfolio. The presentations will cover clinical trial and real-world data on treatments for various blood cancers, particularly multiple myeloma and other hematologic malignancies. Notable emphasis will be placed on novel approaches and addressing unmet needs in rare diseases like warm autoimmune hemolytic anemia. The event signifies JNJ's ongoing commitment to advancing treatment options and improving patient outcomes in hematology.
Read more →JNJIcotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational study of icotrokinra...
Johnson & Johnson announced promising topline results from the ICONIC-LEAD study of icotrokinra, a new oral peptide for treating moderate to severe plaque psoriasis. The study showed that 74% of patients achieved clear or almost clear skin after 24 weeks of treatment, significantly outperforming placebo. The safety profile was consistent with earlier studies, and the results will be presented at upcoming medical congresses. Ongoing studies within the ICONIC program will further assess icotrokinra's potential in various psoriasis-related indications.
Read more →JNJNipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures...
Johnson & Johnson announced results from the Phase 2 DAHLIAS study, revealing that the investigational drug nipocalimab significantly improved disease activity in adults with moderate-to-severe Sjögren's disease. Patients treated with nipocalimab exhibited more than 77% reduction in IgG levels, and improvements were noted across various indicators of disease activity. The study's findings were presented at the American College of Rheumatology Convergence 2024 and support the drug's potential as a new treatment option for this condition. Nipocalimab has also received Breakthrough Therapy Designation from the FDA.
Read more →JNJNipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved...
Johnson & Johnson's nipocalimab has received Breakthrough Therapy Designation from the FDA for the treatment of moderate-to-severe Sjögren's disease. This designation is based on promising results from the Phase 2 DAHLIAS study, which demonstrated over 70% improvement in systemic disease activity compared to placebo. Nipocalimab, previously designated for hemolytic disease, is noted as the only investigational therapy with this BTD status for Sjögren's disease, highlighting its potential to address significant unmet medical needs.
Read more →JNJJohnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma Johnson & Johnson (NYSE:JNJ) today announced the submission of regulatory applications to the U.S. Food and Drug Administration (FDA) and European...
Johnson & Johnson has submitted regulatory applications to the FDA and EMA for DARZALEX FASPRO® and DARZALEX® to be used as a monotherapy treatment for high-risk smoldering multiple myeloma. If approved, it will become the first treatment for this precursor stage of multiple myeloma, aiming to provide an early intervention prior to the onset of active disease. The submissions are backed by data from the ongoing Phase 3 AQUILA study, which compares DARZALEX FASPRO® to active monitoring. Results from this study are anticipated to be presented at the upcoming ASH Annual Meeting in December 2024.
Read more →JNJJohnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024 New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis...
Johnson & Johnson (NYSE: JNJ) will present 43 abstracts showcasing advancements in rheumatic disease treatment at the ACR 2024 Annual Meeting. Among the highlights are promising results from the Phase 2 DAHLIAS study for nipocalimab in Sjögren's Disease, which met its primary endpoint showing significant patient improvement. Additionally, new research on TREMFYA® demonstrates its positive impact on disease burden in psoriatic arthritis, reinforcing the company's commitment to innovative therapies in rheumatology.
Read more →JNJTREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease Johnson & Johnson (NYSE: JNJ) today announced results from the Phase 3 GRAVITI study of TREMFYA® (guselkumab), the first and only IL-23 inhibitor,...
Johnson & Johnson announced positive results from the Phase 3 GRAVITI study of TREMFYA® (guselkumab), showcasing its potential as the first IL-23 inhibitor to offer both subcutaneous and intravenous induction regimens for Crohn's disease. The study reported significant clinical remission and endoscopic response at 48 weeks in adults with moderately to severely active Crohn's disease. Although TREMFYA® has FDA approval for ulcerative colitis, its application for Crohn's disease treatment is under review. The findings may provide patients with more treatment options and increase medication compliance due to self-administration.
Read more →JNJNew SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear skin in the majority of...
Johnson & Johnson (NYSE: JNJ) reported positive outcomes from the Phase 3b SPECTREM study of TREMFYA (guselkumab) for treating moderate plaque psoriasis in adults with low body surface area. The study showed that TREMFYA resulted in clear or almost clear skin for a majority of participants, especially those with affected special sites such as the scalp and face. The findings highlight a significant improvement in skin clearance compared to placebo, with accompanying advancements in quality of life for patients. Additionally, the launch of the TREMFYA Clearance Photo Library aims to enhance visual representation and diagnosis for those with diverse skin tones.
Read more →JNJJohnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress Johnson & Johnson (NYSE: JNJ) announced today that 23 abstracts featuring new real-world and clinical trial data from across its neuropsychiatry...
Johnson & Johnson (NYSE: JNJ) is set to present 23 abstracts at the upcoming U.S. Psychiatric and Mental Health Congress, showcasing new data from its neuropsychiatry portfolio. Key highlights include efficacy and safety data for the SPRAVATO (esketamine) nasal spray and various long-acting injectable treatments for schizophrenia. The presentations aim to shed light on the substantial challenges faced by individuals with major depressive disorder and schizophrenia, emphasizing the company's dedication to neuroscience innovation and patient well-being.
Read more →JNJmedia-relations its.jnj.com Investor contact investor-relations its.jnj.com Johnson Johnson reports Q3 2024 results 2024 Third-Quarter reported sales growth of 5.2% to $22.5 Billion with operational growth
Johnson & Johnson (NYSE: JNJ) reported a 5.2% increase in sales for Q3 2024, amounting to $22.5 billion, alongside operational growth of 6.3%. However, its earnings per share (EPS) showed a significant decrease of 34.3%, attributed to a one-time charge and the impact of the acquired IPR D. Notably, the company made strides in its regulatory pipeline, obtaining approvals for TREMFYA in ulcerative colitis and RYBREVANT + LAZCLUZE for lung cancer. Moreover, JNJ has updated its full-year operational sales guidance upwards, reflecting optimism in its ongoing performance.
Read more →JNJNipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents ...
Johnson & Johnson announced promising results from the Phase 2/3 Vibrance-MG study, showcasing the efficacy of nipocalimab in treating adolescents aged 12-17 with generalized myasthenia gravis. The study reported significant reductions in immunoglobulin G levels and improvement in disease activity measures. Notably, nipocalimab was well-tolerated with no serious adverse events. The findings highlight the potential of this drug as a new treatment option for a population with limited therapeutic alternatives.
Read more →JNJTREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis Johnson & Johnson (NYSE: JNJ) today announced TREMFYA® (guselkumab) data in both Crohn's disease (CD) and ulcerative colitis (UC) showing high rates...
Johnson & Johnson has announced that TREMFYA (guselkumab) has shown impressive results in treating Crohn's disease (CD) and ulcerative colitis (UC), demonstrating high rates of endoscopic remission in both biologic-naïve and biologic-refractory patients. The drug has received U.S. FDA approval for UC, while its application for CD is under review. The data were derived from pooled analyses of the Phase 3 GALAXI and QUASAR studies. TREMFYA stands out as the only IL-23 inhibitor to outperform ustekinumab in clinical trials for CD, potentially offering better outcomes for patients with difficult-to-treat conditions.
Read more →JNJERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer Johnson & Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA® (apalutamide) provided a ...
Johnson & Johnson announced positive results from a large head-to-head real-world study showing that ERLEADA (apalutamide) significantly improves overall survival in patients with metastatic castration-sensitive prostate cancer compared to enzalutamide. In the study of nearly 4,000 patients, ERLEADA demonstrated a 23% reduction in the risk of death at 24 months. The findings, presented at the 6th European Congress of Oncology Pharmacy, highlight the effectiveness of ERLEADA as a treatment option, while also noting the absence of head-to-head randomized trials in this area. However, some limitations exist, including potential inaccuracies in data and the need for further long-term studies.
Read more →JNJJohnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned Johnson & Johnson (NYSE:JNJ) announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
Johnson & Johnson has submitted a supplemental Biologics License Application (sBLA) to the FDA for its DARZALEX FASPRO® quadruplet regimen aimed at treating newly diagnosed multiple myeloma patients who are not eligible for autologous stem cell transplantation (ASCT). The application is supported by positive results from the Phase 3 CEPHEUS study, which demonstrated a 60.9% rate of minimal residual disease (MRD)-negativity and a 43% reduction in risk of progression or death. This indication, if approved, would mark the first FDA-approved treatment regimen specifically for this patient population based on MRD-negativity as a primary endpoint.
Read more →JNJJohnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting Johnson & Johnson§, a global leader in eye health, has announced it's expanding the roll-out of its latest advancement in presbyopia-correcting...
Johnson & Johnson has expanded the roll-out of its TECNIS Odyssey intraocular lens in the U.S., designed for cataract patients seeking improved vision across all distances. This new lens offers patients a full visual range and has shown superior performance over the PanOptix lens, including better clarity in low-light conditions and a smaller readable print size. Early reports suggest that 93% of users experience freedom from glasses after surgery, highlighting the lens's effectiveness in addressing both distance vision and presbyopia.
Read more →JNJTALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma Johnson & Johnson (NYSE: JNJ) today announced updated results from the investigational Phase 1b TRIMM-2 study evaluating the combination of TALVEY®...
Johnson & Johnson has announced updated results from the Phase 1b TRIMM-2 study evaluating the combination of TALVEY® (talquetamab-tgvs), DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), and pomalidomide in patients with relapsed or refractory multiple myeloma. The study reported an overall response rate of 82%, with some treatment arms achieving a 100% response rate. While the safety profile was consistent with the individual therapies, there were notable adverse events such as high rates of neutropenia. The results underscore the combination's potential for significant disease control and support ongoing investigations.
Read more →JNJCARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line Johnson & Johnson (NYSE:JNJ) announced today long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI®...
Johnson & Johnson announced positive long-term results from the Phase 3 CARTITUDE-4 study, indicating that CARVYKTI (ciltacabtagene autoleucel) offers a significant overall survival advantage for patients with relapsed or lenalidomide-refractory multiple myeloma. The treatment showed a 45% reduction in the risk of death compared to standard therapies after a median follow-up of three years. With encouraging quality-of-life metrics and response rates, CARVYKTI is positioned as a transformative therapy in its indication. The results were presented at the 2024 International Myeloma Society Annual Meeting.
Read more →JNJDARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma Johnson & Johnson (NYSE: JNJ) today announced data from three studies highlighting clinical efficacy of DARZALEX® (daratumumab) and DARZALEX FASPRO®...
Johnson & Johnson (JNJ) announced data from three studies highlighting the efficacy of DARZALEX and DARZALEX FASPRO in maintenance regimens for patients with newly diagnosed multiple myeloma. The Phase 3 AURIGA study showed that DARZALEX FASPRO, combined with lenalidomide, doubled the MRD-negative conversion rate at 12 months compared to lenalidomide alone. Additional studies demonstrated durable and deep responses in multiple myeloma patients, suggesting potential improved long-term outcomes. Safety profiles remained consistent with known data, and adverse events particularly included infections and neutropenia, affecting a significant proportion of patients.
Read more →JNJDARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned Johnson & Johnson (NYSE:JNJ) announced today results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with DARZALEX...
Johnson & Johnson announced positive results from the Phase 3 CEPHEUS study indicating that the DARZALEX FASPRO-based quadruplet regimen (D-VRd) significantly improves minimal residual disease negativity and reduces the risk of progression or death in newly diagnosed multiple myeloma patients who are ineligible for transplant. The study demonstrated a notable 60.9% MRD negativity rate and higher complete response rates with D-VRd. Although overall survival data is not yet available, the regimen shows promising potential as a new frontline therapy for this patient group.
Read more →JNJNovel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease Johnson & Johnson (NYSE: JNJ) today announced updated results from the investigational Phase 1b RedirecTT-1 study evaluating the first-ever...
Johnson & Johnson reported updated results from the Phase 1b RedirecTT-1 study, indicating that the bispecific antibody combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) demonstrates a high response rate and durable responses in relapsed or refractory multiple myeloma patients who are triple-class refractory. The overall response rate reached 79.5%, with a complete response rate of 52.3%, and an 18-month duration of response of 85.9%. The safety profile observed was consistent with previous monotherapy findings, though there was a noted increase in Grade 3/4 infections. The results were particularly encouraging for patients with extramedullary disease, who typically have fewer treatment options.
Read more →JNJJohnson & Johnson Celebrates Innovation in Regulated RNA and Protein Degradation with 2024 Dr. Paul Janssen Award for Biomedical Research Johnson & Johnson today announced Lynne Maquat, Ph.D., of the University of Rochester, and Alexander Varshavsky, Ph.D., of the California Institute...
Johnson & Johnson announced Lynne Maquat, Ph.D., and Alexander Varshavsky, Ph.D., as recipients of the 2024 Dr. Paul Janssen Award for Biomedical Research. They were recognized for their significant contributions to the understanding of regulated RNA and protein degradation. Their research has far-reaching implications in treating diseases such as cancer and neurodegeneration. A virtual symposium honoring the winners will be held on January 30, 2025.
Read more →JNJmedia-relations its.jnj.com Investor contact investor-relations its.jnj.com The Plan enables a full and final resolution of the Company's ovarian talc litigation. The Plan would resolve 99.75% of all pendin
Johnson & Johnson's subsidiary, Red River Talc LLC, has filed for a voluntary prepackaged Chapter 11 bankruptcy to address all current and future ovarian cancer claims related to talc products. The proposed plan, which has garnered support from 83% of claimants, includes an increased settlement amount of approximately $8 billion. This collective effort aims to resolve 99.75% of ongoing litigation, representing one of the largest settlements in mass tort bankruptcy cases. The company believes this plan significantly benefits the claimants and offers a more favorable outcome than lengthy trials.
Read more →JNJRYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) in combination...
Johnson & Johnson announced FDA approval for RYBREVANT® (amivantamab-vmjw) in conjunction with standard chemotherapy for advanced non-small cell lung cancer with specific EGFR mutations. This approval is based on Phase 3 MARIPOSA-2 study results, which demonstrated a 52% reduction in disease progression risk compared to chemotherapy alone. This therapy becomes a pivotal second-line option for patients previously treated with EGFR TKIs, addressing significant unmet medical needs in this patient population. RYBREVANT® now has multiple indications established within the year.
Read more →JNJNeoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer Johnson & Johnson (NYSE: JNJ) announced today interim data from the ongoing Phase 2 SunRISe-4 study showing neoadjuvant treatment with...
Johnson & Johnson announced interim data from the Phase 2 SunRISe-4 study showing that the combination of TAR-200 and cetrelimab significantly improved the pathological complete response rate in patients with muscle-invasive bladder cancer compared to cetrelimab alone. This combination treatment effectively reduced tumor size and held promise for enhancing surgical outcomes and lowering recurrence rates. The study's findings, publicly presented at the ESMO Congress, suggest a potential shift in treatment paradigms for MIBC, particularly for patients not suitable for standard chemotherapy. However, some adverse events associated with the treatment were reported.
Read more →JNJNew data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer Johnson & Johnson (NYSE:JNJ) announced today additional results from the pivotal Phase 2b SunRISe-1 study, supporting the safety and efficacy profile ...
Johnson & Johnson announced encouraging results from the Phase 2b SunRISe-1 study of TAR-200, highlighting an 84% complete response rate in patients with high-risk non-muscle-invasive bladder cancer who are unresponsive to BCG therapy. The study demonstrated durable responses, with 82% of participants maintaining their response after nine months. TAR-200 offers a novel treatment approach that may improve patient outcomes while minimizing the need for more invasive procedures like radical cystectomy. The favorable safety profile further supports its potential in bladder cancer therapies.
Read more →JNJRYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT® (amivantamab-vmjw) combined with...
Johnson & Johnson announced encouraging results from the Phase 1b/2 OrigAMI-1 study, showing that RYBREVANT (amivantamab-vmjw) combined with chemotherapy has a 49% overall response rate in patients with metastatic colorectal cancer. The combination treatment demonstrated a median duration of response of 7.4 months and led to successful curative-intent surgery in 21% of patients. The findings suggest RYBREVANT's effectiveness extends beyond lung cancer treatment, indicating significant potential for improving patient outcomes. Ongoing and upcoming Phase 3 trials aim to further explore these benefits.
Read more →JNJRYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT® (amivantamab-vmjw) combined...
Johnson & Johnson announced updated results from the Phase 3 MARIPOSA-2 study, indicating that RYBREVANT (amivantamab-vmjw) in combination with chemotherapy shows a positive trend in overall survival for patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC). After a median follow-up of 18.1 months, 50% of patients on the combination therapy were still alive, compared to 40% in the chemotherapy-only group. The study demonstrated significant benefits in treatment discontinuation rates and reduced risk of symptomatic progression. RYBREVANT plus chemotherapy received regulatory approval from the European Commission in August 2024 based on these findings.
Read more →JNJTREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment...
Johnson & Johnson's TREMFYA (guselkumab) has received FDA approval for treating adults with moderately to severely active ulcerative colitis. It is the only fully-human, dual-acting monoclonal antibody targeting IL-23 for this condition, addressing a significant unmet need in ulcerative colitis management. Clinical data from the QUASAR study demonstrated statistically significant rates of endoscopic remission and overall symptom improvement. This marks the third indication for TREMFYA, as it previously gained approvals for plaque psoriasis and psoriatic arthritis.
Read more →JNJDexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw) Johnson & Johnson (NYSE:JNJ) today announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies...
Johnson & Johnson announced encouraging results from the Phase 2 SKIPPirr study, which investigated methods to reduce infusion-related reactions (IRRs) in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT (amivantamab-vmjw). The study found that pre-treatment with dexamethasone led to a 22.5% IRR rate, representing a significant reduction from the historical 67.4% rate. All recorded IRRs were of Grade 1 or 2 severity, with no serious reactions requiring hospitalization. These findings suggest that incorporating dexamethasone in treatment protocols can enhance patient outcomes.
Read more →JNJRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer Johnson & Johnson (NYSE: JNJ) today announced longer follow-up data from the landmark Phase 3 MARIPOSA study which showed first-line treatment with...
Johnson & Johnson (NYSE: JNJ) reported promising longer-term data from the Phase 3 MARIPOSA study, indicating that the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) provided superior overall survival in patients with advanced EGFR-mutated non-small cell lung cancer compared to osimertinib monotherapy. At three years of follow-up, 61% of patients on the regimen were alive, compared to 53% for osimertinib. The study also revealed trends in improved central nervous system disease control and a favorable efficacy safety profile. Further assessments of overall survival continue and will be essential for establishing the regimen's long-term efficacy.
Read more →JNJJohnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis Johnson & Johnson (NYSE: JNJ) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)...
Johnson & Johnson has submitted a Biologics License Application to the FDA seeking approval for nipocalimab as a treatment for generalized myasthenia gravis (gMG). The submission is based on positive results from the Phase 3 Vivacity-MG3 trial, which showed that nipocalimab combined with standard care outperformed placebo plus standard care, demonstrating sustained control over symptoms. This is a noteworthy step in addressing the unmet therapeutic needs in a large demographic of antibody positive gMG patients.
Read more →JNJJohnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress Johnson & Johnson (NYSE: JNJ) announced today that 11 oral presentations from the Company's industry-leading solid tumor portfolio and pipeline will...
Johnson & Johnson (NYSE: JNJ) has announced that it will present 11 oral studies at the upcoming 2024 World Conference on Lung Cancer and the ESMO Congress. These studies will showcase advancements from its solid tumor portfolio, focusing on innovative therapies for lung, prostate, bladder, and colorectal cancers. Notable among the findings are new data supporting RYBREVANT's efficacy in treating advanced NSCLC and a novel organ-sparing therapy for bladder cancer.
Read more →JNJJoshina Kapoor media-relations its.jnj.com For immediate release Johnson Johnson's Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire Kristen Mulholland Named Chief Human Resourc
Johnson & Johnson has announced the retirement of Dr. Peter M. Fasolo, the Executive Vice President and Chief Human Resources Officer, effective December 31, 2024. He will be succeeded by Kristen Mulholland, who has been with the company since 2005 and has held various HR leadership roles. The transition aims to maintain consistency in the company's human capital strategy, furthering its commitment to employee welfare and organizational culture. Dr. Fasolo leaves a significant legacy, having positively influenced diversity and inclusion initiatives during his tenure.
Read more →JNJRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™...
Johnson & Johnson has secured FDA approval for RYBREVANT (amivantamab-vmjw) in combination with LAZCLUZE (lazertinib) as a first-line treatment for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). This combination is the first and only chemotherapy-free regimen shown to improve progression-free survival compared to osimertinib. The approval is based on the positive results from the Phase 3 MARIPOSA trial, demonstrating significant efficacy and offering a new treatment option for patients with limited alternatives.
Read more →JNJGroundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine Johnson & Johnson (NYSE: JNJ) today announced the results from the Phase 2 open-label UNITY study of nipocalimab for the treatment of alloimmunizeda...
Johnson & Johnson has announced the positive results from its Phase 2 UNITY study of nipocalimab, which is aimed at treating pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn (HDFN). The study, published in The New England Journal of Medicine, reported that 54% of participants achieved a live birth at or after 32 weeks without the need for intrauterine transfusion. As the only therapy in clinical development for such high-risk pregnancies, nipocalimab's results support its further development in Phase 3 trials to address this serious condition.
Read more →JNJDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and...
Johnson & Johnson announced FDA approval for DARZALEX FASPRO, a new quadruplet regimen for newly diagnosed multiple myeloma patients eligible for stem cell transplants. This regimen combines DARZALEX FASPRO with three other drugs and has shown a 60% reduction in the risk of disease progression compared to the standard treatment. The approval is based on positive results from the Phase 3 PERSEUS study, which demonstrated significant improvements in patient outcomes and deepening responses. DARZALEX FASPRO is poised to set new standards of care for this patient population.
Read more →JNJJohnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression Johnson & Johnson (NYSE: JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration...
Johnson & Johnson has submitted a supplemental New Drug Application to the U.S. FDA for the approval of SPRAVATO (esketamine) as the first monotherapy for adults with treatment-resistant depression. The application is backed by data from the Phase 4 TRD4005 study, which demonstrated rapid improvement in depressive symptoms within 24 hours, maintained for at least four weeks. SPRAVATO is already approved in combination with oral antidepressants and has been used in over 100,000 patients worldwide.
Read more →JNJTesia Williams media-relations its.jnj.com Investor contact Jessica Moore investor-relations its.jnj.com Johnson Johnson reports Q2 2024 results 2024 Second-Quarter reported sales growth of 4.3% to $22.4 Bi
Johnson Johnson reported a 4.3% increase in second-quarter 2024 sales, reaching $22.4 billion, with operational growth of 6.6%. Adjusted EPS rose by 10.2% to $2.82, despite a 5.9% decline in reported EPS attributed to special charges. The company highlighted significant progress in its product pipeline and increased guidance for full-year operational sales following recent acquisitions. However, international sales growth was modest, and earnings faced pressures from certain charges.
Read more →JNJCARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study Johnson & Johnson (NYSE:JNJ) announced today positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating ...
Johnson & Johnson announced positive results from the Phase 3 CARTITUDE-4 study evaluating CARVYKTI (ciltacabtagene autoleucel), showing a statistically significant improvement in overall survival compared to standard therapies for relapsed or lenalidomide-refractory multiple myeloma. The safety profile was consistent with existing data, indicating the therapy's viability as a second-line treatment. However, there were noted concerns regarding increased early mortality among patients treated with CARVYKTI, highlighting the need for careful monitoring.
Read more →JNJNipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients Johnson & Johnson (NYSE: JNJ) today announced positive results from the nipocalimab Phase 3 Vivacity-MG3 study in patients with generalized...
Johnson & Johnson (NYSE: JNJ) has announced positive results from the Phase 3 Vivacity-MG3 trial of nipocalimab for generalized myasthenia gravis (gMG), indicating significant improvement in patients' activities of daily living when compared to placebo. The study achieved its primary endpoint, exhibiting superiority in MG-ADL scores over a 24-week period in a broad set of antibody-positive patients. Key secondary endpoints were also met, reinforcing the treatment's efficacy and safety profile similar to placebo. These findings will be presented at the European Academy of Neurology Congress and are set for regulatory submissions.
Read more →JNJJohnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the FDA for TREMFYA® (guselkumab) to treat adults with moderately to severely active Crohn's disease. The submission is supported by promising results from Phase 3 studies, particularly the GALAXI and GRAVITI programs, which demonstrated superior outcomes compared to ustekinumab. If approved, TREMFYA® could provide new treatment options for patients, offering both subcutaneous and intravenous induction therapies. This submission follows a previous application for TREMFYA® in treating ulcerative colitis earlier this year.
Read more →JNJTREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 GRAVITI investigational study of TREMFYA®...
Johnson & Johnson announced positive topline results from the Phase 3 GRAVITI study of TREMFYA (guselkumab) for patients with moderately to severely active Crohn's disease. The study successfully met both co-primary endpoints with significant clinical remission and endoscopic response at 12 weeks. These findings highlight TREMFYA's potential as the only IL-23 inhibitor to offer both subcutaneous and intravenous induction therapies, providing more options for patients. Results from GRAVITI will be presented at upcoming medical meetings and shared with health authorities for regulatory submissions.
Read more →JNJSubcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer Johnson & Johnson (NYSE: JNJ) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)...
Johnson & Johnson has submitted a Biologics License Application (BLA) to the U.S. FDA for subcutaneous amivantamab for patients with EGFR-mutated non-small cell lung cancer (NSCLC). This submission is based on promising results from the Phase 3 PALOMA-3 trial, where subcutaneous administration showed a five-fold reduction in infusion-related reactions and longer overall and progression-free survival compared to intravenous administration. The BLA includes data supporting various dosing schedules. This advancement aims to enhance the treatment experience for patients and healthcare providers.
Read more →JNJTALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median...
Johnson & Johnson's TALVEY™ (talquetamab-tgvs) exhibited significant long-term efficacy in patients with relapsed or refractory multiple myeloma, achieving a 67% overall survival rate at 24 months. The Phase 1/2 MonumenTAL-1 study demonstrated durable responses and high overall response rates, even in patients previously exposed to T-cell redirection therapies. Despite some adverse events and early weight loss in patients, the treatment showed a manageable safety profile, indicating potential as a versatile option in this challenging disease area. The findings were presented at the 2024 European Hematology Association Congress.
Read more →JNJCARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened responses versus two standard therapies for patients with functional high-risk multiple myeloma Johnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. The data show CARVYKTI® (ciltacabtagene...
Johnson & Johnson announced positive results from a subgroup analysis of the Phase 3 CARTITUDE-4 study, showing that CARVYKTI (ciltacabtagene autoleucel) significantly improved progression-free survival compared to standard treatments for patients with high-risk multiple myeloma. The analysis, presented at the ASCO Annual Meeting, indicated that patients receiving CARVYKTI also achieved deeper overall responses and a higher rate of minimal residual disease negativity. Despite a comparable occurrence of serious adverse events between treatments, the study supports CARVYKTI's role as an effective therapy for patients with lenalidomide-refractory multiple myeloma.
Read more →JNJDARZALEX® (daratumumab)-based regimens significantly improve clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma Johnson & Johnson today announced data from the Phase 3 PERSEUS study showing deepening of responses and sustained minimal residual disease (MRD)...
Johnson & Johnson announced promising results from the Phase 3 PERSEUS study for DARZALEX (daratumumab) in newly diagnosed multiple myeloma patients. The study showed that 88% of transplant-eligible patients achieved a complete response, and 47% sustained minimal residual disease (MRD) negativity for over a year. Furthermore, the median overall survival for transplant-ineligible patients reached 7.5 years, marking significant advancements in treatment outcomes. These findings were presented at notable oncology conferences and are likely to influence treatment protocols for multiple myeloma.
Read more →JNJLate-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer Johnson & Johnson announced today new data from the Phase 2 PALOMA-2 study evaluating subcutaneous (SC) amivantamab combined with lazertinib as a...
Johnson & Johnson presented new Phase 2 data from the PALOMA-2 study evaluating subcutaneous amivantamab combined with lazertinib as a first-line treatment for EGFR-mutated non-small cell lung cancer. The findings reveal an overall response rate of 77 percent, comparable to existing intravenous formulations, while demonstrating a more favorable safety profile with significantly fewer infusion-related reactions. These results suggest that subcutaneous administration may better meet the treatment needs of patients with advanced NSCLC. The trial results were prominently featured at the 2024 ASCO Annual Meeting.
Read more →JNJTECVAYLI® (teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma Johnson & Johnson today announced longer-term data from the pivotal Phase 1/2 MajesTEC-1 study of TECVAYLI® (teclistamab-cqyv) showing deep and...
Johnson & Johnson announced promising long-term results from the Phase 1/2 MajesTEC-1 study of TECVAYLI (teclistamab-cqyv) for relapsed or refractory multiple myeloma. The study showed a median duration of response of 24 months and a 63% overall response rate, with deepening responses noted in patients who switched to biweekly dosing. Additionally, the safety profile remained consistent, with a significant reduction in new severe infections over time. These findings suggest that TECVAYLI may transform treatment options for patients with limited alternatives.
Read more →JNJRYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer progression-free survival versus osimertinib in first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer Johnson & Johnson today announced new data from the Phase 3 MARIPOSA study demonstrating the benefit of first-line treatment with RYBREVANT®...
Johnson & Johnson announced positive results from the Phase 3 MARIPOSA study, highlighting the efficacy of RYBREVANT (amivantamab-vmjw) plus lazertinib in improving progression-free survival for patients with high-risk EGFR-mutated non-small cell lung cancer compared to osimertinib. The study enrolled treatment-naïve patients, with a notable 89% exhibiting high-risk disease features. While the combination showcased promising results, it did present higher rates of certain adverse events compared to the standard treatment. These findings suggest that RYBREVANT and lazertinib could become a new standard of care for this patient population.
Read more →JNJFirst results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration Johnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in...
Johnson & Johnson announced promising initial results from the Phase 3 PALOMA-3 study, which evaluated subcutaneous amivantamab combined with lazertinib for patients with advanced or metastatic non-small cell lung cancer (NSCLC). The study showed that subcutaneous administration resulted in a significant reduction in infusion-related reactions and shorter administration times compared to intravenous forms. Additionally, outcomes indicated greater overall and progression-free survival rates for the subcutaneous formulation. The results support the ongoing development and regulatory submissions for this new treatment modality.
Read more →JNJJohnson & Johnson pivotal study of seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes Seltorexant, an investigational first-in-class therapy, met all primary and secondary endpoints in pivotal Phase 3 study in patients with major...
Johnson & Johnson announced positive results from the pivotal Phase 3 MDD3001 trial of seltorexant, an investigational therapy for major depressive disorder (MDD) with insomnia symptoms. The study demonstrated that seltorexant achieved all primary and secondary endpoints, showing significant improvements in depressive symptoms and sleep disturbance outcomes. The findings highlight seltorexant's potential to fill a critical gap in treatment options for patients suffering from this dual condition.
Read more →JNJTREMFYA® (guselkumab) demonstrates superiority versus STELARA® (ustekinumab) in Phase 3 Crohn's disease program Johnson & Johnson today announced the first Phase 3 results for TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn's...
Johnson & Johnson announced positive Phase 3 results for TREMFYA (guselkumab) in treating moderately to severely active Crohn's disease. The study showed that TREMFYA outperformed STELARA (ustekinumab) in various endoscopic endpoints, reinforcing its potential as an advanced therapeutic option. Additionally, both dosing regimens of TREMFYA met their co-primary endpoints against placebo and showed significant clinical improvements compared to ustekinumab. The findings were presented at Digestive Disease Week 2024, marking an important step for Crohn's disease management.
Read more →JNJTREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p 0.001) of...
Johnson & Johnson announced positive results from the Phase 3 QUASAR Maintenance Study for TREMFYA (guselkumab) in treating moderately to severely active ulcerative colitis (UC). The study showed that 50% of patients receiving TREMFYA achieved clinical remission at Week 44, significantly outpacing the placebo group. Additionally, both treatment dosages met all primary and secondary endpoints, indicating strong efficacy. TREMFYA's findings position it as a promising therapy to enhance current treatment options for ulcerative colitis patients.
Read more →JNJTAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of TAR-210,...
Johnson & Johnson announced promising results from a Phase 1 study of TAR-210, showing a 90% recurrence-free survival rate and a 90% complete response rate for patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively. The drug targets FGFR alterations and aims to improve treatment for patients with limited options. These findings were shared at the 2024 AUA Annual Meeting. While the treatment showed significant potential, some patients experienced adverse events that prompted discontinuation of the study.
Read more →JNJPhase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA®...
Johnson & Johnson announced Phase 2 results from the Apa-RP study, presenting a 100% biochemical recurrence-free rate at 24 months for patients with high-risk localized prostate cancer treated with ERLEADA (apalutamide) and androgen deprivation therapy after radical prostatectomy. The study met its primary endpoint and highlighted the need for treatment intensification to prevent disease recurrence. Despite promising results, the study noted that nearly all patients experienced adverse events, with a significant portion classified as severe.
Read more →JNJTAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of investigational ...
Johnson & Johnson announced promising results from Cohort 2 of the Phase 2b SunRISe-1 study, indicating that TAR-200 monotherapy achieved an 82.8% complete response rate in patients with high-risk non-muscle-invasive bladder cancer unresponsive to prior treatment. The study also reported that 98% of patients reached a complete response within 12 weeks. Side effects were noted, with a significant portion of participants experiencing adverse events linked to the treatment. These findings highlight the potential of TAR-200 as a viable treatment option in a patient demographic facing limited choices.
Read more →JNJJohnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn's disease Janssen-Cilag International NV, a Johnson & Johnson company, today announced it has submitted applications to the European Medicines Agency (EMA)...
Johnson & Johnson has submitted regulatory applications to the European Medicines Agency (EMA) for the approval of TREMFYA® (guselkumab) for treating ulcerative colitis and Crohn's disease. This application is supported by promising data from the Phase 3 QUASAR and GALAXI programs, which showed statistically significant improvements in patients' conditions. The drug targets immune-mediated diseases, providing a potential new treatment option for patients with limited effective therapies.
Read more →JNJJohnson Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited in Millions Except Per Share Figures) FIRST QUARTER 2024 2023 Percent Percent Percent Increase Amount to Sales Amount to Sales (Dec
Johnson & Johnson reported a solid performance for the first quarter of 2024, with net earnings from continuing operations reaching $3,255 million, a bounce back from a net loss in the same quarter last year. The company achieved earnings per share of $1.34, significantly improving from a loss per share in 2023. Sales to customers also saw an increase of 2.3%, demonstrating continued demand for its products. Adjusted earnings from continuing operations also indicated a strong financial position.
Read more →JNJTesia Williams media-relations its.jnj.com Investor contact Jessica Moore investor-relations its.jnj.com Johnson Johnson Reports Q1 2024 Results 2024 First-Quarter reported sales growth of 2.3% to $21.4 Bil
Johnson & Johnson reported a 2.3% sales growth to $21.4 billion in Q1 2024, with adjusted earnings per share increasing to $2.71, reflecting a 12.4% rise compared to the previous year. The company highlighted a significant operational growth of 3.9%, primarily in the Innovative Medicine and MedTech segments. CEO Joaquin Duato emphasized the progress in their portfolio and pipeline during the quarter. Additionally, several notable regulatory achievements and approvals were announced, reinforcing the company's position in the healthcare sector.
Read more →JNJUnique molecular properties of nipocalimab enabling differentiated potential in treating generalized myasthenia gravis to be presented at American Academy of Neurology's 2024 Annual Meeting Johnson & Johnson today announced the planned presentation of new non-clinical studies underscoring the molecular properties of nipocalimab, an...
Johnson & Johnson announced new non-clinical studies highlighting nipocalimab's unique properties as a monoclonal antibody targeting FcRn, which may improve treatment outcomes for generalized myasthenia gravis (gMG). At the upcoming American Academy of Neurology's Annual Meeting, the company will showcase data demonstrating nipocalimab's ability to rapidly and effectively lower immunoglobulin G levels. The treatment is positioned to address the significant unmet medical need in gMG, a debilitating condition with no current cure. Nipocalimab's various FDA designations signify its potential in treating autoantibody-driven diseases.
Read more →JNJFindings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization Johnson & Johnson announced today a new analysis of data from the PIONEER AF-PCI clinical trial demonstrating that XARELTO® (rivaroxaban) was...
Johnson & Johnson presented new findings at the ACC.24 regarding XARELTO (rivaroxaban) from the PIONEER AF-PCI clinical trial. The analysis indicated that XARELTO is associated with a reduced risk of clinically significant bleeding and net adverse clinical events when compared to warfarin, specifically among elderly and non-elderly patients undergoing percutaneous coronary intervention. These results were derived from a study involving over 2,000 patients and suggest that XARELTO may offer a safer alternative for managing nonvalvular atrial fibrillation in these patients.
Read more →JNJCARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel;...
Johnson & Johnson announced the FDA's approval of CARVYKTI, a BCMA-targeted therapy for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The approval is supported by the positive outcomes from the Phase 3 CARTITUDE-4 study that demonstrated a 59% reduction in disease progression compared to standard therapies. CARVYKTI offers an innovative treatment option that could lead to treatment-free periods for patients. However, it comes with safety concerns, including potential severe side effects.
Read more →JNJJohnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24 Johnson & Johnson announced today that clinical and real-world evidence from its cardiovascular portfolio will be featured at the American College of ...
Johnson & Johnson will present comprehensive clinical and real-world evidence from its cardiovascular portfolio at the ACC.24 conference in Atlanta, focusing on innovative treatments for conditions like atrial fibrillation and peripheral artery disease. The company aims to showcase its commitment to transforming cardiovascular care and improving patient outcomes through advanced therapeutics and technologies. Key presentations will highlight the efficacy of products like XARELTO, alongside data from significant studies involving patient populations that are often difficult to treat. The event represents an opportunity for Johnson & Johnson to collaborate with healthcare professionals, enhancing their understanding of cutting-edge cardiovascular treatments.
Read more →JNJJohnson & Johnson's nipocalimab granted U.S. FDA Fast Track designation to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant adults Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) for nipocalimab to reduce ...
Johnson & Johnson announced that the FDA has granted Fast Track designation for nipocalimab, aimed at reducing the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant individuals. This designation is intended to expedite the development process for nipocalimab, which is currently the only therapy in clinical trials for FNAIT. The drug functions by blocking FcRn to prevent the transfer of harmful antibodies from the mother to the fetus, potentially mitigating serious health risks for newborns.
Read more →JNJU.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH) OPSYNVI® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that ...
The FDA has approved OPSYNVI® (macitentan and tadalafil) as a once-daily single-tablet combination therapy for pulmonary arterial hypertension (PAH). This therapy is indicated for treatment-naïve patients or those already on similar medications. The approval is based on the results from the Phase 3 A DUE study, which demonstrated significant pulmonary hemodynamic improvements. OPSYNVI® aims to streamline treatment regimens, making it easier for patients and aligning with clinical guidelines recommending early combination therapy.
Read more →JNJRYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson's ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer Johnson & Johnson announced today that new data will be featured at this year's European Lung Cancer Congress (ELCC) taking place from March 20 to 23 ...
Johnson & Johnson announced that new data regarding RYBREVANT (amivantamab) will be presented at the European Lung Cancer Congress (ELCC). Highlights include results from the Phase 3 MARIPOSA study, which has received FDA Priority Review, and the Phase 1b PALOMA study. The data aims to illustrate the potential of RYBREVANT-based regimens in improving treatment outcomes for patients with EGFR-mutated non-small cell lung cancer. There are ongoing efforts to submit regulatory applications for various indications of RYBREVANT in both the U.S. and Europe.
Read more →JNJU.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommends CARVYKTI®...
The U.S. FDA Oncologic Drugs Advisory Committee (ODAC) has unanimously recommended CARVYKTI (ciltacabtagene autoleucel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received prior therapy. This recommendation is based on the positive outcomes from the Phase 3 CARTITUDE-4 study, which evaluated the efficacy and safety of CARVYKTI. Johnson & Johnson is awaiting the FDA's decision on the supplemental Biologics License Application, with a PDUFA date set for April 5, 2024. The recommendation signifies a critical advancement in treatment options for this challenging cancer type.
Read more →JNJJohnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration...
Johnson & Johnson has submitted a supplemental Biologics License Application to the U.S. FDA for TREMFYA (guselkumab) aimed at treating adults with moderately to severely active ulcerative colitis. This submission is backed by data from the Phase 3 QUASAR program, demonstrating superior results in clinical remission among patients compared to placebo. TREMFYA has already been recognized for its efficacy in treating other autoimmune conditions but is not yet approved for ulcerative colitis. The company anticipates collaborating with the FDA on the review process.
Read more →JNJNew data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating...
Johnson & Johnson presented positive results from the FRONTIER 2 clinical trial extension, showing the investigational targeted oral peptide JNJ-2113 maintained skin clearance in patients with moderate-to-severe plaque psoriasis over a year. The study demonstrated sustained efficacy from Week 16 to Week 52, and safety profiles were consistent with prior trials. These findings suggest that JNJ-2113 could address the significant unmet need for effective oral therapies in this patient population as the clinical development program continues with further Phase 3 studies underway.
Read more →JNJRYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression ...
Johnson & Johnson's RYBREVANT (amivantamab-vmjw) has received full FDA approval for use in combination with chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations, based on the Phase 3 PAPILLON study. The study demonstrated a significant improvement in patient outcomes, reducing the risk of disease progression or death by 61% compared to chemotherapy alone. The National Comprehensive Cancer Network has updated its guidelines, recommending this regimen as a new standard of care. Despite its advantages, the therapy carries warnings for serious adverse reactions, necessitating careful patient management.
Read more →JNJTECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) ...
Johnson & Johnson announced that the FDA has approved a supplemental Biologics License Application for TECVAYLI (teclistamab-cqyv), allowing for biweekly dosing in eligible patients with relapsed or refractory multiple myeloma who have maintained a complete response for at least six months. This approval enhances dosing flexibility for patients, addressing an unmet need in treatment regimens. TECVAYLI is the first bispecific antibody targeting BCMA and has been prescribed to over 3,600 patients since its initial approval. However, the drug is associated with serious side effects, including Cytokine Release Syndrome, and its continued approval relies on results from ongoing confirmatory trials.
Read more →JNJJohnson & Johnson's nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN) Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for nipocalimab ...
Johnson & Johnson announced that the FDA granted Breakthrough Therapy Designation to nipocalimab for treating high-risk individuals for severe hemolytic disease of the fetus and newborn (HDFN). This designation was based on positive results from the Phase 2 UNITY clinical trial, which showed a significant rate of live births without the need for intrauterine transfusions. Currently, nipocalimab is the only therapy in clinical development for this serious condition, and enrollment for the Phase 3 AZALEA trial is underway. This development is expected to address the substantial unmet need for safe, effective treatments for HDFN.
Read more →JNJJohnson & Johnson Celebrates Innovation in Novel Drug Delivery Systems with 2023 Dr. Paul Janssen Award Johnson & Johnson today announced Robert Langer, Sc.D., of Massachusetts Institute of Technology (MIT) as the winner of the 2023 Dr. Paul Janssen...
Johnson & Johnson has announced that Dr. Robert Langer from MIT is the recipient of the 2023 Dr. Paul Janssen Award for Biomedical Research. Langer is recognized for his innovative work in developing novel drug delivery systems, which hold significant potential across various medical technologies like anticancer therapies and vaccines. He will be honored at a virtual symposium on February 8, 2024, where he will present his research and insights alongside other prominent scientists. The award includes a $200,000 prize and has previously recognized many scientists who have made impactful contributions to medicine.
Read more →JNJInvestigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine Johnson & Johnson today announced publication in the New England Journal of Medicine (NEJM) of the Phase 2b FRONTIER 1 trial results for JNJ-2113.1...
Johnson & Johnson announced positive results from the Phase 2b FRONTIER 1 trial of JNJ-2113, an oral peptide aimed at treating moderate-to-severe plaque psoriasis. The trial demonstrated significant efficacy, with 79% of participants achieving a 75% reduction in the Psoriasis Area and Severity Index score. Additionally, the therapy showed a favorable safety profile, comparable to placebo, with low rates of adverse events. The findings support ongoing development for JNJ-2113 as a potential new treatment option for psoriasis, with Phase 3 studies already underway.
Read more →JNJJohnson & Johnson reports positive topline results for nipocalimab from a Phase 3 pivotal study in generalized myasthenia gravis (gMG) and a Phase 2 study in Sjögren's Disease (SjD) Johnson & Johnson today announced topline results from the pivotal Phase 3 VIVACITY study of nipocalimab in adults living with generalized myasthenia ...
Johnson & Johnson announced positive topline results for nipocalimab from its pivotal Phase 3 VIVACITY study in generalized myasthenia gravis (gMG) and a Phase 2 study in Sjögren's Disease (SjD). The drug demonstrated significant clinical efficacy, meeting primary endpoints in both studies. These results support further development of nipocalimab, which is already under review for several other autoantibody-driven diseases. The company intends to present comprehensive findings at scientific meetings and pursue regulatory discussions for future market entry.
Read more →JNJJohnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration...
Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for DARZALEX FASPRO® in a regimen aimed at newly diagnosed multiple myeloma patients eligible for transplant. The application is backed by data showing a significant reduction in the risk of disease progression or death when combined with existing therapies. If approved, this regimen could offer a promising new treatment option for this vulnerable patient group, highlighting the company’s commitment to advancing cancer therapy.
Read more →JNJJohnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU Johnson & Johnson announced today new clinical and real-world evidence data will be featured in 18 abstracts at this year's ASCO GU Symposium (San...
Johnson & Johnson has announced that it will feature new clinical and real-world evidence data in 18 abstracts at the upcoming ASCO GU Symposium, focusing on advancements in prostate and bladder cancer treatments. Key updates will include the efficacy of ERLEADA (apalutamide) and niraparib in various stages of prostate cancer, as well as updates on innovative targeted releasing systems for bladder cancer. The data presented underscores the company's dedication to redefining treatment paradigms and improving patient outcomes through early intervention and ongoing clinical studies.
Read more →JNJTesia Williams media-relations its.jnj.com Investor contact Jessica Moore investor-relations its.jnj.com Johnson Johnson Reports Q4 and Full-Year 2023 Results 2023 Fourth-Quarter reported sales growth of 7.
Johnson & Johnson reported its Q4 and full-year 2023 financial results, showing a 7.3% increase in Q4 sales to $21.4 billion. The company experienced significant earnings growth, with Q4 EPS rising by 39.3%. For the full year, the reported sales grew to $85.2 billion, although there was a decline in EPS due to a one-time charge. Johnson & Johnson reaffirmed its guidance for 2024, anticipating operational sales growth of 5.0% to 6.0%. The performance was highlighted by strong growth in the Innovative Medicine segment.
Read more →JNJTREMFYA® (guselkumab) Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Color in New Large Phase 3b Study Data illustrates rapid and significant clearance in moderate to severe scalp psoriasis and significant improvement in scalp itch, as well as...
Johnson & Johnson has announced that its drug TREMFYA (guselkumab) shows significant improvement for individuals with moderate to severe scalp psoriasis, especially among people of color. Results from the Phase 3b VISIBLE study indicate improvements in scalp itch and patient-reported outcomes after just 16 weeks of treatment. The study is notable as it is the first of its kind focusing on diverse skin tones, contributing towards better understanding and treatment of scalp psoriasis. The clinical program will also generate over 20,000 clinical images to aid in disease recognition and patient education.
Read more →JNJU.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for BALVERSA®...
The FDA has granted full approval for Johnson & Johnson's BALVERSA (erdafitinib), a targeted therapy for adults with locally advanced or metastatic urothelial carcinoma with FGFR3 genetic alterations. This approval is based on clinical results from the Phase 3 THOR study, which demonstrated a 36% reduction in the risk of death compared to traditional chemotherapy. BALVERSA represents a significant treatment advancement for patients who have limited options after prior systemic therapies. However, it comes with warnings related to ocular disorders and significant side effects, impacting its patient eligibility.
Read more →JNJJohnson & Johnson Submits Supplemental Biologics License Application and New Drug Application to U.S. FDA Seeking Approval of RYBREVANT® (amivantamab-vmjw) Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration...
Johnson & Johnson has submitted a supplemental Biologics License Application (sBLA) and a New Drug Application (NDA) to the U.S. FDA for the approval of RYBREVANT® in combination with lazertinib. This application is based on data from the Phase 3 MARIPOSA study, which indicated improved progression-free survival in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The combination is proposed as a first-line treatment for adult patients with specific EGFR mutations. This marks the third submission from the RYBREVANT clinical program within four months, highlighting the ongoing development and potential advancements in NSCLC treatment.
Read more →JNJDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet therapy regimen shows significant improvement in outcomes for patients with transplant-eligible newly diagnosed multiple myeloma Johnson & Johnson announced today the first data from the Phase 3 PERSEUS study highlighting significant clinical improvement with a DARZALEX FASPRO® ...
Johnson & Johnson unveiled promising results from the Phase 3 PERSEUS study, where the DARZALEX FASPRO-based quadruplet therapy significantly improved outcomes for patients with transplant-eligible newly diagnosed multiple myeloma. The regimen demonstrated a 58% reduced risk of disease progression or death compared to standard treatments and showed higher rates of complete response. Presentation of the data occurred at the recent ASH 2023 conference, with findings published in The New England Journal of Medicine. These results may establish a new standard of care for this patient population, although overall survival data remains preliminary.
Read more →JNJNew Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Johnson & Johnson announced today an analysis from the Phase 1/2 MonumenTAL-1 study of TALVEY™ (talquetamab-tgvs) in patients with relapsed or...
Johnson & Johnson has released new findings from the MonumenTAL-1 study, demonstrating the effectiveness of TALVEY™ (talquetamab-tgvs) in treating patients with relapsed or refractory multiple myeloma (RRMM). The analysis indicates that patients successfully received subsequent treatment options after TALVEY™, including CAR-T therapies and bispecific antibodies. Further results presented at the 2023 ASH Annual Meeting highlighted TALVEY™'s versatility, including promising outcomes in combination with pomalidomide, establishing its potential in various treatment stages for RRMM. Despite some reported adverse events, the overall findings promote TALVEY™ as a significant addition to RRMM therapies.
Read more →JNJTreatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple Myeloma Johnson & Johnson announced today new patient-reported outcomes (PRO) from the Phase 3 CARTITUDE-4 study of CARVYKTI® (ciltacabtagene autoleucel;...
Johnson & Johnson announced promising results from the Phase 3 CARTITUDE-4 study on CARVYKTI (ciltacabtagene autoleucel) for treating relapsed and lenalidomide-refractory multiple myeloma. The patient-reported outcomes indicated significant improvements in health-related quality of life, including reductions in pain, fatigue, and emotional distress. Additionally, CARVYKTI treatment resulted in a median time until worsening symptoms that exceeded standard care regimens. These findings were presented at the 2023 American Society of Hematology Annual Meeting.
Read more →JNJJohnson & Johnson's Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted TAR-200 Breakthrough Therapy Designation (BTD) for the ...
Johnson & Johnson has announced that its investigational product TAR-200 has been granted Breakthrough Therapy Designation by the U.S. FDA for treating high-risk non-muscle-invasive bladder cancer patients who are not candidates for radical cystectomy. This designation was supported by preliminary results from the ongoing Phase 2b SunRISe-1 study, highlighting TAR-200's potential to provide sustained local release of gemcitabine. J&J emphasizes that this therapy offers a novel interventional approach in an area of significant unmet medical need, particularly for patients with limited treatment options.
Read more →JNJaddition, there will be risks and uncertainties related to the ability of the Johnson Johnson family of companies to successfully integrate the products and employees operations and clinical work of Laminar, Inc., as wel
Johnson & Johnson MedTech has successfully acquired Laminar, Inc. for $400 million, along with future milestone payments. This acquisition aims to enhance J&J's product offerings in the treatment of non-valvular atrial fibrillation (AFib) by leveraging Laminar's innovative device designed for left atrial appendage elimination, which received FDA approval for a pivotal study. However, this acquisition is expected to lead to a reduction in adjusted earnings per share for fiscal year 2023, and there are potential risks related to the integration and future performance of Laminar's products.
Read more →JNJDocument Media Contacts Tesia Williams media-relations its.jnj.com Investor Relations Jessica Moore Investor-relations its.jnj.com Johnson Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice Pre
Johnson Johnson announced that Ashley McEvoy will step down from her role as Executive Vice President and Worldwide Chairman of MedTech to pursue other opportunities, effective October 20, 2023. She will support the transition until Q1 2024. Tim Schmid has been appointed as her successor, bringing 30 years of experience within the company, including his recent role as Company Group Chairman of MedTech for the Asia Pacific region. The leadership change highlights Johnson Johnson's focus on maintaining a strong talent base for ongoing business transformation.
Read more →JNJTesia Williams media-relations its.jnj.com Investor contact Jessica Moore investor-relations its.jnj.com JOHNSON JOHNSON REPORTS Q3 2023 RESULTS 2023 Third-Quarter reported sales growth of 6.8% to $21.4 Bil
Johnson & Johnson reported its third-quarter results for 2023, showcasing a sales growth of 6.8% and adjusted earnings per share increasing by 19.3%. The company highlighted significant advances in its Innovative Medicine and MedTech sectors, propelling operational growth. Moreover, J&J acknowledged a substantial one-time gain of approximately $21 billion from discontinued operations related to its Consumer Health business. The company is optimistic and is revising its full-year guidance upwards, reflecting confidence in its future performance.
Read more →JNJApplications Open for Johnson & Johnson's Second Health Equity Innovation Challenge Johnson & Johnson today announced applications for the 2023 - 2024 Health Equity Innovation Challenge are officially open in five U.S. cities:...
Johnson & Johnson has announced the opening of applications for its 2023-2024 Health Equity Innovation Challenge in five major U.S. cities, seeking innovative solutions to health inequities. The competition aims to support local entrepreneurs and organizations with seed funding of up to $75,000. Applications are being accepted until November 6, and a panel of public health experts will evaluate the proposals. The initiative reflects Johnson & Johnson's commitment to closing the racial health gap and enhancing equitable healthcare access in underserved communities.
Read more →JNJJohnson Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation Company expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, a
Johnson & Johnson has updated its financial projections for 2023 following the completion of the Kenvue separation. The company anticipates reported sales growth between 7.0% and 8.0%, alongside adjusted operational earnings per share projected at $10.00 to $10.10. This guidance also incorporates a share count reduction of approximately 191 million shares, which is expected to benefit earnings per share. Johnson & Johnson has maintained its quarterly dividend of $1.19 per share and secured $13.2 billion from Kenvue's IPO and debt offering.
Read more →JNJThe following are certain preliminary results of selected unaudited financial and other information of Johnson Johnson for the fiscal three and six months ended
Johnson & Johnson has released preliminary unaudited financial results for the fiscal periods ending July 2, 2023. The reported sales for Q2 2023 totaled approximately $25.53 billion, reflecting a 6.3% increase compared to Q2 2022. However, these results remain subject to management's final review and adjustments may occur. It's important to note that the preliminary results may not accurately represent actual results, and there are significant declines observed in the six-month net earnings when compared to the previous year.
Read more →JNJ▲ +6.1%on this newsshared move
JOHNSON JOHNSON REPORTS 2023 SECOND-QUARTER RESULTS 2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excludi
Johnson & Johnson reported a robust performance in Q2 2023, achieving a sales growth of 6.3% to $25.5 billion and increasing EPS by 8.9% to $1.96. The company also raised its full-year guidance based on strong operational results, particularly outside the COVID-19 vaccine segment. Significant contributions came from pharmaceutical and MedTech sectors, while consumer health also saw notable growth. Furthermore, J&J announced strategic moves, including the planned separation of Kenvue, to focus on its core pharmaceutical and MedTech innovation.
Read more →JNJJOHNSON JOHNSON REPORTS 2023 FIRST-QUARTER RESULTS 2023 First-Quarter reported sales growth of 5.6% to $24.7 Billion with operational growth of 9.0%* and adjusted operational growth of 7.6%* 2023 First-Quarter basic loss
Johnson & Johnson reported its first-quarter 2023 results, showing a 5.6% increase in sales to $24.7 billion, with adjusted operational growth in multiple segments. Despite a basic loss per share of ($0.03) due to a one-time charge, adjusted EPS rose slightly. The company has also increased its full-year guidance for both adjusted operational sales and earnings. Notably, while certain products saw sales growth, others experienced declines, particularly in the pharmaceutical segment.
Read more →JNJCopies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Neither of LTL M
Johnson & Johnson's subsidiary LTL Management LLC has re-filed for voluntary Chapter 11 bankruptcy protection to resolve cosmetic talc litigation claims. This reorganization plan is supported by more than 60,000 claimants and includes a financial commitment of $8.9 billion over 25 years. The company maintains that its talcum powder products are safe and that these claims lack scientific merit, hoping to resolve litigation efficiently and equitably through this bankruptcy process.
Read more →JNJJOHNSON JOHNSON REPORTS 2022 FOURTH-QUARTER AND FULL YEAR RESULTS 2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs
Johnson & Johnson reported a 4.4% decline in fourth-quarter sales to $23.7 billion, driven mainly by reduced COVID-19 vaccine sales and unfavorable foreign exchange impacts. Despite this decline, the company noted an operational growth of 4.6% excluding the vaccine segment. Additionally, they reported an adjusted EPS increase of 10.3% for the fourth quarter. For 2023, Johnson & Johnson expects adjusted operational sales growth of around 4% and adjusted EPS of $10.50, showing a cautious optimism for growth.
Read more →JNJJohnson & Johnson Completes Acquisition of Abiomed Broadens MedTech Portfolio with World Leading Solutions for Heart Recovery Strengthens Position in High-Growth MedTech Segments
Johnson & Johnson Completes Acquisition of Abiomed Broadens MedTech Portfolio with World Leading Solutions for Heart Recovery Strengthens Position in High-Growth MedTech Segments NEW BRUNSWICK, N.J. December 22, 2022 Johnson & Johnson (NYSE: JNJ), the world s largest, most div
Read more →JNJJohnson & Johnson to Acquire Abiomed Strengthens Johnson & Johnson s MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to Mo
FOR IMMEDIATE RELEASE Johnson & Johnson to Acquire Abiomed Strengthens Johnson & Johnson s MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson
Read more →JNJJOHNSON JOHNSON REPORTS 2022 THIRD-QUARTER RESULTS Reported sales growth of 1.9% to $23.8 Billion with operational growth of 8.1%* and adjusted operational growth of 8.2%* Earnings per share of (EPS) of $1.68 increasing
JOHNSON JOHNSON REPORTS 2022 THIRD-QUARTER RESULTS Reported sales growth of 1.9% to $23.8 Billion with operational growth of 8.1%* and adjusted operational growth of 8.2%* Earnings per share of (EPS) of $1.68 increasing 22.6% and adjusted EPS of $2.55 decreasing by 1.9%* Compa
Read more →JNJBeLatina TV HOST, CELEBRITY DENTIST AND FORMER THE REAL HOUSEWIVES OF MIAMI STAR KARENT SIERRA SHARES HER 3-STEP ROUTINE FOR A HEALTHY SUMMER SMILE! BACKGROUND: This summer, the most essential and attractive accessory you will need is a radiant smile! Karent Sierra, celebrity dentist and star of...
NEW BRUNSWICK, N.J. , July 20, 2022 /PRNewswire/ -- This summer, the most essential and attractive accessory you will need is a radiant smile! Karent Sierra , celebrity dentist and star of The Real Housewives of Miami season two knows firsthand the importance of clean teeth and
Read more →JNJJOHNSON JOHNSON REPORTS 2022 SECOND-QUARTER RESULTS Total sales growth of 3.0% to $24.0 Billion with operational growth of 8.0%* and adjusted operational growth of 8.1%* Earnings per share of $1.80 decreasing 23.4% and a
JOHNSON JOHNSON REPORTS 2022 SECOND-QUARTER RESULTS Total sales growth of 3.0% to $24.0 Billion with operational growth of 8.0%* and adjusted operational growth of 8.1%* Earnings per share of $1.80 decreasing 23.4% and adjusted earnings per share of $2.59 increasing 4.4%* Comp
Read more →JNJJohnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of the new J&J Satellite Center for Global Health Discovery (Satellite Center) ...
The new Satellite Center will work to accelerate discovery research against flaviviruses, including dengue, which impacts 400 million people each year This effort will build on Johnson & Johnson's decade-long legacy and ongoing collaboration with Duke-NUS in early-stage dengue r
Read more →JNJLos principales agentes de cambio locales que abordan las brechas de equidad en la salud en los Estados Unidos ganan el Reto de Innovación en Equidad Sanitaria de Johnson & Johnson Catorce innovadores de Chicago, Detroit, Los Ángeles, Nueva Orleans, Nueva York y Filadelfia recibirán financiamiento inicial por más de un millón de ...
Catorce innovadores de Chicago , Detroit , Los Ángeles, Nueva Orleans, Nueva York y Filadelfia recibirán financiamiento inicial por más de un millón de dólares, tutoría de expertos y otras facilidades para promover soluciones de equidad en la salud NUEVA BRUNSWICK , Nueva Jersey
Read more →JNJTop Local Changemakers Addressing Health Equity Gaps Across the U.S. Named Johnson & Johnson Health Equity Innovation Challenge Awardees After an extensive search for the top changemakers in six key U.S. cities, Johnson & Johnson today announced the 14 awardees of its Health Equity...
Fourteen innovators in Chicago , Detroit , Los Angeles , New Orleans, New York and Philadelphia to receive seed funding from a pool of over $1M , mentorship and more to advance health equity solutions NEW BRUNSWICK, N.J. , June 14, 2022 /PRNewswire/ -- After an extensive search
Read more →JNJJohnson & Johnson Releases 2021 Health for Humanity Report Highlighting Performance on ESG Priorities and Progress Against Public Commitments Johnson & Johnson (NYSE: JNJ) today published its 2021 Health for Humanity Report, which shares progress against its purpose-driven Health for...
NEW BRUNSWICK, N.J. , June 8, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today published its 2021 Health for Humanity Report , which shares progress against its purpose-driven Health for Humanity 2025 Goals and serves as its annual disclosure on environmental, social and
Read more →JNJJohnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort, Rancho Palos...
NEW BRUNSWICK, N.J. , May 12, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Goldman Sachs 43 rd Annual Global Healthcare Conference at the Terranea Resort, Rancho Palos Verdes, CA on Thursday, June 16 th . Jennifer Taubert , Executive Vice President,
Read more →JNJJohnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company Johnson & Johnson (the Company ) (NYSE: JNJ) today announced the appointment of Thibaut Mongon as Chief Executive Officer Designate and Paul Ruh as...
The Company has also appointed Paul Ruh as CFO Designate Mongon and Ruh to Assume New Leadership Roles Upon the Completion of the Planned Separation of the Consumer Health Business Planned Separation Expected to Occur in 2023 NEW BRUNSWICK, N.J. , May 11, 2022 /PRNewswire/ --
Read more →JNJJohnson & Johnson to Participate in the Bernstein 38th Annual Strategic Decisions Conference Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1st, at the New York...
This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com . A webcast replay will be available approximately 48-hrs after the live webcast. SOURCE Johnson & Johnson 21 %
Read more →JNJJohnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR) The new Center is focused on outpacing the rising threat of antimicrobial resistance (AMR) and builds on Johnson & Johnson's longstanding commitment...
The new Center is focused on outpacing the rising threat of antimicrobial resistance (AMR) and builds on Johnson & Johnson's longstanding commitment to tackle this challenge The Satellite Center in Cape Town is the second site to open in Johnson & Johnson's network of research c
Read more →JNJJohnson & Johnson to Participate in the UBS Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the UBS Global Healthcare Conference on Tuesday, May 24th. Mathai Mammen, Executive Vice President, ...
NEW BRUNSWICK, N.J. , April 20, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the UBS Global Healthcare Conference on Tuesday, May 24 th . Mathai Mammen , Executive Vice President, Pharmaceuticals R&D, will represent the Company in a session scheduled at
Read more →JNJJohnson & Johnson Announces Dividend Increase of 6.6% Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 6.6% increase in the quarterly dividend, from $1.06 per...
NEW BRUNSWICK, N.J. , April 19, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a 6.6% increase in the quarterly dividend, from $1.06 per share to $1.13 per share. "In recognition of our 2021 results, strong financial
Read more →JNJJohnson & Johnson Reports Q1 2022 Results Total sales growth of 5.0% to $23.4 Billion with operational growth of 7.7%* and adjusted operational growth of 7.9%* Earnings per share of $1.93...
NEW BRUNSWICK, N.J. , April 19, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced results for first-quarter 2022. "Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson
Read more →JNJJOHNSON JOHNSON REPORTS 2022 FIRST-QUARTER RESULTS Total sales growth of 5.0% to $23.4 Billion with operational growth of 7.7%* and adjusted operational growth of 7.9%* Earnings per share of $1.93 decreasing 16.8% and ad
JOHNSON JOHNSON REPORTS 2022 FIRST-QUARTER RESULTS Total sales growth of 5.0% to $23.4 Billion with operational growth of 7.7%* and adjusted operational growth of 7.9%* Earnings per share of $1.93 decreasing 16.8% and adjusted earnings per share of $2.67 increasing 3.1%* Compa
Read more →JNJJohnson & Johnson to Participate in the BofA Securities 2022 Healthcare Conference NEW BRUNSWICK, N.J., April 7, 2022 Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities 2022 Healthcare Conference at the Encore...
NEW BRUNSWICK, N.J. , April 7, 2022 Johnson & Johnson (NYSE: JNJ ) will participate in the BofA Securities 2022 Healthcare Conference at the Encore Hotel in Las Vegas, Nevada on Wednesday, May 11 th . Ashley McEvoy, Executive Vice President, Worldwide Chairman, MedTech will repre
Read more →JNJJohnson & Johnson to Host Investor Conference Call on First-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 19th to review first-quarter...
NEW BRUNSWICK, N.J. , March 15, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday , April 19 th to review first-quarter results. Joseph J. Wolk , Executive Vice President and Chief Financial Office
Read more →JNJJohnson & Johnson Names Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, to its Board of Directors Johnson & Johnson (NYSE: JNJ) announced today that Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, has been appointed to its...
NEW BRUNSWICK, N.J. , Feb. 15, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today that Darius Adamczyk , Chairman and Chief Executive Officer of Honeywell, has been appointed to its Board of Directors. "I am delighted to welcome Darius to Johnson & Johnson's Boa
Read more →JNJJohnson & Johnson to Participate in the Raymond James 43rd Annual Institutional Investors Conference Johnson & Johnson (NYSE: JNJ) will participate in the Raymond James 43rd Annual Institutional Investors Conference on Tuesday, March 8th. Joseph J....
NEW BRUNSWICK, N.J. , Feb. 9, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Raymond James 43rd Annual Institutional Investors Conference on Tuesday, March 8 th . Joseph J. Wolk, Executive Vice President and Chief Financial Officer, will represent the
Read more →JNJJohnson & Johnson to Participate in the Cowen 42nd Annual Health Care Virtual Conference Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 42nd Annual Health Care Virtual Conference on Monday, March 7th. Mathai Mammen, Executive ...
NEW BRUNSWICK, N.J. , Feb. 7, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Cowen 42 nd Annual Health Care Virtual Conference on Monday, March 7 th . Mathai Mammen , Executive Vice President, Pharmaceuticals R&D will represent the Company in a sessio
Read more →JNJJohnson & Johnson to Participate in Citi's 2022 Virtual Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in Citi's 2022 Virtual Healthcare Conference on Wednesday, February 23rd, Ashley McEvoy, Executive...
NEW BRUNSWICK, N.J. , Jan. 27, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in Citi's 2022 Virtual Healthcare Conference on Wednesday, February 23 rd , Ashley McEvoy , Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company
Read more →JNJJohnson & Johnson Reports Q4 and Full-Year 2021 Results Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. Our 2021 performance reflects continued strength across ...
NEW BRUNSWICK, N.J. , Jan. 25, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced results for fourth-quarter and full year 2021. "Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the
Read more →JNJJOHNSON JOHNSON REPORTS 2021 FOURTH-QUARTER AND FULL YEAR RESULTS 2021 Fourth-Quarter Sales of $24.8 Billion reflecting growth of 10.4%, operational sales growth of 11.6%*, and adjusted operational sales growth of 12.3%*
JOHNSON JOHNSON REPORTS 2021 FOURTH-QUARTER AND FULL YEAR RESULTS 2021 Fourth-Quarter Sales of $24.8 Billion reflecting growth of 10.4%, operational sales growth of 11.6%*, and adjusted operational sales growth of 12.3%* 2021 Full-Year Sales of $93.8 Billion reflecting growth o
Read more →JNJReal World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States Johnson & Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the...
NEW BRUNSWICK, N.J. , Jan. 6, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson & Johnson COVID
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for First Quarter 2022 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2022 of $1.06 per...
NEW BRUNSWICK, N.J. , Jan. 4, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2022 of $1.06 per share on the company's common stock. The dividend is payable on March 8, 2022 to s
Read more →JNJJohnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant Johnson & Johnson (NYSE: JNJ) (the Company) today announced new preliminary results from the South African Phase 3b Sisonke study which showed that a ...
NEW BRUNSWICK, N.J. , Dec. 30, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced new preliminary results from the South African Phase 3b Sisonke study which showed that a homologous (same vaccine) booster shot of the Johnson & Johnson COVID-19 vacc
Read more →JNJJohnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
CHMP recommendation based on data showing a booster (second shot) of the Johnson & Johnson COVID-19 vaccine increased protection to 75 percent against symptomatic COVID-19 infection globally Data also demonstrated 100 percent protection against severe COVID-19, at least 14 days
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 25th to review fourth-quarter ...
NEW BRUNSWICK, N.J. , Dec. 10, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday , January 25 th to review fourth-quarter results. Joaquin Duato , incoming Chief Executive Officer, Joseph J. Wolk ,
Read more →JNJJohnson & Johnson Appoints Senior Leaders to Executive Committee Johnson & Johnson (NYSE: JNJ) (the Company) today announced the appointment of several senior leaders to the Company's Executive Committee....
NEW BRUNSWICK, N.J. , Dec. 9, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced the appointment of several senior leaders to the Company's Executive Committee. Separately, the Company announced that Mr. Michael Sneed , Executive Vice President, Glo
Read more →JNJWorld Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster Johnson & Johnson (NYSE: JNJ) (the Company) today announced the interim recommendation by the Strategic Advisory Group of Experts on Immunization...
NEW BRUNSWICK, N.J. , Dec. 9, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced the interim recommendation by the Strategic Advisory Group of Experts on Immunization (SAGE) for the World Health Organization (WHO) supporting the use of the Johnson &
Read more →JNJJohnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses Johnson & Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from...
NEW BRUNSWICK, N.J. , Dec. 5, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch , M.D., Ph.D., et a
Read more →JNJJohnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and Consumers, and Unlock Value through Intent to Separate Consumer Health Business Johnson & Johnson (the Company ) (NYSE: JNJ) today announced its intent to separate the Company's Consumer Health business, creating a new publicly...
NEW BRUNSWICK, N.J. , Nov. 12, 2021 /PRNewswire/ -- Johnson & Johnson (the "Company") (NYSE: JNJ ) today announced its intent to separate the Company's Consumer Health business, creating a new publicly traded company. The planned separation would create two global leaders that ar
Read more →JNJJohnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for the World's Most Vulnerable People through Novel Humanitarian Buffer Johnson & Johnson (NYSE: JNJ) (the Company) has entered into an agreement with the U.S. Government and Gavi, the Vaccine Alliance (Gavi), to enable...
NEW BRUNSWICK, N.J. , Nov. 10, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) has entered into an agreement with the U.S. Government and Gavi, the Vaccine Alliance (Gavi), to enable access to its single-shot COVID-19 vaccine through a novel mechanism – the COVA
Read more →JNJJohnson & Johnson Endows Research!America Outstanding Achievement in Public Health Awards Johnson & Johnson (NYSE: JNJ) today announced that it has provided a $5MM endowment to Research!America to create an annual award to recognize...
NEW BRUNSWICK, N.J. , Nov. 9, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that it has provided a $5MM endowment to Research!America to create an annual award to recognize individuals and organizations working to make a profound difference in public health.
Read more →JNJU.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines Johnson & Johnson (the Company) (NYSE: JNJ) today announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on...
NEW BRUNSWICK, N.J. , Oct. 21, 2021 /PRNewswire/ -- Johnson & Johnson (the Company) (NYSE: JNJ ) today announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), has recommended its COVID-19 vaccine as a booster f
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2021 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2021 of $1.06 per...
NEW BRUNSWICK, N.J. , Oct. 21, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2021 of $1.06 per share on the company's common stock. The dividend is payable on December 7, 2021
Read more →JNJJohnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA)...
NEW BRUNSWICK, N.J. , Oct. 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 1
Read more →JNJJohnson & Johnson Reports Q3 2021 Results Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021. Our third-quarter results demonstrate solid performance across Johnson ...
NEW BRUNSWICK, N.J. , Oct. 19, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced results for third-quarter 2021. "Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing
Read more →JNJJOHNSON JOHNSON REPORTS 2021 THIRD-QUARTER RESULTS Total sales growth of 10.7% to $23.3 Billion with operational growth of 9.9%* and adjusted operational growth of 10.6%* Earnings per share of $1.37 increasing 3.0% and a
JOHNSON JOHNSON REPORTS 2021 THIRD-QUARTER RESULTS Total sales growth of 10.7% to $23.3 Billion with operational growth of 9.9%* and adjusted operational growth of 10.6%* Earnings per share of $1.37 increasing 3.0% and adjusted earnings per share of $2.60 increasing 18.2%* Com
Read more →JNJJohnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products...
NEW BRUNSWICK, N.J. , Oct. 15, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Au
Read more →JNJJohnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims Johnson & Johnson (NYSE: JNJ) (the Company) today announced that LTL Management LLC (LTL), a newly created and separate subsidiary of Johnson &...
NEW BRUNSWICK, N.J. , Oct. 14, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced that LTL Management LLC (LTL), a newly created and separate subsidiary of Johnson & Johnson, that was established to hold and manage claims in the cosmetic talc litiga
Read more →JNJJohnson & Johnson to Host Business Review Highlighting Pharmaceuticals Johnson & Johnson (NYSE: JNJ) will hold a Business Review for the investment community on Thursday, November 18, 2021, in which company leaders will...
NEW BRUNSWICK, N.J. , Oct. 13, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will hold a Business Review for the investment community on Thursday, November 18, 2021 , in which company leaders will share a detailed review of its Pharmaceuticals business, differentiated strat
Read more →JNJDr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson To Retire, Effective December 31, 2021 Johnson & Johnson (NYSE: JNJ) today announced that Paul Stoffels M.D., currently Vice Chairman of the Executive Committee and Chief Scientific...
NEW BRUNSWICK, N.J. , Oct. 12, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that Paul Stoffels M.D ., currently Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson, will retire from the Company effective December 31, 2
Read more →JNJJohnson & Johnson Announces Jessica Moore as Vice President of Investor Relations Johnson & Johnson (NYSE: JNJ) today announced the appointment of Jessica Moore to Vice President of Investor Relations for Johnson & Johnson,...
NEW BRUNSWICK, N.J. , Oct. 12, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the appointment of Jessica Moore to Vice President of Investor Relations for Johnson & Johnson, effective November 1, 2021 . Ms. Moore will report to Mr. Joseph Wolk , Executive Vic
Read more →JNJJohnson & Johnson to Participate in the Credit Suisse 30th Annual Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate virtually in the Credit Suisse 30th Annual Healthcare Conference on Wednesday, November 10th. Ashley...
NEW BRUNSWICK, N.J. , Oct. 11, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate virtually in the Credit Suisse 30th Annual Healthcare Conference on Wednesday, November 10 th. Ashley McEvoy , Executive Vice President, Worldwide Chairman, Medical Devices will re
Read more →JNJJanssen Announces Novel Mechanism of Action that Shows Promise Against Dengue in Data Published in Nature The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today, in collaboration with the KU Leuven Rega Institute and the KU...
BEERSE, Belgium , Oct. 6, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today, in collaboration with the KU Leuven Rega Institute and the KU Leuven Centre for Drug Design and Discovery (CD3), the publication of new preclinical
Read more →JNJJohnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine Johnson & Johnson (NYSE: JNJ) (the Company) announced it has submitted data to the U.S. Food and Drug Administration (FDA) to support use of a...
NEW BRUNSWICK, N.J. , Oct. 5, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) announced it has submitted data to the U.S. Food and Drug Administration (FDA) to support use of a booster shot of the Johnson & Johnson COVID-19 vaccine in individuals 18 years of age
Read more →JNJJohnson & Johnson Celebrates COVID-19 Vaccine Science Superheroes Johnson & Johnson (NYSE: JNJ) today announced Katalin Karikó, Ph.D. of BioNTech Pharmaceuticals and the University of Pennsylvania and Drew Weissman, ...
NEW BRUNSWICK, N.J. , Sept. 28, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced Katalin Karikó, Ph.D. of BioNTech Pharmaceuticals and the University of Pennsylvania and Drew Weissman , M.D., Ph.D., of the University of Pennsylvania as winners of the 2021 Dr. P
Read more →JNJJohnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S. Johnson & Johnson (NYSE: JNJ) (the Company) today announced new data reinforcing the strong and long-lasting protection of its COVID-19 vaccine. New...
NEW BRUNSWICK, N.J. , Sept. 21, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced new data reinforcing the strong and long-lasting protection of its COVID-19 vaccine. New data also showed that protection against COVID-19 increases when a booster sh
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Third-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 19th to review third-quarter...
NEW BRUNSWICK, N.J. , Sept. 16, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday , October 19 th to review third-quarter results. Joseph J. Wolk , Executive Vice President and Chief Financial Offi
Read more →JNJJohnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (the Company) (NYSE: JNJ) Ebola vaccine...
NEW BRUNSWICK, N.J. , Sept. 13, 2021 /PRNewswire/ -- Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (the Company) (NYSE: JNJ ) Ebola vaccine regimen, Zabdeno ® (Ad26.ZEBOV) and Mvabea ® (MVA-BN-Filo), generated robust humo
Read more →JNJJohnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa Johnson & Johnson (NYSE: JNJ), together with a consortium of global partners, today announced results from the primary analysis of a Phase 2b HIV...
NEW BRUNSWICK, N.J. , Aug. 31, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ), together with a consortium of global partners, today announced results from the primary analysis of a Phase 2b HIV vaccine clinical trial known as the Imbokodo study (also known as HVTN 705 /HPX20
Read more →JNJJohnson & Johnson Seeks Global Nominees for Award Geared at Female Researchers Working in Science, Technology, Engineering, Math, Manufacturing and Design Johnson & Johnson (NYSE: JNJ) today announced it is accepting applications for its 2022 Women in STEM2D (WiSTEM2D) Scholars Award. The award, which...
NEW BRUNSWICK, N.J. , Aug. 26, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced it is accepting applications for its 2022 Women in STEM 2 D (WiSTEM 2 D) Scholars Award. The award, which aims to support assistant or associate academic professors in the disciplin
Read more →JNJJohnson & Johnson to Participate in the Cantor Virtual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Cantor Virtual Global Healthcare Conference on Tuesday, September 28th. Mathai Mammen, Global...
NEW BRUNSWICK, N.J. , Aug. 26, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Cantor Virtual Global Healthcare Conference on Tuesday, September 28 th . Mathai Mammen, Global Head, Research & Development Janssen Research Development and Scott White , C
Read more →JNJJohnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine Johnson & Johnson (NYSE: JNJ) (the Company) today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously...
NEW BRUNSWICK, N.J. , Aug. 25, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine. In July, the Compan
Read more →JNJAlex Gorsky to Serve as Executive Chairman and Transition Role of Chief Executive Officer of Johnson Johnson to Joaquin Duato, Effective
Alex Gorsky to Serve as Executive Chairman and Transition Role of Chief Executive Officer of Johnson Johnson to Joaquin Duato, Effective January 3, 2022 New Brunswick, N.J. (August 19, 2021) - Johnson Johnson (NYSE JNJ) today announced that Mr. Alex Gorsky, currently Chairman an
Read more →JNJJohnson & Johnson to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, September 15th. Joseph J. ...
NEW BRUNSWICK, N.J. , Aug. 12, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, September 15 th . Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Mathai Mamme
Read more →JNJJohnson & Johnson to Participate in Barclays Global Consumer Staples Virtual Conference Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Virtual Conference on Friday, September 10th. Thibaut Mongon,...
NEW BRUNSWICK, N.J. , Aug. 9, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Barclays Global Consumer Staples Virtual Conference on Friday, September 10 th . Thibaut Mongon , Executive Vice President Worldwide Chairman, Consumer Health will represent
Read more →JNJJohnson & Johnson to Participate in the Virtual Wells Fargo Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Virtual Wells Fargo Healthcare Conference on Friday, September 10th. Joaquin Duato, Vice...
NEW BRUNSWICK, N.J. , July 27, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Virtual Wells Fargo Healthcare Conference on Friday, September 10 th . Joaquin Duato, Vice Chairman of the Executive Committee will represent the Company in a session schedu
Read more →JNJJOHNSON JOHNSON REPORTS 2021 SECOND-QUARTER RESULTS Strong sales growth of 27.1% to $23.3 Billion in Second Quarter 2021 with operational growth of 23.0%* and adjusted operational growth of 23.8%* EPS of $2.35 increased
JOHNSON JOHNSON REPORTS 2021 SECOND-QUARTER RESULTS Strong sales growth of 27.1% to $23.3 Billion in Second Quarter 2021 with operational growth of 23.0%* and adjusted operational growth of 23.8%* EPS of $2.35 increased 72.8% in Second Quarter 2021 and adjusted EPS of $2.48 inc
Read more →JNJJohnson & Johnson Reports Q2 2021 Results Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. Our second-quarter results showcase Johnson & Johnson's diversified...
NEW BRUNSWICK, N.J. , July 21, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced results for second-quarter. "Our second-quarter results showcase Johnson & Johnson's diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Con
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2021 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2021 of $1.06 per...
NEW BRUNSWICK, N.J. , July 19, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2021 of $1.06 per share on the company's common stock. The dividend is payable on September 7, 2021
Read more →JNJJohnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA® and AVEENO® Aerosol Sunscreen Products Due to the Presence of Benzene Johnson & Johnson Consumer Inc. (JJCI) (NYSE: JNJ) is voluntarily recalling all lots of five NEUTROGENA® and AVEENO® aerosol sunscreen product lines...
NEW BRUNSWICK, N.J. , July 14, 2021 /PRNewswire/ -- Johnson & Johnson Consumer Inc. (JJCI) (NYSE: JNJ ) is voluntarily recalling all lots of five NEUTROGENA ® and AVEENO ® aerosol sunscreen product lines to the consumer level. Internal testing identified low levels of benzene in
Read more →JNJPositive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent...
NEW BRUNSWICK, N.J. , July 1, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SAR
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 21st to review second-quarter...
NEW BRUNSWICK, N.J. , June 9, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday , July 21 st to review second-quarter results. Joseph J. Wolk , Executive Vice President and Chief Financial Office
Read more →JNJJohnson & Johnson Releases 2020 Health for Humanity Report Highlighting Performance and Progress on Environmental, Social and Governance Priorities Johnson & Johnson (NYSE: JNJ) today published the 2020 Health for Humanity Report (Report), which serves as the Company's annual disclosure on...
NEW BRUNSWICK, N.J. , June 9, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today published the 2020 Health for Humanity Report (Report), which serves as the Company's annual disclosure on environmental, social and governance (ESG) performance and illustrates progress towar
Read more →JNJJohnson & Johnson to Host Live ESG Investor Update Webcast Johnson & Johnson (NYSE: JNJ) announced today it will host an Environmental, Social and Governance (ESG) Investor Update Webcast at 8:00 a.m....
NEW BRUNSWICK, N.J. , May 24, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today it will host an Environmental, Social and Governance (ESG) Investor Update Webcast at 8:00 a.m. (Eastern Time) on June 23, 2021 . The webcast will discuss progress made in advancing
Read more →JNJJohnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa Johnson & Johnson (NYSE: JNJ) (the Company) today announced the World Health Organization (WHO) and the government of Sierra Leone have begun...
NEW BRUNSWICK, N.J. , May 13, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced the World Health Organization (WHO) and the government of Sierra Leone have begun administering the Company's Ebola vaccine regimen as part of a WHO early access clinic
Read more →JNJJohnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision Johnson & Johnson (NYSE: JNJ) (the Company) today announced that vaccinations with the Company's COVID-19 single-shot vaccine will resume for all...
"As the global pandemic continues to devastate communities around the world, we believe a single-shot, easily transportable COVID-19 vaccine with demonstrated protection against multiple variants can help protect the health and safety of people everywhere. We will collaborate wit
Read more →JNJJohnson & Johnson Consumer Health Presents New Data on Skincare for Cancer Patients at the American Academy of Dermatology VMX 2021 Johnson & Johnson Consumer Health today presented findings from one of the first clinical studies examining a daily skincare regimen as adjunctive...
SKILLMAN, N.J. , April 23, 2021 /PRNewswire/ -- Johnson & Johnson Consumer Health today presented findings from one of the first clinical studies examining a daily skincare regimen as adjunctive therapy for cancer patients at the American Academy of Dermatology (AAD) Virtual Meet
Read more →JNJJohnson & Johnson Consumer Health Reveals New Skin Health Research at American Academy of Dermatology VMX 2021 Johnson & Johnson Consumer Health will present new research including among the first of its kind study on restorative skincare for cancer patients,...
SKILLMAN, N.J. , April 23, 2021 /PRNewswire/ -- Johnson & Johnson Consumer Health will present new research including among the first of its kind study on restorative skincare for cancer patients, new advances in multicultural skincare, the emotional impact of acne, and more to t
Read more →JNJJOHNSON JOHNSON REPORTS 2021 FIRST-QUARTER RESULTS 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%* 2021 First Quarter EPS o
JOHNSON JOHNSON REPORTS 2021 FIRST-QUARTER RESULTS 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%* 2021 First Quarter EPS of $2.32 increased 6.9% adjusted EPS of $2.59 increased 12.
Read more →JNJJohnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) Review Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee...
NEW BRUNSWICK, N.J. , April 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has provided updated guidance for use of the Company's COVID-19 vaccine
Read more →JNJJohnson & Johnson Announces Dividend Increase of 5.0% Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 5.0% increase in the quarterly dividend, from $1.01 per...
NEW BRUNSWICK, N.J. , April 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a 5.0% increase in the quarterly dividend, from $1.01 per share to $1.06 per share. "Despite a year of unprecedented disruption, Johnson &
Read more →JNJJohnson & Johnson annonce un accord d'achat anticipé avec l'African Vaccine Acquisition Trust pour le vaccin candidat COVID-19 de la société Janssen Pharmaceutica NV, l'une des sociétés pharmaceutiques Janssen de Johnson & Johnson (NYSE : JNJ) (la Société), a conclu un accord avec...
Jusqu'à 400 millions de doses du vaccin candidat à injection unique de la société seront mises à la disposition des États membres de l'Union africaine La disponibilité du vaccin est soumise à l'approbation des autorités nationales Les données ont démontré que le candidat vaccin
Read more →JNJJohnson & Johnson anuncia un acuerdo de compra anticipado con el African Vaccine Acquisition Trust, el fideicomiso para la adquisición de vacunas para África, de la vacuna candidata contra la COVID-19 de la empresa Janssen Pharmaceutica NV, una de las empresas farmacéuticas Janssen de Johnson & Johnson (NYSE: JNJ) (la Empresa), ha concertado un acuerdo con el...
NUEVA BRUNSWICK , New Jersey , 30 de marzo de 2021 /PRNewswire/ -- Janssen Pharmaceutica NV, una de las empresas farmacéuticas Janssen de Johnson & Johnson (NYSE: JNJ ) (la Empresa), ha concertado un acuerdo con el African Vaccine Acquisition Trust (AVAT), el fideicomiso para la
Read more →JNJJohnson & Johnson anuncia acordo de compra antecipada com o Fundo Africano de Aquisição de Vacinas para a candidata à vacina contra a COVID-19 da empresa A Janssen Pharmaceutica NV, uma das empresas farmacêuticas Janssen da Johnson & Johnson (NYSE: JNJ) (a empresa), firmou um acordo com o Fundo...
NEW BRUNSWICK , Nova Jersey , 29 de março de 2021 /PRNewswire/ -- A Janssen Pharmaceutica NV, uma das empresas farmacêuticas Janssen da Johnson & Johnson (NYSE: JNJ ) (a empresa), firmou um acordo com o Fundo Africano de Aquisição de Vacinas (AVAT) para disponibilizar até 220 mil
Read more →JNJJohnson & Johnson gibt Vorab-Kaufvertrag mit dem African Vaccine Acquisition Trust für den COVID-19 Impfstoffkandidaten des Unternehmens bekannt Janssen Pharmaceutica NV, eine der Janssen Pharmaceutical Companies von Johnson & Johnson (NYSE: JNJ) (das Unternehmen), hat eine Vereinbarung mit...
Bis zu 400 Millionen Dosen des Single-Shot-Impfstoffkandidaten des Unternehmens werden den Mitgliedsstaaten der Afrikanischen Union zur Verfügung gestellt Die Verfügbarkeit des Impfstoffs hängt von den nationalen behördlichen Genehmigungen ab Die Daten haben gezeigt, dass der I
Read more →JNJJohnson& Johnson anuncia un acuerdo de compra para la vacuna candidata de COVID-19 de la empresa - Johnson & Johnson anuncia un acuerdo de compra anticipada con el African Vaccine Acquisition Trust para la vacuna candidata de COVID-19 de la...
- Johnson & Johnson anuncia un acuerdo de compra anticipada con el African Vaccine Acquisition Trust para la vacuna candidata de COVID-19 de la empresa Hasta 400 millones de dosis de la vacuna candidata de una sola inyección de la Compañía se pondrán a disposición de los estados
Read more →JNJJohnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 Vaccine Candidate Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement...
Up to 400 million doses of the Company's single-shot vaccine candidate will be made available to African Union member states Availability of the vaccine is subject to national regulatory approvals Data have demonstrated vaccine candidate protects against COVID-19 related hospit
Read more →JNJJohnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its...
NEW BRUNSWICK, N.J. , March 12, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companie
Read more →JNJJohnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S. Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on...
NEW BRUNSWICK, N.J. , Feb. 28, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vac
Read more →JNJJohnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization...
NEW BRUNSWICK, N.J. , Feb. 27, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceut
Read more →JNJJohnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological...
NEW BRUNSWICK, N.J. , Feb. 26, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Au
Read more →JNJJohnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the...
NEW BRUNSWICK, N.J. , Feb. 19, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-
Read more →JNJJohnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug...
NEW BRUNSWICK, N.J. , Feb. 4, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigati
Read more →JNJJohnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating...
NEW BRUNSWICK, N.J. , Jan. 29, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Ja
Read more →JNJJOHNSON JOHNSON REPORTS 2020 FOURTH-QUARTER AND FULL YEAR RESULTS 2020 Fourth-Quarter Sales of $22.5 Billion reflecting growth of 8.3%, operational growth of 7.1%* and adjusted operational growth of 7.3%* 2020 Full-Year
JOHNSON JOHNSON REPORTS 2020 FOURTH-QUARTER AND FULL YEAR RESULTS 2020 Fourth-Quarter Sales of $22.5 Billion reflecting growth of 8.3%, operational growth of 7.1%* and adjusted operational growth of 7.3%* 2020 Full-Year Sales of $82.6 Billion reflecting growth of 0.6%, operatio
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for First Quarter 2021 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2021 of $1.01 per...
NEW BRUNSWICK, N.J. , Jan. 4, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2021 of $1.01 per share on the company's common stock. The dividend is payable on March 9, 2021 to s
Read more →JNJPress Contact Kim Montagnino (631) 375-8779 kmontag its.jnj.com Investor Contact Christopher DelOrefice (732)524-2955 cdelorefice its.jnj.com For Immediate Release Johnson Johnson Names Dr. Nadja West, retired United Sta
Press Contact Kim Montagnino (631) 375-8779 kmontag its.jnj.com Investor Contact Christopher DelOrefice (732)524-2955 cdelorefice its.jnj.com Johnson Johnson Names Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General to its
Read more →JNJJohnson & Johnson Names Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General to its Board of Directors Johnson & Johnson (NYSE: JNJ) announced today that Dr. Nadja West, retired United States Army lieutenant general and former United States Army...
NEW BRUNSWICK, N.J. , Dec. 3, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today that Dr. Nadja West , retired United States Army lieutenant general and former United States Army Surgeon General has been appointed to its Board of Directors. "I am pleased to welc
Read more →JNJJohnson & Johnson Announces Fireside Chat Webcast on Janssen's Eye Disease Portfolio The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new pre-recorded fireside chat webcast focused on the company's eye...
NEW BRUNSWICK, N.J. , Dec. 3, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new pre-recorded fireside chat webcast focused on the company's eye disease portfolio. Hosted by Cowen, the webcast is intended for investors and other i
Read more →JNJNew Survey Finds Critical Need for Education on Cataracts and Modern Treatment Options Today, Johnson & Johnson Vision* announced findings from a new survey** that assessed awareness of cataracts among adults around the world. Cataracts ...
SANTA ANA, Calif. , Dec. 1, 2020 /PRNewswire/ -- Today, Johnson & Johnson Vision* announced findings from a new survey** that assessed awareness of cataracts among adults around the world. Cataracts are the leading cause of blindness globally, 1 with more than 90% of people devel
Read more →JNJJohnson & Johnson to Address Racial and Social Injustice Through Platform that Aims to Eliminate Health Inequities for People of Color Johnson & Johnson (NYSE: JNJ) announced today $100 million in commitments and collaborations over the next five years to invest in and promote health ...
NEW BRUNSWICK, N.J. , Nov. 17, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today $100 million in commitments and collaborations over the next five years to invest in and promote health equity solutions for Black people and other communities of color in the Unite
Read more →JNJJohnson & Johnson and U.S. Department of Health & Human Services Expand Agreement to Support Next Phase of COVID-19 Vaccine Candidate Research and Development Johnson & Johnson (NYSE: JNJ) (the Company) announced the expansion to the partnership between its Janssen Pharmaceutical Companies (Janssen) and the ...
NEW BRUNSWICK, N.J. , Nov. 14, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) announced the expansion to the partnership between its Janssen Pharmaceutical Companies (Janssen) and the Biomedical Advanced Research and Development Authority (BARDA), which is part
Read more →JNJJohnson & Johnson to Host Virtual Medical Devices Update Johnson & Johnson (NYSE: JNJ) will hold a virtual Medical Devices Update for the investment community on Thursday, November 19, 2020, in which...
NEW BRUNSWICK, N.J. , Nov. 6, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will hold a virtual Medical Devices Update for the investment community on Thursday, November 19, 2020 , in which leadership will focus on the Company's differentiated and competitive platforms acro
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2020 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2020 of $1.01 per...
NEW BRUNSWICK, N.J. , Oct. 22, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2020 of $1.01 per share on the company's common stock. The dividend is payable on December 8, 2020
Read more →JNJJOHNSON JOHNSON REPORTS 2020 THIRD-QUARTER RESULTS Sales of $21.1 billion reflecting an overall and operational increase of 1.7%*, and adjusted operational increase of 2.0%* despite the estimated negative impact of the C
JOHNSON JOHNSON REPORTS 2020 THIRD-QUARTER RESULTS Sales of $21.1 billion reflecting an overall and operational increase of 1.7%*, and adjusted operational increase of 2.0%* despite the estimated negative impact of the COVID-19 pandemic EPS of $1.33 increased 101.5% adjusted EP
Read more →JNJA Johnson & Johnson anuncia a aprovação pela Comissão Europeia do contrato para fornecer 200 milhões de doses da candidata à vacina da Janssen para a COVID-19 A Johnson & Johnson (NYSE: JNJ) (a Empresa) anunciou hoje que a Comissão Europeia (CE), em nome dos Estados-membros da União Europeia (UE), aprovou...
NEW BRUNSWICK, N.J., 10 de outubro de 2020 /PRNewswire/ -- A Johnson & Johnson (NYSE: JNJ ) (a Empresa) anunciou hoje que a Comissão Europeia (CE), em nome dos Estados-membros da União Europeia (UE), aprovou um contrato de compra antecipada no qual as empresas farmacêuticas Janss
Read more →JNJJohnson & Johnson annonce que la Commission européenne a approuvé un accord visant à fournir 200 millions de doses du vaccin-candidat contre la COVID-19 de Janssen Johnson & Johnson (NYSE: JNJ) (la Société) a annoncé aujourd'hui que la Commission européenne (CE), agissant au nom des États membres de l'Union...
L'accord offre aux États membres de l'Union européenne l'option d'obtenir jusqu'à 200 millions de doses supplémentaires pour un total de 400 millions de doses NEW BRUNSWICK, New Jersey, 9 octobre 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (la Société) a annoncé aujourd'
Read more →JNJJohnson & Johnson gibt die Zustimmung der Europäischen Kommission zu Vertrag über die Lieferung von 200 Millionen Dosen des COVID-19-Impfstoffkandidaten von Janssen bekannt Johnson & Johnson (NYSE: JNJ) (das Unternehmen) gab heute bekannt, dass die Europäische Kommission (EK), die im Namen der Mitgliedstaaten der...
Vertrag bietet Option für Mitgliedstaaten der Europäischen Union bis zu 200 Millionen zusätzliche Dosen für insgesamt bis zu 400 Millionen Dosen zu sichern NEW BRUNSWICK, New Jersey , 9. Oktober 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (das Unternehmen) gab heute beka
Read more →JNJJohnson & Johnson anuncia aprobación por parte de la Comisión Europea del acuerdo para proveer 200 millones de dosis de la candidata para vacuna contra la COVID-19 de Janssen Johnson & Johnson (NYSE: JNJ) (la compañía) anunció hoy que la Comisión Europea (CE), actuando en nombre de los estados miembros de la Unión Europea...
NEW BRUNSWICK, Nueva Jersey, 9 de octubre de 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (la compañía) anunció hoy que la Comisión Europea (CE), actuando en nombre de los estados miembros de la Unión Europea (UE), aprobó un acuerdo de compra anticipada en el que las Compa
Read more →JNJJohnson & Johnson suministrará 200 millones de dosis del candidato a vacuna de COVID-19 de Janssen Johnson & Johnson (NYSE: JNJ) (la Compañía) ha anunciado hoy que la Comisión Europea (CE), actuando el nombre de los Estados miembro de la Unión...
- Johnson & Johnson anuncia la aprobación de la Comisión Europea del acuerdo para suministrar 200 millones de dosis del candidato a vacuna de COVID-19 de Janssen El acuerdo ofrece la opción de los Estados miembro de la Unión Europea de asegurar 200 millones de dosis adicionales
Read more →JNJJohnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen's COVID-19 Vaccine Candidate Johnson & Johnson (NYSE: JNJ) (the Company) today announced the European Commission (EC), acting on behalf of the European Union (EU) Member States,...
Agreement provides option for European Union Member States to secure up to 200 million additional doses for a total of up to 400 million doses NEW BRUNSWICK, N.J., Oct. 8, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced the European Commission (
Read more →JNJJohnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc. Johnson & Johnson (NYSE: JNJ) today announced it has successfully completed its acquisition of Momenta Pharmaceuticals, Inc. ( Momenta ), a company...
NEW BRUNSWICK, N.J. , Oct. 1, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced it has successfully completed its acquisition of Momenta Pharmaceuticals, Inc. ("Momenta"), a company that discovers and develops novel therapies for immune-mediated diseases, in an
Read more →JNJJohnson & Johnson inicia el ensayo clínico de fase 3 de la candidata a la vacuna contra la COVID-19 de Janssen a nivel global Johnson & Johnson (NYSE: JNJ) (la Empresa) anunció hoy el lanzamiento de su ensayo de fase 3 (ENSEMBLE) pivotal, a gran escala y para múltiples...
Los primeros participantes reciben la dosis en el ensayo de fase 3 (ENSEMBLE) que evalúa la seguridad y eficacia de la candidata a la vacuna contra la COVID-19 de Janssen, JNJ-78436735, también conocida como Ad26.COV2.S NEW BRUNSWICK , Nueva Jersey , 24 de septiembre de 2020 /PR
Read more →JNJA Johnson & Johnson inicia a Fase 3 do principal estudo clínico global da candidata à vacina contra a COVID-19 da Janssen Johnson & Johnson (NYSE: JNJ) (a empresa) anunciou hoje o lançamento da Fase 3 do seu estudo clínico em grande escala, fundamental e multinacional (o ...
Os primeiros participantes já receberam a dose na Fase 3 do estudo (ENSEMBLE) que avalia a segurança e eficácia da candidata à vacina contra a COVID-19 da Janssen, a JNJ-78436735, também conhecida como Ad26.COV2.S NEW BRUNSWICK , Nova Jersey , 24 de setembro de 2020 /PRNewswire/
Read more →JNJJohnson & Johnson entreprend un essai clinique pivot de phase 3 du vaccin-candidat contre la COVID-19 de Janssen à l'échelle mondiale Johnson & Johnson (NYSE: JNJ) (la Société) a annoncé aujourd'hui le lancement de l'essai pivot de phase 3 à grande échelle (ENSEMBLE), dans plusieurs ...
Les premiers participants à l'essai de phase 3 (ENSEMBLE) ont évalué l'innocuité et l'efficacité du vaccin-candidat contre la COVID-19 de Janssen, JNJ-78436735, aussi appelé Ad26.COV2.S. NEW BRUNSWICK, New Jersey, 24 septembre 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ )
Read more →JNJJohnson & Johnson startet globale Phase 3-Zulassungsstudie für Janssens COVID-19-Impfstoffkandidaten Johnson & Johnson (NYSE: JNJ) (das Unternehmen) gab heute den Start seiner groß angelegten, internationalen Phase 3-Zulassungsstudie (ENSEMBLE) für...
Ersten Teilnehmern der Phase 3-Studie (ENSEMBLE) zur Bewertung der Sicherheit und Wirksamkeit von Janssens COVID-19-Impfstoffkandidaten JNJ-78436735, auch unter der Bezeichnung Ad26.COV2.S bekannt, Dosierung verabreicht NEW BRUNSWICK, New Jersey , 24. Sept. 2020 /PRNewswire/ --
Read more →JNJJohnson & Johnson inicia el ensayo clínico en Fase 3 del candidato de vacuna para la COVID-19 de Janssen Johnson & Johnson (NYSE: JNJ) (la compañía) anunció hoy el lanzamiento de su ensayo pivote en Fase 3 a gran escala para múltiples países (ENSEMBLE)...
- Johnson & Johnson inicia el ensayo clínico pivote mundial en Fase 3 del candidato de vacuna para la COVID-19 de Janssen Los primeros participantes reciben la dosis del ensayo en Fase 3 (ENSEMBLE) que evalúa la eficacia y seguridad del candidato de vacuna de la COVID-19 de Jans
Read more →JNJJohnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its...
First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen's COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S NEW BRUNSWICK, N.J. , Sept. 23, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced
Read more →JNJCall for Award Applicants: Johnson & Johnson Seeks Female Researchers Working in Science, Technology, Engineering, Math, Manufacturing and Design Johnson & Johnson today announced that it is accepting applications for its 2021 Women in STEM2D (WiSTEM2D) Scholars Award, aimed at supporting...
NEW BRUNSWICK, N.J. , Sept. 14, 2020 /PRNewswire/ -- Johnson & Johnson today announced that it is accepting applications for its 2021 Women in STEM 2 D (WiSTEM 2 D) Scholars Award, aimed at supporting assistant or associate academic professors in the disciplines of Science, Techn
Read more →JNJJohnson & Johnson Celebrates Role of Scientists In Society with 2020 Dr. Paul Janssen Award for Biomedical Research, Part of the Champions of Science® Initiative Johnson & Johnson (NYSE: JNJ) today announced Lewis Cantley, Ph.D., of Weill Cornell Medicine and NewYork-Presbyterian as the winner of the 2020 Dr....
NEW BRUNSWICK, N.J. , Aug. 20, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced Lewis Cantley , Ph.D., of Weill Cornell Medicine and NewYork-Presbyterian as the winner of the 2020 Dr. Paul Janssen Award for Biomedical Research for his incisive research revealin
Read more →JNJJohnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company ...
NEW BRUNSWICK, N.J. , Aug. 19, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in
Read more →JNJJohnson & Johnson gibt Vereinbarung mit der US-Regierung für 100 Millionen Dosen eines COVID-19-Impfstoffkandidaten bekannt Johnson & Johnson (NYSE: JNJ) (nachfolgend „das Unternehmen ) verkündete heute, dass ihre Janssen Pharmaceutical Companies eine Vereinbarung mit der...
Unternehmen will umfassenden weltweiten Zugang zum COVID-19-Impfstoffkandidaten im Anschluss an die Zulassung durch die Aufsichtsbehörden sicherstellen NEW BRUNSWICK, New Jersey, 6. August 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (nachfolgend „das Unternehmen") verkün
Read more →JNJJohnson & Johnson annonce un accord avec le gouvernement des États-Unis pour 100 millions de doses du vaccin expérimental contre la COVID-19 Johnson & Johnson (NYSE : JNJ) (la société) a annoncé aujourd'hui que ses sociétés pharmaceutiques Janssen ont conclu un accord avec le gouvernement...
L'entreprise œuvre pour garantir un large accès mondial au candidat vaccin contre la COVID-19, après l'approbation des organismes de réglementation NEW BRUNSWICK, New Jersey , 6 août 2020 /PRNewswire/ -- Johnson & Johnson (NYSE : JNJ ) (la société) a annoncé aujourd'hui que ses
Read more →JNJJohnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S....
Company working to ensure broad global access to COVID-19 vaccine candidate, following approval from regulators NEW BRUNSWICK, N.J., Aug. 5, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into a
Read more →JNJJohnson & Johnson anuncia acuerdo con el gobierno de los Estados Unidos para 100 millones de dosis de la vacuna experimental para el covid-19 Johnson & Johnson (NYSE: JNJ) (la Compañía ) anunció hoy que las Janssen Pharmaceutical Companies han firmado un acuerdo con el gobierno de los...
La compañía busca asegurar amplio acceso global a la vacuna candidata para el covid-19 después de la aprobación de los reguladores NUEVO BRUNSWICK , Nueva Jersey , 5 de agosto de 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (la "Compañía") anunció hoy que las Janssen Phar
Read more →JNJJohnson & Johnson anuncia contrato com o governo dos EUA para fornecer 100 milhões de doses da vacina investigacional para COVID-19 A Johnson & Johnson (NYSE: JNJ) (a empresa) anunciou hoje que a Janssen Pharmaceutical Companies firmou um contrato com o governo dos EUA para a...
NOVA BRUNSWICK, Nova Jersey, 5 de agosto de 2020 /PRNewswire/ -- A Johnson & Johnson (NYSE: JNJ ) (a empresa) anunciou hoje que a Janssen Pharmaceutical Companies firmou um contrato com o governo dos EUA para a fabricação doméstica em grande escala e fornecimento nos EUA de 100 m
Read more →JNJJohnson& Johnson anuncia un acuerdo con el Gobierno de Estados Unidos Johnson & Johnson (NYSE: JNJ) (la compañía) anunció hoy que Janssen Pharmaceutical Companies ha llegado a un acuerdo con el Gobierno de Estados...
- Johnson & Johnson anuncia un acuerdo con el Gobierno de Estados Unidos para 100 millones de dosis de la vacuna investigacional de la COVID-19 La compañía está trabajando para asegurar un amplio acceso mundial al candidato de la vacuna de la COVID-19, tras las aprobaciones norm
Read more →JNJDose única de candidata a vacina da Johnson & Johnson contra COVID-19 demonstra proteção robusta em estudos pré-clínicos A Johnson & Johnson (NYSE: JNJ) (a Empresa) anunciou hoje que a sua principal candidata a vacina protegeu contra infecção pelo SARS-CoV-2, o vírus...
NEW BRUNSWICK , Nova Jersey , 30 de julho de 2020 /PRNewswire/ -- A Johnson & Johnson (NYSE: JNJ ) (a Empresa) anunciou hoje que a sua principal candidata a vacina protegeu contra infecção pelo SARS-CoV-2, o vírus que causa a COVID-19, em estudos pré-clínicos. Os dados, publicado
Read more →JNJBuenos resultados del candidato a vacuna COVID-19 de Johnson & Johnson Johnson & Johnson (NYSE: JNJ) (la Compañía) anunció hoy su candidato principal a la vacuna protegido contra la infección por SARS-CoV-2, el virus que ...
- La dosis única del candidato a la vacuna COVID-19 de Johnson & Johnson demuestra una protección sólida en los estudios preclínicos El estudio publicado en Nature muestra que la vacuna investigacional SARS-CoV-2 de J&J provoca una fuerte respuesta inmunitaria que protege contra
Read more →JNJLa vacuna candidata de una sola dosis contra el COVID-19 de Johnson & Johnson brinda una contundente protección en estudios preclínicos Johnson & Johnson (NYSE: JNJ) (en adelante, la Compañía) anunció hoy que, en estudios preclínicos, su principal candidata a vacuna mostró proteger de ...
NEW BRUNSWICK , Nueva Jersey , 30 de julio de 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (en adelante, la Compañía) anunció hoy que, en estudios preclínicos, su principal candidata a vacuna mostró proteger de la infección con SARS-CoV-2, el virus causante de la COVID-19.
Read more →JNJEinzeldosis des COVID-19-Impfstoffkandidaten von Johnson & Johnson zeigt in präklinischen Studien zuverlässigen Schutz Johnson & Johnson (NYSE: JNJ) (das Unternehmen) gab heute bekannt, dass sein führender Impfstoffkandidat in präklinischen Studien vor einer Infektion ...
In Journal Nature veröffentlichte Studie zeigt, dass der von J&J entwickelte SARS-CoV-2-Impfstoff eine starke Immunantwort auslöst, die vor einer Infektion schützt Erste klinische Phase-1/2a-Studie am Menschen läuft jetzt in den USA und Belgien; Beginn der klinischen Studie der
Read more →JNJUne dose unique du candidat-vaccin de Johnson & Johnson démontre un fort degré de protection contre la COVID-19 dans le cadre d'études précliniques Johnson & Johnson (NYSE : JNJ) (la Société) a annoncé aujourd'hui que son principal candidat-vaccin protège contre une infection par le SRAS-CoV-2,...
Une étude publiée dans la revue Nature montre que le vaccin expérimental de J&J contre le SARS-CoV-2 déclenche une forte réponse immunitaire qui protège contre une infection ultérieure Le premier essai clinique de phase 1/2a chez l'homme est en cours aux États-Unis et en Belgiqu
Read more →JNJSingle Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus...
NEW BRUNSWICK, N.J. , July 30, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature , s
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2020 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2020 of $1.01 per...
NEW BRUNSWICK, N.J. , July 20, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2020 of $1.01 per share on the company's common stock. The dividend is payable on September 8, 2020
Read more →JNJJOHNSON JOHNSON REPORTS 2020 SECOND-QUARTER RESULTS Sales of $18.3 billion reflecting a decline of 10.8%, operational decline of 9.0%* and adjusted operational decline of 8.8%*, primarily driven by the negative impact of
JOHNSON JOHNSON REPORTS 2020 SECOND-QUARTER RESULTS Sales of $18.3 billion reflecting a decline of 10.8%, operational decline of 9.0%* and adjusted operational decline of 8.8%*, primarily driven by the negative impact of the COVID-19 pandemic EPS of $1.36 decreased 34.6% adjust
Read more →JNJStop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries The Stop TB Partnership and Johnson & Johnson (NYSE: JNJ) – with support from the Global Fund to Fight AIDS, TB and Malaria, and the U.S. Agency for...
GENEVA , July 6, 2020 /PRNewswire/ -- The Stop TB Partnership and Johnson & Johnson (NYSE: JNJ ) – with support from the Global Fund to Fight AIDS, TB and Malaria, and the U.S. Agency for International Development (USAID) – today announced joint efforts to help enable low- and mi
Read more →JNJJohnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the...
NEW BRUNSWICK, N.J. , June 10, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SA
Read more →JNJJohnson & Johnson to Host Annual Health for Humanity Investor Webcast Johnson & Johnson (NYSE: JNJ), the world's largest and most broadly-based healthcare company, announced today it will host a Health for Humanity...
NEW BRUNSWICK, N.J. , June 4, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ), the world's largest and most broadly-based healthcare company, announced today it will host a Health for Humanity investor webcast at 8:00 a.m. Eastern Time on June 18, 2020 . The webcast will high
Read more →JNJJohnson & Johnson to Participate in the Goldman Sachs 41st Annual Global Virtual Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 41st Annual Global Virtual Healthcare Conference on Tuesday, June 10. Jennifer...
NEW BRUNSWICK, N.J. , May 28, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Goldman Sachs 41st Annual Global Virtual Healthcare Conference on Tuesday, June 10 . Jennifer Taubert, Executive Vice President, Worldwide Chairman Pharmaceuticals will repre
Read more →JNJJohnson & Johnson to Provide Webcast Fireside Chat on Clinical Data to be Presented at the American Society of Clinical Oncology and the Janssen Oncology Strategy and Portfolio The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) will participate in a pre-recorded fireside chat webcast hosted by Cantor...
NEW BRUNSWICK, N.J. , May 18, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ ) will participate in a pre-recorded fireside chat webcast hosted by Cantor Fitzgerald focused on clinical data being presented at the virtual 2020 American Soc
Read more →JNJFederal Judge Excludes Certain Plaintiff Expert Testimony from Talc Ovarian Cancer Trials, Deeming Them Not Scientifically Sound Johnson & Johnson ( the Company ) (NYSE: JNJ) today announced that U.S. District Judge Freda L. Wolfson, chief judge of the District of New Jersey,...
NEW BRUNSWICK, N.J. , April 27, 2020 /PRNewswire/ -- Johnson & Johnson ("the Company") (NYSE: JNJ ) today announced that U.S. District Judge Freda L. Wolfson , chief judge of the District of New Jersey , who is presiding over the federal multidistrict litigation (MDL) involving c
Read more →JNJJohnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company's Goal to Supply More Than One Billion Vaccine Doses Globally Johnson & Johnson (the Company) (NYSE: JNJ) today announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and...
NEW BRUNSWICK, N.J. , April 23, 2020 /PRNewswire/ -- Johnson & Johnson (the Company) (NYSE: JNJ ) today announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to support the manufacturing of its lead investigati
Read more →JNJJOHNSON & JOHNSON REPORTS 2020 FIRST-QUARTER RESULTS: Sales of $20.7 Billion reflecting strong growth of 3.3%, operational growth of 4.8%* and adjusted operational growth of 5.6%*, inclusive of the overall estimated nega
JOHNSON & JOHNSON REPORTS 2020 FIRST-QUARTER RESULTS: New Brunswick, N.J. (April 14, 2020) - Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarter
Read more →JNJJohnson & Johnson Announces Dividend Increase of 6.3% Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 6.3% increase in the quarterly dividend rate, from $0.95 per ...
NEW BRUNSWICK, N.J. , April 14, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. "In recognition of our 2019 results, strong finan
Read more →JNJJohnson & Johnson Postpones 2020 Medical Devices Business Review Due to the Coronavirus Johnson & Johnson (NYSE: JNJ) today announced that, in light of the evolving situation with the coronavirus outbreak (COVID-19), it will reschedule...
NEW BRUNSWICK, N.J. , April 1, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that, in light of the evolving situation with the coronavirus outbreak (COVID-19), it will reschedule its 2020 Medical Devices Business Review that was planned to take place on May
Read more →JNJJohnson & Johnson to Host Virtual Annual Meeting of Shareholders Johnson & Johnson (NYSE: JNJ) today announced that the 2020 Annual Meeting of Shareholders will now be conducted exclusively online by remote...
The meeting will be held at 10:00 a.m. Eastern Time on April 23, 2020 and will be conducted in a virtual format only. Shareholders will not be able to attend the 2020 annual meeting in person, however shareholders of record as of the close of business on February 25, 2020 will be
Read more →JNJJohnson & Johnson gibt potenziellen Wirkstoffkandidaten für COVID-19-Impfung bekannt; neue, wegweisende Partnerschaft mit dem US-Ministerium für Gesundheitspflege und Soziale Dienste; geplante weltweite Lieferung von einer Milliarde Impfungen für den Notfalleinsatz im Rahmen der Pandemie Johnson & Johnson und die „Biomedical Advanced Research and Development Authority (BARDA) investieren gemeinsam mehr als 1 Milliarde US-Dollar in...
Johnson & Johnson und die „Biomedical Advanced Research and Development Authority" (BARDA) investieren gemeinsam mehr als 1 Milliarde US-Dollar in die Erforschung und Entwicklung eines neuen Coronavirus-Impfstoffes; das Unternehmen geht davon aus, spätestens im September 2020 kli
Read more →JNJJohnson & Johnson anuncia un candidato vacunal líder para el COVID-19 - Johnson & Johnson anuncia un candidato vacunal líder para el COVID-19; nueva asociación sin precedentes con el Departamento de Salud y Servicios...
- Johnson & Johnson anuncia un candidato vacunal líder para el COVID-19; nueva asociación sin precedentes con el Departamento de Salud y Servicios Humanos de EE. UU.; y compromiso para suministrar mil millones de vacunas en todo el mundo para el uso de emergencia durante la pande
Read more →JNJJohnson & Johnson annonce un candidat-vaccin principal contre la COVID-19, un nouveau partenariat historique avec le ministère de la Santé et des Services sociaux des États-Unis, ainsi qu'un engagement à fournir un milliard de vaccins à travers le monde pour une utilisation d'urgence pandémique Johnson & Johnson et la BARDA investissent ensemble plus d'un milliard de dollars dans la recherche et le développement d'un nouveau vaccin contre le ...
Johnson & Johnson et la BARDA investissent ensemble plus d'un milliard de dollars dans la recherche et le développement d'un nouveau vaccin contre le coronavirus ; l'entreprise prévoit de lancer la phase 1 des études cliniques sur l'homme d'un candidat-vaccin au plus tard en sept
Read more →JNJA Johnson & Johnson anuncia possível principal vacina para o COVID-19; histórica parceria com o Departamento de Saúde e Serviços Humanos dos EUA; e compromisso de fornecer um bilhão de vacinas mundialmente para uso em casos de pandemia A Johnson & Johnson (NYSE: JNJ) (a empresa) anunciou hoje a seleção de uma possível principal vacina contra a COVID-19 a partir de construções nas...
NEW BRUNSWICK , Nova Jersey , 30 de março de 2020 /PRNewswire/ -- A Johnson & Johnson (NYSE: JNJ ) (a empresa) anunciou hoje a seleção de uma possível principal vacina contra a COVID-19 a partir de construções nas quais vem trabalhando desde janeiro de 2020: a ampliação significa
Read more →JNJJohnson & Johnson anuncia una vacuna experimental inicial para la COVID-19, una nueva colaboración histórica con el Departamento de Salud y Servicios Humanos de los EE. UU. y su compromiso para suministrar mil millones de vacunas en todo el mundo para uso de emergencia ante la pandemia Johnson & Johnson (NYSE: JNJ) (la empresa) anunció hoy la selección de una vacuna experimental inicial contra la COVID-19 a partir de preparados en...
NEW BRUNSWICK , Nueva Jersey , 30 de marzo de 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) (la empresa) anunció hoy la selección de una vacuna experimental inicial contra la COVID-19 a partir de preparados en los que trabaja desde enero de 2020; la importante expansión de
Read more →JNJJohnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use Johnson & Johnson (NYSE: JNJ) (the Company) today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on ...
Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020 Johnson & Johnson Will Establish New U.S. Vaccine M
Read more →JNJJohnson & Johnson to Host Investor Conference Call on First-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter...
NEW BRUNSWICK, N.J. , March 17, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday , April 14 th to review first-quarter results. Joseph J. Wolk , Executive Vice President, Chief Financial Officer a
Read more →JNJJohnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess...
NEW BRUNSWICK, N.J. , March 13, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center (BIDMC) to support the development of a preventive vaccine cand
Read more →JNJJohnson & Johnson to Participate in Barclays Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Healthcare Conference on Wednesday, March 11th, at the Loews Miami Beach Hotel, ...
NEW BRUNSWICK, N.J. , Feb. 26, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Barclays Global Healthcare Conference on Wednesday, March 11 th , at the Loews Miami Beach Hotel, Miami Beach , FL. Ciro Romer , Company Group Chairman, Medical Devices Nort
Read more →JNJJohnson & Johnson Launches Heartline™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke Johnson & Johnson (NYSE: JNJ) today announced that the Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Apple, opened...
NEW BRUNSWICK, N.J. , Feb. 25, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that the Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Apple, opened enrollment for the Heartline Study . The study is designed to explore if the Hear
Read more →JNJJohnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 Treatments Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies will expand its existing partnership with the Biomedical...
NEW BRUNSWICK, N.J. , Feb. 18, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Janssen Pharmaceutical Companies will expand its existing partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Ass
Read more →JNJJohnson & Johnson to Participate in the 9th Annual SVB Leerink Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, Feb. 26th, at Lotte New York...
NEW BRUNSWICK, N.J. , Feb. 12, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 9 th Annual SVB Leerink Global Healthcare Conference on Wednesday, Feb. 26 th , at Lotte New York Palace, NY. Ashley McEvoy , Executive Vice President, Worldwide Chairman, M
Read more →JNJJohnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies will further expedite its investigational coronavirus vaccine ...
NEW BRUNSWICK, N.J. , Feb. 11, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Janssen Pharmaceutical Companies will further expedite its investigational coronavirus vaccine program through an expanded collaboration with the Biomedical Advanced Resear
Read more →JNJJohnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat Johnson & Johnson (NYSE: JNJ) today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged...
NEW BRUNSWICK, N.J. , Jan. 29, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) ou
Read more →JNJJOHNSON & JOHNSON REPORTS 2019 FOURTH-QUARTER AND FULL YEAR RESULTS: 2019 Fourth-Quarter Sales of $20.7 Billion reflecting growth of 1.7%, operational growth of 2.6%* and adjusted operational growth of 3.4%* 2019 Full-Ye
JOHNSON & JOHNSON REPORTS 2019 FOURTH-QUARTER AND FULL YEAR RESULTS: New Brunswick, N.J. (January 22, 2020) - Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2019. "We delivered strong underlying sales and earnings growth in 2019, driven by
Read more →JNJDr. Paul Janssen Award for Biomedical Research Issues 2020 Call for Nominations to Celebrate Champions of Science Nominations are now being accepted for the 2020 Dr. Paul Janssen Award for Biomedical Research. This prestigious award celebrates dedicated...
NEW BRUNSWICK, N.J. , Jan. 6, 2020 /PRNewswire/ -- Nominations are now being accepted for the 2020 Dr. Paul Janssen Award for Biomedical Research. This prestigious award celebrates dedicated researchers and champions of science whose basic or clinical discoveries have made, or ha
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for First Quarter 2020 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2020 of $0.95 per...
NEW BRUNSWICK, N.J., Jan. 2, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2020 of $0.95 per share on the company's common stock. The dividend is payable on March 10, 2020 to s
Read more →JNJKellie McLaughlin Mobile: (609) 468-8356 Investor contacts: Lesley Fishman Chris DelOrefice Office: (732) 524-3922 Office: (732) 524-2955 Janssen Announces Completion of Acquisition of Investigational Ber
Media contacts: Kellie McLaughlin Mobile: (609) 468-8356 Investor contacts: Lesley Fishman Chris DelOrefice Office: (732) 524-3922 Office: (732) 524-2955 Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc. HORSHAM, PA - December 30,
Read more →JNJJohnson & Johnson Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer Johnson & Johnson announced today the acquisition of TARIS Biomedical LLC (TARIS), a privately-owned biotechnology company specializing in the...
NEW BRUNSWICK, N.J. , Dec. 20, 2019 /PRNewswire/ -- Johnson & Johnson announced today the acquisition of TARIS Biomedical LLC (TARIS), a privately-owned biotechnology company specializing in the development of a novel drug delivery technology for the treatment of bladder diseases
Read more →JNJJohnson & Johnson Announces Agreement to Acquire Remaining Stake in Verb Surgical Inc. Dedicated to shaping the next frontier of surgery, Johnson & Johnsoni (NYSE: JNJ) today announced an agreement to acquire the remaining stake in Verb ...
NEW BRUNSWICK, N.J. , Dec. 20, 2019 /PRNewswire/ -- Dedicated to shaping the next frontier of surgery, Johnson & Johnson i (NYSE: JNJ ) today announced an agreement to acquire the remaining stake in Verb Surgical Inc. following a successful strategic collaboration with Verily , a
Read more →JNJJohnson & Johnson to Participate in 38th Annual JP Morgan Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 38th Annual JP Morgan Health Care Conference on Monday, January 13, at the Westin St. Francis...
NEW BRUNSWICK, N.J. , Dec. 19, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 38 th Annual JP Morgan Health Care Conference on Monday, January 13 , at the Westin St. Francis in San Francisco. Ashley McEvoy , Executive Vice President, Worldwide Chairma
Read more →JNJTrês brasileiros vencem desafio latino-americano de histórias de ciência promovido pela Johnson & Johnson A Johnson & Johnson premiou três brasileiros entre os cinco ganhadores do Champions of Science Storytelling Challenge. O anúncio foi feito pela...
SÃO PAULO, 17 de dezembro de 2019 /PRNewswire/ -- A Johnson & Johnson premiou três brasileiros entre os cinco ganhadores do Champions of Science Storytelling Challenge . O anúncio foi feito pela companhia durante a Reunião Regional da UNESCO , que comemorou os 70 anos da entidade
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review...
NEW BRUNSWICK, N.J. , Dec. 10, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday , January 22 nd to review fourth-quarter results. Alex Gorsky , Chairman and Chief Executive Officer; Joseph J. Wo
Read more →JNJJohnson & Johnson Announces Commitment to Support Republic of Rwanda's Preparedness Against Ebola Outbreak Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies will provide up to 200,000 Ebola vaccine regimens to the...
NEW BRUNSWICK, N.J. , Dec. 8, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Janssen Pharmaceutical Companies will provide up to 200,000 Ebola vaccine regimens to the Republic of Rwanda . This commitment will support a new immunization program led by
Read more →JNJJohnson & Johnson Names Hubert Joly, Executive Chairman of Best Buy and Mark A. Weinberger, Former EY Global Chairman and CEO to its Board of Directors Johnson & Johnson (NYSE: JNJ) announced today that Hubert Joly, Executive Chairman of Best Buy Co., Inc, and Mark A. Weinberger, Former EY Global...
NEW BRUNSWICK, N.J. , Dec. 5, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today that Hubert Joly , Executive Chairman of Best Buy Co., Inc, and Mark A. Weinberger , Former EY Global Chairman and CEO, have been appointed to its Board of Directors. "I am very ple
Read more →JNJPress Contacts: Ernie Knewitz Cristal Downing (732) 524-1090 (732) 524-3283 media-relations@its.jnj.com cdowning@its.jnj.com Investor Contacts: Christopher DelOrefice Lesley Fishman (732) 524-2955 (732) 524-3922 CDelorf@
Press Contacts: Ernie Knewitz Cristal Downing (732) 524-1090 (732) 524-3283 media-relations@its.jnj.com cdowning@its.jnj.com Investor Contacts: Christopher DelOrefice Lesley Fishman (732) 524-2955 (732) 524-3922 CDelorf@its.jnj.com LFishma@its.jnj.com Johnson & Johnson Names
Read more →JNJJohnson & Johnson Announces Donation of up to 500,000 Regimens of Janssen's Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC) The government of the Democratic Republic of the Congo (DRC) has decided to use the investigational Ebola vaccine regimen currently being developed...
NEW BRUNSWICK, N.J. , Oct. 31, 2019 /PRNewswire/ -- The government of the Democratic Republic of the Congo (DRC) has decided to use the investigational Ebola vaccine regimen currently being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson as part of an expan
Read more →JNJJohnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) THIRD QUARTER 2019 2018 Percent Percent Percent Increase Amount to Sales Amount to Sales (
Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) THIRD QUARTER 2019 2018 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customer
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2019 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2019 of $0.95 per...
NEW BRUNSWICK, N.J. , Oct. 17, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2019 of $0.95 per share on the company's common stock. The dividend is payable on December 10, 201
Read more →JNJJOHNSON & JOHNSON REPORTS 2019 THIRD-QUARTER RESULTS: Sales of $20.7 billion reflecting growth of 1.9%, operational growth of 3.2%* and adjusted operational growth of 5.2%* EPS of $1.81 increased 25.7%; adjusted EPS of $
JOHNSON & JOHNSON REPORTS 2019 THIRD-QUARTER RESULTS: New Brunswick, N.J. (October 15, 2019) - Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2019. "Our third-quarter results represent strong performance, driven by competitive underlying growth in Pharma
Read more →JNJJohnson & Johnson lança desafio de inovação para startups Startups da área de saúde de toda a América Latina poderão inscrever seus projetos no Latin America Innovation Challenge 2019 da Johnson & Johnson...
SÃO PAULO, 10 de outubro de 2019 /PRNewswire/ -- Startups da área de saúde de toda a América Latina poderão inscrever seus projetos no Latin America Innovation Challenge 2019 da Johnson & Johnson Innovation. O vencedor do desafio receberá mentoria de especialistas da J&J para ace
Read more →JNJJohnson & Johnson Releases Inaugural You Belong: Diversity & Inclusion Impact Review Johnson & Johnson (NYSE: JNJ), the world's largest and most broadly-based healthcare company, today published You Belong: Diversity & Inclusion...
NEW BRUNSWICK, N.J. , Oct. 7, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ), the world's largest and most broadly-based healthcare company, today published You Belong: Diversity & Inclusion Impact Review (Impact Review), which demonstrates how a strategic Diversity & Inclus
Read more →JNJJohnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis Johnson & Johnson (NYSE: JNJ) today announced it has committed to ensuring more than $500 million is dedicated to world class research & development...
NEW BRUNSWICK, N.J. , Oct. 4, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery programs over the next four years to accelerate global efforts to
Read more →JNJJohnson & Johnson Reaches Settlement Agreement with Two Ohio Counties Ahead of Upcoming Opioid Trial Johnson & Johnson (NYSE: JNJ) and its Janssen Pharmaceutical Companies today announced a settlement agreement with the Ohio counties of Cuyahoga and...
NEW BRUNSWICK, N.J. , Oct. 1, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) and its Janssen Pharmaceutical Companies today announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties' claims with no admission of liability
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Third Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 15th to review third-quarter...
NEW BRUNSWICK, N.J. , Sept. 18, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday , October 15 th to review third-quarter results. Joseph J. Wolk , Executive Vice President, Chief Financial Officer
Read more →JNJJohnson & Johnson annonce les six lauréats du Champions of Science Africa Innovation Challenge 2.0 au 28ème Forum économique mondial sur l'Afrique - Attribution de 300 000 USD, création d'un réseau étendu de mentorat et de liens appuyant l'expansion et la durabilité des entreprises et des...
- Attribution de 300 000 USD , création d'un réseau étendu de mentorat et de liens appuyant l'expansion et la durabilité des entreprises et des programmes - Un investissement significatif dans des domaines de soins de santé critiques – livraison de sang, burnout des professionne
Read more →JNJJohnson & Johnson to Participate in the 2019 Morgan Stanley 17th Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2019 Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10th, at The ...
NEW BRUNSWICK, N.J. , Aug. 29, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2019 Morgan Stanley 17 th Annual Global Healthcare Conference on Tuesday, September 10 th , at The Grand Hyatt Hotel in New York. Peter F. Lebowitz , M.D., Ph.D. Global Ther
Read more →JNJJohnson & Johnson To Appeal Flawed Opioid Judgment in Oklahoma Company did not cause opioid crisis; neither facts nor law support this outcome Company confident it has strong grounds for appeal
Johnson & Johnson To Appeal Flawed Opioid Judgment in Oklahoma Company did not cause opioid crisis; neither facts nor law support this outcome Company confident it has strong grounds for appeal NEW BRUNSWICK, NJ - August 26, 2019: Johnson & Johnson (NYSE: JNJ) and its Janssen
Read more →JNJJohnson & Johnson to Participate in Barclays Global Consumer Staples Conference Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Conference on Thursday, September 5th, at the...
NEW BRUNSWICK, N.J. , Aug. 8, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Barclays Global Consumer Staples Conference on Thursday, September 5 th , at the InterContinental, Boston , MA. Thibault Mongon , Executive Vice President, Worldwide Chairman
Read more →JNJJohnson & Johnson to Participate in the Wells Fargo Securities 2019 Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the 14th Annual Wells Fargo Securities Healthcare Conference on Thursday, September 5th, at The...
NEW BRUNSWICK, N.J. , Aug. 8, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 14 th Annual Wells Fargo Securities Healthcare Conference on Thursday, September 5 th , at The Westin Copley Place in Boston, MA. Ashley McEvoy, Executive Vice President, Wor
Read more →JNJJOHNSON & JOHNSON REPORTS 2019 SECOND-QUARTER RESULTS: Sales of $20.6 billion reflecting a decline of 1.3%, operational growth of 1.6%* and adjusted operational growth of 3.7%* EPS of $2.08 increased 43.4%; adjusted EPS
JOHNSON & JOHNSON REPORTS 2019 SECOND-QUARTER RESULTS: New Brunswick, N.J. (July 16, 2019) - Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2019. "We delivered solid second-quarter underlying sales growth and strong earnings growth that enables us to ma
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2019 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2019 of $0.95 per...
NEW BRUNSWICK, N.J., July 15, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2019 of $0.95 per share on the company's common stock. The dividend is payable on September 10, 2019
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 16th, to review second-quarter...
NEW BRUNSWICK, N.J. , June 18, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday , July 16 th , to review second-quarter results. Joseph J. Wolk , Executive Vice President, Chief Financial Officer
Read more →JNJRelatório da Johnson & Johnson revela avanços na 'Saúde para a Humanidade' A Johnson & Johnson apresenta seu relatório anual de sustentabilidade 'Saúde para a Humanidade', detalhando os avanços alcançados em 2018. O material ...
SÃO PAULO, 18 de junho de 2019 /PRNewswire/ -- A Johnson & Johnson apresenta seu relatório anual de sustentabilidade 'Saúde para a Humanidade ', detalhando os avanços alcançados em 2018. O material conta como a empresa utiliza o tamanho e alcance do seu negócio para promover mais
Read more →JNJJohnson & Johnson Releases 2018 Health for Humanity Report Johnson & Johnson (NYSE: JNJ), the world's largest and most broadly-based healthcare company, today released its 2018 Health for Humanity Report...
NEW BRUNSWICK, N.J. , June 5, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ), the world's largest and most broadly-based healthcare company, today released its 2018 Health for Humanity Report detailing the Company's progress in its environmental, social and governance (ESG)
Read more →JNJJohnson & Johnson Celebrates Scientists Across Generations and Geographies with 2019 Dr. Paul Janssen Award for Biomedical Research and Champions of Science® Storytelling Challenge Johnson & Johnson today named Franz-Ulrich Hartl, M.D. of the Max Planck Institute of Biochemistry and Arthur Horwich, M.D., of Yale School of...
PHILADELPHIA , June 3, 2019 /PRNewswire/ -- Johnson & Johnson today named Franz-Ulrich Hartl , M.D. of the Max Planck Institute of Biochemistry and Arthur Horwich , M.D. , of Yale School of Medicine and Howard Hughes Medical Institute as winners of the 2019 Dr. Paul Janssen Award
Read more →JNJJohnson & Johnson to Participate in Bernstein's 35th Annual Strategic Decisions Conference Johnson & Johnson (NYSE: JNJ) will participate in Bernstein's 35th Annual Strategic Decisions Conference on Thursday, May 30, at the Grand Hyatt, New ...
This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com . A webcast replay will be available approximately two hours after the live webcast. SOURCE Johnson & Johnson Related Links http://www.j
Read more →JNJJohnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review Johnson & Johnson (NYSE: JNJ) will host a meeting today with industry analysts to review the strategy of its Janssen Pharmaceutical Companies to...
NEW BRUNSWICK, N.J. , May 15, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a meeting today with industry analysts to review the strategy of its Janssen Pharmaceutical Companies to deliver above-market, compound annual growth through 2023. The company will also di
Read more →JNJJohnson & Johnson Announces Dividend Increase of 5.6% Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 5.6% increase in the quarterly dividend rate, from $0.90 per ...
NEW BRUNSWICK, N.J. , April 25, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a 5.6% increase in the quarterly dividend rate, from $0.90 per share to $0.95 per share. The increase was announced this morning at the Ann
Read more →JNJPress Contacts: Ernie Knewitz Cristal Downing (732) 524-6623 (732) 524-3283 (917) 697-2318 (M) (908) 616-8833 (M) Investor Contacts: Christopher DelOrefice Lesley Fishman (732) 524-2955 (732) 524-3922 Johnson & Johnson A
Press Contacts: Ernie Knewitz Cristal Downing (732) 524-6623 (732) 524-3283 (917) 697-2318 (M) (908) 616-8833 (M) Investor Contacts: Christopher DelOrefice Lesley Fishman (732) 524-2955 (732) 524-3922 Johnson & Johnson Announces Dividend Increase of 5.6% New Brunswick, N.J.
Read more →JNJJohnson & Johnson to Host Pharmaceutical Business Review Johnson & Johnson (NYSE: JNJ) will host a review of its Pharmaceutical businesses for the investment community beginning at 8:30 a.m. (Eastern Time)...
NEW BRUNSWICK, N.J. , April 24, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a review of its Pharmaceutical businesses for the investment community beginning at 8:30 a.m. (Eastern Time) on Wednesday , May 15, 2019 at the Hyatt Regency Hotel in New Brunswick, New
Read more →JNJJOHNSON & JOHNSON REPORTS 2019 FIRST-QUARTER RESULTS: Sales of $20.0 billion reflecting growth of 0.1%, operational growth of 3.9%* and adjusted operational growth of 5.5%* EPS of $1.39 decreased 13.1%; adjusted EPS of $
JOHNSON & JOHNSON REPORTS 2019 FIRST-QUARTER RESULTS: New Brunswick, N.J. (April 16, 2019) - Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2019. "Our strong first-quarter results reflect continued underlying operational sales and adjusted EPS growth," s
Read more →JNJJohnson & Johnson Completes Divestiture of Advanced Sterilization Products (ASP) to Fortive Corporation Johnson & Johnson (NYSE: JNJ) today announced that it has completed the divestiture of its Advanced Sterilization Products (ASP) business, a division ...
NEW BRUNSWICK, N.J. , April 1, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that it has completed the divestiture of its Advanced Sterilization Products (ASP) business, a division of Ethicon, Inc.*, to Fortive Corporation (NYSE: FTV ) for an aggregate value
Read more →JNJJohnson & Johnson Announces Completion of Acquisition of Auris Health, Inc. Johnson & Johnson (NYSE: JNJ) announced today that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion...
NEW BRUNSWICK, N.J. , April 1, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion , in the aggreg
Read more →JNJGlobal Media Relations: Ernie Knewitz (732) 524-6623 Investor Relations: Matt Stuckley (732) 524-2617 Christopher DelOrefice (732) 524-2955 Johnson & Johnson Announces Completion of Acquisition of A
Global Media Relations: Ernie Knewitz (732) 524-6623 Investor Relations: Matt Stuckley (732) 524-2617 Christopher DelOrefice (732) 524-2955 Johnson & Johnson Announces Completion of Acquisition of Auris Health, Inc. Auris will Enable Johnson & Johnson to Deliver on the Promise
Read more →JNJJohnson & Johnson to Host Investor Conference Call on First-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16th, to review first-quarter...
NEW BRUNSWICK, N.J. , March 19, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday , April 16 th , to review first-quarter results. Joseph J. Wolk , Executive Vice President, Chief Financial Officer
Read more →JNJJohnson & Johnson to Participate in Barclays Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Healthcare Conference on Thursday, Mar. 14, at the Loews Miami Beach Hotel,...
NEW BRUNSWICK, N.J. , Feb. 28, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Barclays Global Healthcare Conference on Thursday, Mar. 14 , at the Loews Miami Beach Hotel, Miami , FL. Tom Cavanaugh , President, Oncology and Catherine Owen , President,
Read more →JNJJohnson & Johnson to Participate in the 8th Annual SVB Leerink Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, Feb. 28th, at Lotte New York...
NEW BRUNSWICK, N.J. , Feb. 14, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, Feb. 28 th , at Lotte New York Palace, NY. Ashley McEvoy , Executive Vice President, Worldwide Chairman, Me
Read more →JNJJohnson & Johnson Nomeia Pat Smallcombe Como Chairman do Grupo, EMEA Consumer Johnson & Johnson Consumidor anuncia a nomeação de Pat Smallcombe para a posição de Chairman do Grupo, Europa, Médio Oriente, África (EMEA), a partir ...
ZUG, Suíça, February 13, 2019 /PRNewswire/ -- Johnson & Johnson Consumidor anuncia a nomeação de Pat Smallcombe para a posição de Chairman do Grupo, Europa, Médio Oriente, África (EMEA), a partir de 1 de Janeiro de 2019. Smallcombe terá funções de liderança para a área EMEA Cons
Read more →JNJJohnson & Johnson Announces Agreement to Acquire Auris Health, Inc. Focused on creating the next frontier of surgery, Johnson & Johnson (NYSE: JNJ), today announced that Ethicon, Inc., entered into a definitive...
NEW BRUNSWICK, N.J. , Feb. 13, 2019 /PRNewswire/ -- Focused on creating the next frontier of surgery, Johnson & Johnson (NYSE: JNJ ), today announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4 billion in cash. Addi
Read more →JNJJohnson & Johnson to Participate in the 2019 CAGNY Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2019 CAGNY Conference on Tuesday, Feb. 19, at The Boca Raton Resort, Boca Raton, FL. Alison...
NEW BRUNSWICK, N.J. , Feb. 5, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2019 CAGNY Conference on Tuesday, Feb. 19 , at The Boca Raton Resort, Boca Raton , FL. Alison Lewis , Global Chief Marketing Officer for Johnson & Johnson Consumer, Inc. will
Read more →JNJJohnson & Johnson nomina Pat Smallcombe, Company Group Chairman, EMEA Consumer Johnson & Johnson Consumer ha annunciato la nomina di Pat Smallcombe alla posizione di Company Group Chairman, Europe, Middle East, Africa (EMEA),...
ZURIGO, Svizzera, January 24, 2019 /PRNewswire/ -- Johnson & Johnson Consumer ha annunciato la nomina di Pat Smallcombe alla posizione di Company Group Chairman, Europe , Middle East , Africa (EMEA), con decorrenza 1 ° gennaio 2019. Smallcombe avrà la responsabilità di tutto il
Read more →JNJJohnson & Johnson Reports 2018 Fourth-Quarter Results: 2018 Fourth-Quarter Sales of $20.4 Billion increased 1.0%; EPS was $1.12 2018 Full-Year Sales of $81.6 Billion increased 6.7%, Full-Year EPS was $5.61 Adjusted 2018
EX-99.15 2 a2018q4exhibit9915.htm EXHIBIT 99.15 Exhibit Exhibit 99.15 ` Johnson & Johnson Reports 2018 Fourth-Quarter Results: 2018 Fourth-Quarter Sales of $20.4 Billion increased 1.0%; EPS was $1.12 2018 Full-Year Sales of $81.6 Billion increased 6.7%, Full-Year EPS was $5.61 Ad
Read more →JNJErnie Knewitz Donna Lorenson (732) 524-6623 (410) 258-8571 (917) 697-2318 (M) dlorens@its.jnj.com eknewitz@its.jnj.com Mel Tyndale-Biscoe +65 8798 2475 (Singapore) Investor Contact:
Media Contacts: Ernie Knewitz Donna Lorenson (732) 524-6623 (410) 258-8571 (917) 697-2318 (M) dlorens@its.jnj.com eknewitz@its.jnj.com Mel Tyndale-Biscoe +65 8798 2475 (Singapore) Investor Contact: Lisa Romanko (732) 524-2034 Johnson & Johnson Completes Acquisition of
Read more →JNJJohnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention Johnson & Johnson (NYSE: JNJ) today announced that Janssen Pharmaceuticals, Inc., member of the Johnson & Johnson Family of Companies, entered into a ...
NEW BRUNSWICK, N.J. , Jan. 17, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that Janssen Pharmaceuticals, Inc., member of the Johnson & Johnson Family of Companies, entered into a research study in collaboration with Apple Inc. to investigate whether a new
Read more →JNJJohnson & Johnson Completes Acquisition of Ci:z Holdings Co., Ltd. Johnson & Johnson (NYSE:JNJ) today announced the completion of the acquisition of Ci:z Holdings Co., Ltd. (TYO: 4924) (the Company ) for a total...
NEW BRUNSWICK, N.J. , Jan. 17, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the completion of the acquisition of Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company") for a total purchase price of approximately ¥230 billion. The acquisition was completed thro
Read more →JNJJohnson & Johnson Announces completion of Offer for Ci:z Holdings Co., Ltd. Johnson & Johnson (NYSE: JNJ) today announced that the conditions to its public tender offer for all of the outstanding shares of Ci:z Holdings Co.,...
NEW BRUNSWICK, N.J. , Jan. 11, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that the conditions to its public tender offer for all of the outstanding shares of Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company") not already held by Johnson & Johnson or its
Read more →JNJJohnson & Johnson Recommends Rejection Of Below-Market Mini-Tender Offer By Peer & Peri LLC Johnson & Johnson (NYSE: JNJ) received notice of an unsolicited mini-tender offer by Peer & Peri LLC (Peer & Peri) to purchase up to 30,000 shares...
NEW BRUNSWICK, N.J. , Jan. 11, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) received notice of an unsolicited "mini-tender" offer by Peer & Peri LLC (Peer & Peri) to purchase up to 30,000 shares of common stock of Johnson & Johnson, representing approximately 0.001% of the
Read more →JNJDr. Paul Janssen Award for Biomedical Research Issues 2019 Call for Nominations to Celebrate Champions of Science Nominations are now being accepted for the 2019 Dr. Paul Janssen Award for Biomedical Research. This prestigious award celebrates today's most...
NEW BRUNSWICK, N.J. , Jan. 10, 2019 /PRNewswire/ -- Nominations are now being accepted for the 2019 Dr. Paul Janssen Award for Biomedical Research. This prestigious award celebrates today's most dedicated researchers and champions of science whose basic or clinical discoveries ha
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for First Quarter 2019 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2019 of $0.90 per...
NEW BRUNSWICK, N.J. , Jan. 2, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2019 of $0.90 per share on the company's common stock. The dividend is payable on March 12, 2019 to
Read more →JNJJohnson & Johnson to Participate in 37th Annual JP Morgan Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 37th Annual JP Morgan Health Care Conference on Monday, Jan. 7th, at the Westin St. Francis in...
NEW BRUNSWICK, N.J. , Dec. 24, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 37 th Annual JP Morgan Health Care Conference on Monday, Jan. 7 th , at the Westin St. Francis in San Francisco. Joseph J. Wolk , Executive Vice President and Chief Financia
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 22nd, to review...
NEW BRUNSWICK, N.J. , Dec. 19, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday , January 22 nd , to review fourth-quarter results. Alex Gorsky , Chairman and Chief Executive Officer; Joseph J. Wo
Read more →JNJJohnson & Johnson Announces $5 Billion Share Repurchase Program Johnson & Johnson (NYSE: JNJ) today announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common...
NEW BRUNSWICK, N.J. , Dec. 17, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock. "Based on our continued strong performance and, more importantly, the c
Read more →JNJErnie Knewitz Cristal Downing (732) 524-6623 (732) 524-3283 (917) 697-2318 (M) (908) 616-8833 Investor Contacts: Christopher DelOrefice Lesley Fishman (732) 524-2955 (732) 524-3922 J
Media Contacts: Ernie Knewitz Cristal Downing (732) 524-6623 (732) 524-3283 (917) 697-2318 (M) (908) 616-8833 Investor Contacts: Christopher DelOrefice Lesley Fishman (732) 524-2955 (732) 524-3922 Johnson & Johnson Announces $5 Billion Share Repurchase Program New Brunswick,
Read more →JNJStatement on Reuters Talc Article Johnson & Johnson (NYSE: JNJ) today issued the following statement regarding speculation about the safety of our products. The Reuters article is...
NEW BRUNSWICK, N.J. , Dec. 14, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today issued the following statement regarding speculation about the safety of our products. The Reuters article is one-sided, false, and inflammatory. Johnson & Johnson's baby powder is safe and
Read more →JNJActress, Playwright And Advocate Danai Gurira Partners With Johnson & Johnson To Help End HIV/AIDS As She Addresses Global Citizen And Visits HIV Clinical Trial In South Africa Actress, playwright and activist Danai Gurira hit the red carpet at the Mandela 100 Global Citizen Festival in Johannesburg before making a powerful...
JOHANNESBURG , Dec. 3, 2018 /PRNewswire/ -- Actress, playwright and activist Danai Gurira hit the red carpet at the Mandela 100 Global Citizen Festival in Johannesburg before making a powerful and emotional speech at the event spotlighting the women across Africa who are partici
Read more →JNJJohnson & Johnson to Participate in the BMO Prescriptions for Success Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the BMO Prescriptions for Success Healthcare Conference on Wednesday, December 12th, at The...
NEW BRUNSWICK, N.J. , Nov. 26, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the BMO Prescriptions for Success Healthcare Conference on Wednesday, December 12 th , at The Mandarin Oriental, New York. Ciro Römer, Company Group Chairman for the Johnson & J
Read more →JNJJohnson & Johnson to Participate in the Citi's 2018 Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Citi's 2018 Global Healthcare Conference on Wednesday, December 5th, at the Lotte New York...
NEW BRUNSWICK, N.J. , Nov. 12, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Citi's 2018 Global Healthcare Conference on Wednesday, December 5 th , at the Lotte New York Palace Hotel in New York City. Joseph J. Wolk , Executive Vice President and Chi
Read more →JNJJohnson & Johnson lance le concours Africa Innovation Challenge 2.0 Johnson & Johnson a lancé aujourd'hui le concours Champions of Science Africa Innovation Challenge 2.0, le second concours à l'échelle du continent...
La société appelle les entrepreneurs africains à proposer des idées dans six catégories : santé mentale, emballages de grande consommation, solutions botaniques, soutien aux travailleurs de la santé, outils de santé numérique et chirurgie essentielle Les start-ups et les innovat
Read more →JNJJohnson & Johnson startet die Africa Innovation Challenge 2.0. Johnson & Johnson hat heute die Africa Innovation Challenge 2.0 „Champions of Science ins Leben gerufen. Dabei handelt es sich um den zweiten...
Aufruf an afrikanische Unternehmer, Ideen in sechs Kategorien einzureichen: Psychische Gesundheit, Konsumverpackungen, pflanzliche Lösungen, Unterstützung von Gesundheitspersonal, digitale Gesundheitswerkzeuge und grundlegende chirurgische Versorgung Gewinnen von in Afrika ansäs
Read more →JNJJohnson & Johnson presenta el Desafío 2.0 Innovación en África Johnson & Johnson presentó hoy el Africa Innovation Challenge 2.0 (Desafío 2.0 Innovación en África) de Champions of Science, la segunda competición...
Se busca a emprendedores africanos para que envíen ideas en seis categorías: salud mental, embalaje de productos, soluciones botánicas, asistencia a los trabajadores de salud, herramientas de salud digital e intervenciones quirúrgicas esenciales. Los innovadores africanos y empr
Read more →JNJJohnson & Johnson to Participate in the Credit Suisse 27th Annual Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13th, at The Phoenician in ...
NEW BRUNSWICK, N.J. , Nov. 6, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13 th , at The Phoenician in Scottsdale, AZ. Scott White , Company Group Chairman, North America Pharmace
Read more →JNJJohnson & Johnson Announces Offer to Acquire Ci:z Holdings Co., Ltd. Johnson & Johnson (NYSE: JNJ) today announced that they have agreed with Ci:z Holdings Co., Ltd. (TYO: 4924) (the Company ), a Japanese company...
NEW BRUNSWICK, N.J. , Oct. 23, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that they have agreed with Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company"), a Japanese company focused on the marketing, development and distribution of a broad range of dermoco
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2018 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2018 of $0.90 per...
NEW BRUNSWICK, N.J. , Oct. 18, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2018 of $0.90 per share on the company's common stock. The dividend is payable on December 11, 201
Read more →JNJJohnson & Johnson Reports 2018 Third-Quarter Results: 2018 Third-Quarter Sales of $20.3 Billion Increased 3.6% versus 2017 2018 Third-Quarter EPS was $1.44 2018 Adjusted Third-Quarter EPS of $2.05 increased 7.9%* Strong
EX-99.15 2 a8k2018q3exhibit9915.htm EXHIBIT 99.15 Exhibit Exhibit 99.15 Johnson & Johnson Reports 2018 Third-Quarter Results: 2018 Third-Quarter Sales of $20.3 Billion Increased 3.6% versus 2017 2018 Third-Quarter EPS was $1.44 2018 Adjusted Third-Quarter EPS of $2.05 increased 7
Read more →JNJWhere will the next big idea in healthcare come from? Johnson & Johnson is counting on nurses. There's a reason the saying goes, nurse someone back to health. Throughout history, nurses have been important facilitators of health – caring for...
NEW BRUNSWICK, N.J. , Oct. 1, 2018 /PRNewswire/ -- There's a reason the saying goes, "nurse someone back to health." Throughout history, nurses have been important facilitators of health – caring for the sick when others would not, identifying smarter and better ways to heal and
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Third-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 16th, to review third-quarter ...
NEW BRUNSWICK, N.J. , Sept. 19, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday , October 16 th , to review third-quarter results. Joseph J. Wolk , Executive Vice President, Chief Financial Offic
Read more →JNJJohnson & Johnson to Host Investor Conference Call on the Phase 3 MARINER and COMMANDER HF Studies for XARELTO® Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Monday, August 27th, to review the Phase 3...
NEW BRUNSWICK, N.J. , Aug. 27, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Monday , August 27 th , to review the Phase 3 MARINER and COMMANDER HF studies for XARELTO ® presented at the European Socie
Read more →JNJJohnson & Johnson to Participate in the 2018 Morgan Stanley 16th Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Morgan Stanley 16th Annual Global Healthcare Conference on Friday, September 14th, at The...
NEW BRUNSWICK, N.J. , Aug. 27, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2018 Morgan Stanley 16 th Annual Global Healthcare Conference on Friday, September 14 th , at The Grand Hyatt Hotel in New York. Alex Gorsky , Chairman and Chief Executive O
Read more →JNJUPDATE: Johnson & Johnson to Host Investor Conference Call on the Pharmaceutical Business Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Thursday, September 13th, to review its...
NEW BRUNSWICK, N.J. , Aug. 27, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 10 :00 a.m. (Eastern Time) on Thursday , September 13th, to review its Pharmaceutical Business. Joaquin Duato, Vice Chairman of the Executive Committee;
Read more →JNJJohnson & Johnson to Host Investor Conference Call on the Pharmaceutical Business Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Thursday, September 13th, to review its...
NEW BRUNSWICK, N.J. , Aug. 20, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Thursday , September 13 th , to review its Pharmaceutical Business. Joaquin Duato, Vice Chairman of the Executive Committee;
Read more →JNJJohnson & Johnson Announces Chris DelOrefice as Vice President of Investor Relations Johnson & Johnson (NYSE: JNJ) announced today the appointment of Chris DelOrefice to Vice President of Investor Relations for Johnson & Johnson,...
NEW BRUNSWICK, N.J. , Aug. 8, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today the appointment of Chris DelOrefice to Vice President of Investor Relations for Johnson & Johnson, effective August 13, 2018 . Mr. DelOrefice will report to Mr. Joseph Wolk , Executi
Read more →JNJJohnson & Johnson to Participate in Barclays Global Consumer Staples Conference Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Conference on Thursday, Sept. 6th, at the InterContinental,...
NEW BRUNSWICK, N.J. , Aug. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Barclays Global Consumer Staples Conference on Thursday, Sept. 6 th , at the InterContinental, Boston , MA. Jorge Mesquita , Executive Vice President, Worldwide Chairman, Con
Read more →JNJJohnson & Johnson to Participate in the 2018 Wells Fargo 13th Annual Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Wells Fargo 13th Annual Healthcare Conference on Thursday, Sept. 6th, at The Westin Boston ...
NEW BRUNSWICK, N.J. , Aug. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2018 Wells Fargo 13 th Annual Healthcare Conference on Thursday, Sept. 6 th , at The Westin Boston Waterfront in Boston, MA. Alex Gorsky, Chairman and Chief Executive Officer
Read more →JNJJohnson & Johnson Reports 2018 Second-Quarter Results: 2018 Second-Quarter Sales of $20.8 Billion Increased 10.6% versus 2017 2018 Second-Quarter EPS was $1.45 2018 Adjusted Second-Quarter EPS of $2.10 increased 14.8%* A
EX-99.15 2 a8k2018q2exhibit9915.htm EXHIBIT 99.15 Exhibit Exhibit 99.15 Johnson & Johnson Reports 2018 Second-Quarter Results: 2018 Second-Quarter Sales of $20.8 Billion Increased 10.6% versus 2017 2018 Second-Quarter EPS was $1.45 2018 Adjusted Second-Quarter EPS of $2.10 increa
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2018 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2018 of $0.90 per...
NEW BRUNSWICK, N.J. , July 16, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2018 of $0.90 per share on the company's common stock. The dividend is payable on September 11, 201
Read more →JNJJohnson & Johnson's Official Statement in Response to Today's Verdict in St. Louis Trial Johnson & Johnson (NYSE: JNJ) issued the following statement regarding today's verdict in the St. Louis court. Johnson & Johnson is deeply...
NEW BRUNSWICK, N.J. , July 12, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) issued the following statement regarding today's verdict in the St. Louis court. "Johnson & Johnson is deeply disappointed in the verdict, which was the product of a fundamentally unfair process t
Read more →JNJPress Contacts: Ernie Knewitz (732) 524-6623 (917) 697-2318 (M) Investor Contacts: Joseph J. Wolk Lesley Fishman (732) 524-1142 (732) 524-3922 Johnson & Johnson Announces Retirement of Group Worldwi
Press Contacts: Ernie Knewitz (732) 524-6623 (917) 697-2318 (M) Investor Contacts: Joseph J. Wolk Lesley Fishman (732) 524-1142 (732) 524-3922 Johnson & Johnson Announces Retirement of Group Worldwide Chairman, Sandra E. Peterson New Brunswick, NJ June 22, 2018 -- Johnson
Read more →JNJJohnson & Johnson Appoints Senior Leaders to Executive Committee Johnson & Johnson (NYSE: JNJ) today announced the appointment of a number of senior leaders to the Company's Executive Committee. Specifically:...
NEW BRUNSWICK, N.J. , June 22, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the appointment of a number of senior leaders to the Company's Executive Committee. "These appointments recognize the enormous talent among the senior leadership team of Johnson &
Read more →JNJJohnson & Johnson Announces Retirement of Group Worldwide Chairman, Sandra E. Peterson Johnson & Johnson (NYSE: JNJ) announced today that Sandra (Sandi) E. Peterson, Group Worldwide Chairman for Johnson & Johnson, has announced her...
NEW BRUNSWICK, N.J. , June 22, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today that Sandra (Sandi) E. Peterson , Group Worldwide Chairman for Johnson & Johnson, has announced her plans to retire from J&J effective October 1, 2018 . During her career at Johnso
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 17, to review second-quarter...
NEW BRUNSWICK, N.J. , June 19, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday , July 17, to review second-quarter results. Alex Gorsky , Chairman and Chief Executive Officer and Joseph J. Wolk ,
Read more →JNJJohnson & Johnson annonce l'acceptation de l'offre irrévocable de Platinum Equity pour l'acquisition de LifeScan, Inc. Johnson & Johnson (NYSE : JNJ) a annoncé aujourd'hui avoir accepté l'offre irrévocable de Platinum Equity, précédemment annoncée le 16 mars 2018,...
NEW BRUNSWICK, New Jersey , 12 juin 2018 /PRNewswire/ -- Johnson & Johnson (NYSE : JNJ ) a annoncé aujourd'hui avoir accepté l'offre irrévocable de Platinum Equity, précédemment annoncée le 16 mars 2018, d'acquisition de son activité LifeScan, et ce, pour environ 2,1 milliards US
Read more →JNJJohnson & Johnson gibt Annahme bindenden Angebotes von Platinum Equity zum Erwerb von LifeScan Inc. bekannt Johnson & Johnson (NYSE: JNJ) hat heute die Annahme eines zuvor am 16. März 2018 verkündeten bindenden Angebotes von Platinum Equity bekannt gegeben, ...
NEW BRUNSWICK, New Jersey , 12. Juni 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) hat heute die Annahme eines zuvor am 16. März 2018 verkündeten bindenden Angebotes von Platinum Equity bekannt gegeben, den Geschäftsbereich LifeScan für ca. 2,1 Milliarden USD zu erwerben. L
Read more →JNJJohnson & Johnson anuncia la aceptación de una oferta vinculante de Platinum Equity para adquirir LifeScan, Inc. Johnson & Johnson (NYSE: JNJ) dio a conocer hoy que aceptó la oferta vinculante de Platinum Equity, anunciada el 16 de marzo de 2018, para adquirir...
NUEVO BRUNSWICK , Nueva Jersey , 12 de junio de 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) dio a conocer hoy que aceptó la oferta vinculante de Platinum Equity, anunciada el 16 de marzo de 2018, para adquirir su empresa LifeScan por unos USD 2.100 millones. LifeScan, Inc
Read more →JNJJohnson & Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc. Johnson & Johnson (NYSE: JNJ) today announced that it has accepted the binding offer from Platinum Equity, previously announced on March 16, 2018, to ...
NEW BRUNSWICK, N.J. , June 12, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that it has accepted the binding offer from Platinum Equity, previously announced on March 16, 2018 , to acquire its LifeScan business for approximately $2.1 billion . LifeScan, Inc
Read more →JNJJohnson & Johnson anuncia aceitação da proposta vinculativa da Platinum Equity para aquisição da LifeScan, Inc. A Johnson & Johnson (NYSE: JNJ) anunciou hoje que aceitou a proposta vinculativa da Platinum Equity, anunciada anteriormente em 16 de março de 2018,...
NEW BRUNSWICK , Nova Jersey , 12 de junho de 2018 /PRNewswire/ -- A Johnson & Johnson (NYSE: JNJ ) anunciou hoje que aceitou a proposta vinculativa da Platinum Equity, anunciada anteriormente em 16 de março de 2018, para a aquisição de seu negócio LifeScan por aproximadamente US$
Read more →JNJJohnson & Johnson anuncia la aceptación de la oferta vinculante de Platinum Equity para adquirir LifeScan, Inc. Johnson & Johnson (NYSE: JNJ) ha anunciado hoy que ha aceptado la oferta vinculante de Platinum Equity, anunciada previamente el 16 de marzo de 2018, ...
NUEVO BRUNSWICK , Nueva Jersey , 12 de junio de 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) ha anunciado hoy que ha aceptado la oferta vinculante de Platinum Equity, anunciada previamente el 16 de marzo de 2018, para adquirir su negocio de LifeScan aproximadamente por 210
Read more →JNJJohnson & Johnson Announces Binding Offer from Fortive Corporation to Acquire Advanced Sterilization Products (ASP) Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Fortive Corporation (NYSE: FTV) to acquire its Advanced...
NEW BRUNSWICK, N.J. , June 6, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that it has received a binding offer from Fortive Corporation (NYSE: FTV ) to acquire its Advanced Sterilization Products (ASP) business, a division of Ethicon, Inc.*, for an aggrega
Read more →JNJJohnson & Johnson avança nas metas de Saúde para a Humanidade A Johnson & Johnson divulgou ontem seu relatório anual Saúde para a Humanidade , destacando os principais avanços da companhia em 2017 em direção a...
NEW BRUNSWICK, N.J. , 6 de junho de 2018 /PRNewswire/ -- A Johnson & Johnson divulgou ontem seu relatório anual "Saúde para a Humanidade", destacando os principais avanços da companhia em 2017 em direção a seus compromissos sociais, ambientais e de governança para continuar traba
Read more →JNJJohnson & Johnson Announces Progress Toward Health for Humanity Goals Johnson & Johnson (NYSE: JNJ) today released its 2017 Health for Humanity Report, demonstrating its approach and the considerable progress it has...
NEW BRUNSWICK, N.J. , June 5, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today released its 2017 Health for Humanity Report , demonstrating its approach and the considerable progress it has made toward an ambitious social, environmental and governance commitment to advan
Read more →JNJJames Allison, Ph.D., Wins 2018 Dr. Paul Janssen Award for Biomedical Research Johnson & Johnson (NYSE: JNJ) today named James Allison, Ph.D., of University of Texas MD Anderson Cancer Center, winner of the 2018 Dr. Paul Janssen ...
BOSTON , June 4, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today named James Allison , Ph.D., of University of Texas MD Anderson Cancer Center, winner of the 2018 Dr. Paul Janssen Award for Biomedical Research, and launched several new programs as part of our Champions
Read more →JNJJohnson & Johnson to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, at the Terranea...
NEW BRUNSWICK, N.J. , May 29, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12 , at the Terranea Resort in Rancho Palos Verdes, California. Tom Cavanaugh, President, Oncology, Ja
Read more →JNJJohnson & Johnson to Participate in the 2018 UBS Global Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2018 UBS Global Health Care Conference on Monday, May 21st, at the Grand Hyatt, New York. Sandi ...
NEW BRUNSWICK, N.J. , May 3, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2018 UBS Global Health Care Conference on Monday, May 21 st , at the Grand Hyatt, New York . Sandi Peterson, Executive Vice President, Group Worldwide Chairman will represent
Read more →JNJJohnson & Johnson to Host Consumer and Medical Devices Business Review Johnson & Johnson (NYSE: JNJ) will host a review of its Consumer and Medical Devices businesses for the investment community beginning with a...
NEW BRUNSWICK, N.J. , May 2, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a review of its Consumer and Medical Devices businesses for the investment community beginning with a continental breakfast and access to exhibits at 8:00 a.m. (Eastern Time) on Wednesday ,
Read more →JNJJohnson & Johnson presenta Instituto de Educación Médica Continuada para Latinoamérica, con foco en tecnología y medicina para el futuro Johnson & Johnson ha presentado, en San Pablo (Brasil), el Johnson & Johnson Institute (JJI), centro de educación médica continuada, modernamente...
SÃO PAULO, 27 de abril de 2018 /PRNewswire/ -- Johnson & Johnson ha presentado, en San Pablo (Brasil), el Johnson & Johnson Institute (JJI), centro de educación médica continuada, modernamente equipado para ofrecer entrenamiento en procedimientos quirúrgicos innovadores. El Insti
Read more →JNJJohnson & Johnson Announces Dividend Increase of 7.1% Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate, from $0.84 per ...
NEW BRUNSWICK, N.J. , April 26, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate, from $0.84 per share to $0.90 per share. The increase was announced this morning at the Ann
Read more →JNJJohnson & Johnson to Participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Deutsche Bank 43rd Annual Health Care Conference on Wednesday, May 9th, at The...
NEW BRUNSWICK, N.J. , April 24, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2018 Deutsche Bank 43 rd Annual Health Care Conference on Wednesday, May 9 th , at The InterContinental Boston. Mathai Mammen, MD, Ph.D., Global Head, Research & Developmen
Read more →JNJJohnson & Johnson Reports 2018 First-Quarter Results: 2018 First-Quarter Sales of $20.0 Billion Increased 12.6% versus 2017 2018 First-Quarter EPS was $1.60 2018 Adjusted First-Quarter EPS of $2.06 increased 12.6%* Sales
EX-99.15 2 a8k2018q1exhibit9915.htm EXHIBIT 99.15 Exhibit Exhibit 99.15 Johnson & Johnson Reports 2018 First-Quarter Results: 2018 First-Quarter Sales of $20.0 Billion Increased 12.6% versus 2017 2018 First-Quarter EPS was $1.60 2018 Adjusted First-Quarter EPS of $2.06 increased
Read more →JNJDominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson Johnson & Johnson (NYSE: JNJ) today announced that Dominic J. Caruso, Executive Vice President, Chief Financial Officer, has elected to retire in...
NEW BRUNSWICK, N.J. , March 20, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that Dominic J. Caruso , Executive Vice President, Chief Financial Officer, has elected to retire in September 2018 after a distinguished 19-year career with the Company. Caruso wa
Read more →JNJJohnson & Johnson anuncia una oferta vinculante de Platinum Equity para adquirir LifeScan, Inc. Johnson & Johnson (NYSE: JNJ) ha anunciado hoy que ha recibido una oferta vinculante de Platinum Equity, una importante empresa de inversión privada, ...
NUEVO BRUNSWICK, N.J., 16 de marzo de 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) ha anunciado hoy que ha recibido una oferta vinculante de Platinum Equity, una importante empresa de inversión privada, para adquirir su negocio de LifeScan aproximadamente por 2100 millones
Read more →JNJJohnson & Johnson gibt verbindliches Angebot von Platinum Equity zur Übernahme von LifeScan, Inc. bekannt Johnson & Johnson (NYSE: JNJ) verkündete heute, dass es ein verbindliches Angebot von Platinum Equity, einer führenden privaten Investmentfirma, zur...
NEW BRUNSWICK, New Jersey , 16. März 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) verkündete heute, dass es ein verbindliches Angebot von Platinum Equity, einer führenden privaten Investmentfirma, zur Übernahme der Geschäftssparte LifeScan von Johnson & Johnson für ca. 2,1
Read more →JNJJohnson & Johnson anuncia oferta vinculante de Platinum Equity para adquirir LifeScan, Inc. Johnson & Johnson (NYSE: JNJ) anunció hoy haber recibido una oferta vinculante de Platinum Equity, una importante firma de inversión privada, para...
NEW BRUNSWICK , Nueva Jersey , 16 de marzo de 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) anunció hoy haber recibido una oferta vinculante de Platinum Equity, una importante firma de inversión privada, para adquirir su negocio LifeScan en una cifra cercana a los $2.100 mi
Read more →JNJJohnson & Johnson anuncia proposta vinculativa da Platinum Equity para aquisição da LifeScan, Inc. A Johnson & Johnson (NYSE: JNJ) anunciou hoje que recebeu uma proposta vinculativa da Platinum Equity, uma empresa privada líder de investimentos,...
NEW BRUNSWICK , Nova Jersey , 16 de março de 2018 /PRNewswire/ -- A Johnson & Johnson (NYSE: JNJ ) anunciou hoje que recebeu uma proposta vinculativa da Platinum Equity, uma empresa privada líder de investimentos, para aquisição de seu negócio LifeScan por aproximadamente US$ 2,1
Read more →JNJJohnson & Johnson annonce une offre ferme de Platinum Equity pour acquérir LifeScan, Inc. Johnson & Johnson (NYSE : JNJ) a annoncé aujourd'hui avoir reçu une offre ferme de Platinum Equity, un important cabinet d'investissement privé, pour ...
NEW BRUNSWICK, New Jersey , 16 mars 2018 /PRNewswire/ -- Johnson & Johnson (NYSE : JNJ ) a annoncé aujourd'hui avoir reçu une offre ferme de Platinum Equity, un important cabinet d'investissement privé, pour acquérir son entreprise LifeScan pour un montant d'environ 2,1 milliards
Read more →JNJJohnson & Johnson to Participate in Barclays Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Healthcare Conference on Tuesday, Mar. 13, at the Loews Miami Beach Hotel,...
NEW BRUNSWICK, N.J. , March 6, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Barclays Global Healthcare Conference on Tuesday, Mar. 13 , at the Loews Miami Beach Hotel, Miami , FL. Joaquin Duato , Executive Vice President, Worldwide Chairman, Pharmac
Read more →JNJJohnson & Johnson to Participate in Cowen 38th Annual Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 38th Annual Healthcare Conference on Tuesday, Mar. 13, at The Boston Marriott Copley...
NEW BRUNSWICK, N.J. , Feb. 20, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Cowen 38th Annual Healthcare Conference on Tuesday, Mar. 13 , at The Boston Marriott Copley Place, Boston . Ashley McEvoy , Company Group Chairman, Consumer Medical Devices
Read more →JNJJohnson & Johnson to Participate in the 2018 CAGNY Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2018 CAGNY Conference on Thursday, Feb. 22, at The Boca Raton Resort, Boca Raton, FL. Jorge...
NEW BRUNSWICK, N.J. , Feb. 8, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2018 CAGNY Conference on Thursday, Feb. 22 , at The Boca Raton Resort, Boca Raton , FL. Jorge Mesquita , Executive Vice President, Worldwide Chairman, Consumer and Alison Lew
Read more →JNJJanssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio Janssen Research & Development, LLC (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast focusing on the Phase 3 SPARTAN...
NEW BRUNSWICK, N.J. , Feb. 8, 2018 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and Johnson & Johnson (NYSE: JNJ ) will provide a pre-recorded webcast focusing on the Phase 3 SPARTAN data for the investigational compound apalutamide in non-metastatic castration-r
Read more →JNJJohnson & Johnson to Participate in RBC Capital Markets 2018 Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, Feb. 21, at the Lotte New...
NEW BRUNSWICK, N.J. , Feb. 7, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, Feb. 21 , at the Lotte New York Palace in New York City. Dominic Caruso , Executive Vice President, Chief
Read more →JNJJohnson & Johnson to Participate in the Leerink Partners 7th Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, Feb. 14, at Lotte New...
NEW BRUNSWICK, N.J. , Jan. 31, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, Feb. 14 , at Lotte New York Palace, NY. Dominic Caruso , Executive Vice President, Chief Financial Off
Read more →JNJJohnson & Johnson Reports 2017 Fourth-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $20.2 billion for the fourth quarter of 2017, an increase of 11.5% as compared to the fourth...
NEW BRUNSWICK, N.J. , Jan. 23, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $20.2 billion for the fourth quarter of 2017, an increase of 11.5% as compared to the fourth quarter of 2016. Operational sales results increased 9.4% and the positive impa
Read more →JNJJohnson & Johnson Issues Statement on ZYTIGA® Inter Partes Reviews Johnson & Johnson (NYSE: JNJ) issued the following statement regarding today's Inter Partes Reviews regarding ZYTIGA® (abiraterone acetate): We are...
NEW BRUNSWICK, N.J. , Jan. 17, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) issued the following statement regarding today's Inter Partes Reviews regarding ZYTIGA ® (abiraterone acetate): About Johnson & Johnson Caring for the world, one person at a time, inspires and uni
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for First Quarter 2018 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2018 of $0.84 per...
NEW BRUNSWICK, N.J. , Jan. 2, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2018 of $0.84 per share on the company's common stock. The dividend is payable on March 13, 2018 to
Read more →JNJJohnson & Johnson to Participate in 36th Annual JP Morgan Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 36th Annual JP Morgan Health Care Conference on Monday, Jan. 8, at the Westin St. Francis in...
NEW BRUNSWICK, N.J. , Dec. 19, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 36 th Annual JP Morgan Health Care Conference on Monday, Jan. 8 , at the Westin St. Francis in San Francisco. Alex Gorsky , Chairman and Chief Executive Officer, will repres
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 23rd, to review...
NEW BRUNSWICK, N.J. , Dec. 19, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday , January 23 rd , to review fourth-quarter results. Alex Gorsky , Chairman and Chief Executive Officer; Dominic Caru
Read more →JNJJohnson & Johnson to Participate in the BMO Capital Markets Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the BMO Capital Markets Healthcare Conference on Thursday, Dec. 14, at the Westin Grand Central, in ...
NEW BRUNSWICK, N.J. , Nov. 30, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the BMO Capital Markets Healthcare Conference on Thursday, Dec. 14 , at the Westin Grand Central, in New York, NY . Sandi Peterson, Executive Vice President, Group Worldwide Cha
Read more →JNJJohnson & Johnson to Participate in the Citi 2017 Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Citi 2017 Global Healthcare Conference on Thursday, Dec. 7, at Lotte New York Palace, NY....
NEW BRUNSWICK, N.J. , Nov. 20, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Citi 2017 Global Healthcare Conference on Thursday, Dec. 7 , at Lotte New York Palace, NY. Joaquin Duato , Executive Vice President, Worldwide Chairman, Pharmaceuticals will
Read more →JNJNew VA and Johnson & Johnson Campaign Encourages Public to Take Note of Veterans at Risk for Suicide In advance of Veterans Day, the Department of Veterans Affairs (VA), in partnership with Johnson & Johnson (NYSE: JNJ), today announced a new public...
WASHINGTON , Oct. 30, 2017 /PRNewswire/ -- In advance of Veterans Day , the Department of Veterans Affairs (VA), in partnership with Johnson & Johnson (NYSE: JNJ ), today announced a new public service announcement, " No Veteran Left Behind ," to address the tragic rate of Vetera
Read more →JNJJohnson & Johnson to Participate in the 26th Annual Credit Suisse Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 26th Annual Credit Suisse Health Care Conference on Wednesday, Nov. 8, at The Phoenician in...
NEW BRUNSWICK, N.J. , Oct. 25, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 26th Annual Credit Suisse Health Care Conference on Wednesday, Nov. 8 , at The Phoenician in Scottsdale, AZ. Vanessa Broadhurst , President, Cardiovascular & Metabolism, Jan
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2017 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2017 of $0.84 per...
NEW BRUNSWICK, N.J. , Oct. 19, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2017 of $0.84 per share on the company's common stock. The dividend is payable on December 12, 201
Read more →JNJJohnson & Johnson Reports 2017 Third-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $19.7 billion for the third quarter of 2017, an increase of 10.3% as compared to the third...
NEW BRUNSWICK, N.J. , Oct. 17, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $19.7 billion for the third quarter of 2017, an increase of 10.3% as compared to the third quarter of 2016. Operational sales results increased 9.5% and the positive impact
Read more →JNJJohnson & Johnson Announces Completion of Codman Neurosurgery Divestiture to Integra LifeSciences Holding Corporation Johnson & Johnson (NYSE: JNJ) today announced the completion of the divestiture of its Codman Neurosurgery business to Integra LifeSciences Holding...
NEW BRUNSWICK, N.J. , Oct. 2, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the completion of the divestiture of its Codman Neurosurgery business to Integra LifeSciences Holding Corporation for an approximate value of $1.045 billion, subject to customary adj
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Third-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 17th, to review third-quarter ...
NEW BRUNSWICK, N.J. , Sept. 14, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 17 th , to review third-quarter results. Dominic Caruso , Executive Vice President, Chief Financial Office
Read more →JNJJohnson & Johnson Launches Dr. Paul Janssen Project to Catalyze and Convene Champions of Science Across Generations and Geographies Johnson & Johnson (NYSE: JNJ) today launched the Dr. Paul Janssen Project – a multi-faceted public engagement initiative that extends the legacy of...
NEW YORK , Sept. 13, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today launched the Dr. Paul Janssen Project – a multi-faceted public engagement initiative that extends the legacy of Dr. Paul Janssen – one of the most accomplished industry researchers and humanitarians of
Read more →JNJJohnson & Johnson to Participate in 2017 Morgan Stanley Global Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2017 Morgan Stanley Global Health Care Conference on Wednesday, Sept. 13, at The Grand Hyatt...
NEW BRUNSWICK, N.J. , Aug. 14, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2017 Morgan Stanley Global Health Care Conference on Wednesday, Sept. 13 , at The Grand Hyatt Hotel in New York. Dominic Caruso , Executive Vice President, Chief Financial O
Read more →JNJJohnson & Johnson to Participate in Barclays Global Consumer Staples Conference Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Conference on Tuesday, Sept. 5, at the InterContinental,...
NEW BRUNSWICK, N.J. , Aug. 4, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Barclays Global Consumer Staples Conference on Tuesday, Sept. 5 , at the InterContinental, Boston , MA. Jorge Mesquita , Executive Vice President, Worldwide Chairman, Consume
Read more →JNJJohnson & Johnson to Participate in the 2017 Wells Fargo 12th Annual Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2017 Wells Fargo 12th Annual Healthcare Conference on Wednesday, Sept. 6, at The Westin Boston...
NEW BRUNSWICK, N.J. , Aug. 4, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2017 Wells Fargo 12 th Annual Healthcare Conference on Wednesday, Sept. 6 , at The Westin Boston Waterfront in Boston, MA. Alex Gorsky, Chairman and Chief Executive Officer a
Read more →JNJJohnson & Johnson Reports 2017 Second-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second...
NEW BRUNSWICK, N.J. , July 18, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016. Operational sales results increased 2.9% and the negative impac
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2017 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2017 of $0.84 per...
NEW BRUNSWICK, N.J. , July 17, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2017 of $0.84 per share on the company's common stock. The dividend is payable on September 12, 201
Read more →JNJJohnson & Johnson Releases 2016 Health for Humanity Report Johnson & Johnson has released its 2016 Health for Humanity Report sharing progress on environmental, social and governance measures, which advance...
NEW BRUNSWICK, N.J. , June 22, 2017 /PRNewswire/ -- Johnson & Johnson has released its 2016 Health for Humanity Report sharing progress on environmental, social and governance measures, which advance the Company's mission to profoundly improve the course of health for humanity. O
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 18th, to review second-quarter...
NEW BRUNSWICK, N.J. , June 20, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 18th , to review second-quarter results. Alex Gorsky , Chairman and Chief Executive Officer; Dominic Caruso ,
Read more →JNJDouglas Wallace, Ph.D., Wins 2017 Dr. Paul Janssen Award for Biomedical Research Johnson & Johnson (NYSE: JNJ) today named Douglas Wallace, Ph.D., of Children's Hospital of Philadelphia, winner of the 2017 Dr. Paul Janssen Award...
SAN DIEGO , June 20, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today named Douglas Wallace , Ph.D., of Children's Hospital of Philadelphia , winner of the 2017 Dr. Paul Janssen Award for Biomedical Research, and launched a campaign for champions of science as part of th
Read more →JNJJohnson & Johnson Announces Completion of Acquisition of Actelion Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Actelion Ltd for a total purchase price of approximately $30...
NEW BRUNSWICK, N.J. , June 16, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the completion of the acquisition of Actelion Ltd for a total purchase price of approximately $30 billion in cash. The acquisition was completed through an all-cash public tender of
Read more →JNJJohnson & Johnson Announces Expected Settlement of Actelion Tender Offer on June 16, 2017 Johnson & Johnson (NYSE: JNJ) today announced that, with today's receipt of approval of the proposed acquisition of Actelion Ltd (SIX: ATLN) from the ...
NEW BRUNSWICK, N.J. , June 9, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that, with today's receipt of approval of the proposed acquisition of Actelion Ltd (SIX: ATLN) from the European Commission (EC), all regulatory approvals required to complete the tr
Read more →JNJJohnson & Johnson to Participate in the Goldman Sachs 38th Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15, at the Terranea...
NEW BRUNSWICK, N.J. , May 25, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15 , at the Terranea Resort in Rancho Palos Verdes, California . Sandi Peterson, Executive Vice Presi
Read more →JNJJohnson & Johnson Showcases Strong Pipeline of Transformational Medicines at its Pharmaceutical Business Review Meeting At a meeting today with industry analysts, senior leaders of Johnson & Johnson (NYSE: JNJ) and its Janssen Pharmaceutical Companies will announce...
NEW BRUNSWICK, N.J. , May 17, 2017 /PRNewswire/ -- At a meeting today with industry analysts, senior leaders of Johnson & Johnson (NYSE: JNJ ) and its Janssen Pharmaceutical Companies will announce plans to launch or file for regulatory approval more than 10 new products with blo
Read more →JNJJohnson & Johnson to Participate in the Jefferies 2017 Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Jefferies 2017 Global Healthcare Conference on Thursday, June 8, at the Grand Hyatt New York....
NEW BRUNSWICK, N.J. , May 11, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Jefferies 2017 Global Healthcare Conference on Thursday, June 8 , at the Grand Hyatt New York. Alex Gorsky, Chairman and Chief Executive Officer will represent the Company in
Read more →JNJJohnson & Johnson to Participate in the 2017 UBS Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2017 UBS Global Healthcare Conference on Tuesday, May 23, at the Grand Hyatt New York. Dominic...
NEW BRUNSWICK, N.J. , May 5, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2017 UBS Global Healthcare Conference on Tuesday, May 23 , at the Grand Hyatt New York. Dominic Caruso, Executive Vice President, Chief Financial Officer will represent the Co
Read more →JNJJohnson & Johnson Introduces Two New Interactive Experiences Showcasing More Than 130 Years Of Healthcare Innovation Today, Johnson & Johnson (NYSE: JNJ), the world's largest healthcare company, launches Johnson & Johnson Our Story at the Powerhouse and Johnson &...
NEW BRUNSWICK, N.J. , May 1, 2017 /PRNewswire/ -- Today, Johnson & Johnson (NYSE: JNJ ), the world's largest healthcare company, launches Johnson & Johnson Our Story at the Powerhouse and Johnson & Johnson Our Story to take visitors on a journey through time and around the world
Read more →JNJJohnson & Johnson Announces Dividend Increase of 5.0% Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 5.0% increase in the quarterly dividend rate, from $0.80 per ...
NEW BRUNSWICK, N.J. , April 27, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a 5.0% increase in the quarterly dividend rate, from $0.80 per share to $0.84 per share. The increase was announced this morning at the Ann
Read more →JNJJohnson & Johnson Reports 2017 First-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $17.8 billion for the first quarter of 2017, an increase of 1.6% as compared to the first...
NEW BRUNSWICK, N.J. , April 18, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $17.8 billion for the first quarter of 2017, an increase of 1.6% as compared to the first quarter of 2016. Operational sales results increased 2.0% and the negative impact
Read more →JNJJohnson & Johnson Publishes Interim Result for Actelion Tender Offer and Declares the Tender Offer Successful Johnson & Johnson (NYSE: JNJ) today announced that its Swiss subsidiary, Janssen Holding GmbH ( Janssen ), published the provisional notice of the...
NEW BRUNSWICK, N.J. , March 31, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Swiss subsidiary, Janssen Holding GmbH ("Janssen"), published the provisional notice of the interim result of its all-cash public tender offer in Switzerland to acquire al
Read more →JNJJohnson & Johnson to Host Investor Conference Call on First-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 18th, to review first-quarter...
NEW BRUNSWICK, N.J. , March 21, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 18 th , to review first-quarter results. Dominic Caruso , Vice President, Finance and Chief Financial Office
Read more →JNJJohnson & Johnson gibt Gewinner der ersten Africa Innovation Challenge bekannt Johnson & Johnson (NYSE: JNJ) gab heute beim Global Entrepreneurship Congress die Gewinner der ersten Africa Innovation Challenge bekannt. Die...
Wettbewerbsbeitrag des 85 Jahre langen Engagements des Unternehmens für die Unterstützung von Unternehmern, wissenschaftlichen Bildungsmöglichkeiten und Gesundheitssystemen auf dem ganzen Kontinent KAPSTADT, Südafrika, 15. März 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ )
Read more →JNJJohnson & Johnson Names Winners of First Africa Innovation Challenge Johnson & Johnson (NYSE: JNJ) today named the winners of the first Africa Innovation Challenge at the Global Entrepreneurship Congress. The...
CAPE TOWN, South Africa , March 14, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today named the winners of the first Africa Innovation Challenge at the Global Entrepreneurship Congress. The initiative, which received nearly 500 submissions from innovators and entrepreneur
Read more →JNJJohnson & Johnson Completes Acquisition of Abbott Medical Optics Johnson & Johnson (NYSE: JNJ) today announced it has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott....
NEW BRUNSWICK, N.J. , Feb. 27, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced it has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition was originally announced Sept. 16, 2016
Read more →JNJJohnson & Johnson Publishes Prospectus For Actelion Tender Offer Today Janssen Holding GmbH, a Swiss subsidiary of Johnson & Johnson (NYSE:JNJ), has published the Offer Prospectus for its previously announced...
NEW BRUNSWICK, N.J. , Feb. 16, 2017 /PRNewswire/ -- Today Janssen Holding GmbH, a Swiss subsidiary of Johnson & Johnson (NYSE: JNJ ), has published the Offer Prospectus for its previously announced all-cash tender offer to acquire all of the outstanding shares of Actelion Ltd (SI
Read more →JNJJohnson & Johnson to Participate in Barclays Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Healthcare Conference on Tuesday, Mar. 14, at the Loews Miami Beach Hotel,...
NEW BRUNSWICK, N.J. , Feb. 14, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Barclays Global Healthcare Conference on Tuesday, Mar. 14 , at the Loews Miami Beach Hotel, Miami , FL. Jennifer Taubert , Company Group Chairman, The Americas will represen
Read more →JNJJohnson & Johnson Adds Hospital Medical Devices to Sandra Peterson Responsibilities Johnson & Johnson (NYSE: JNJ) today announced that in addition to her current responsibilities, Sandra Peterson, Group Worldwide Chair, will assume...
NEW BRUNSWICK, N.J. , Feb. 2, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that in addition to her current responsibilities, Sandra Peterson , Group Worldwide Chair, will assume leadership of its Hospital Medical Device business, effective June 1 , when Gar
Read more →JNJJohnson & Johnson to Participate in RBC Capital Markets 2017 Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the RBC Capital Markets 2017 Global Healthcare Conference on Thursday, Feb. 23, at the Lotte New...
NEW BRUNSWICK, N.J. , Jan. 27, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the RBC Capital Markets 2017 Global Healthcare Conference on Thursday, Feb. 23 , at the Lotte New York Palace in New York City. Sandi Peterson , Executive Vice President, Group
Read more →JNJJohnson & Johnson To Acquire Actelion For $30 Billion With Spin-Out Of New R&D Company Johnson & Johnson (NYSE:JNJ) and Actelion Ltd. (SIX:ATLN) today announced that they have entered into a definitive transaction agreement under which...
NEW BRUNSWICK, N.J. and ALLSCHWIL and BASEL, Switzerland , Jan. 26, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) and Actelion Ltd. (SIX:ATLN) today announced that they have entered into a definitive transaction agreement under which Johnson & Johnson will launch an all-cas
Read more →JNJInvestor Conference Call: Johnson & Johnson to Acquire Actelion for $30 Billion With Spin-Out of New R&D Company Johnson & Johnson (NYSE: JNJ) and Actelion Ltd. (SIX: ATLN) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Thursday, Jan....
NEW BRUNSWICK, N.J. , Jan. 26, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) and Actelion Ltd. (SIX: ATLN) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Thursday, Jan. 26 th , to discuss the announcement that they have entered into a definitive ag
Read more →JNJJohnson & Johnson to Participate in the 2017 CAGNY Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2017 CAGNY Conference on Wednesday, Feb. 22, at The Boca Raton Resort, Boca Raton, FL. Jorge...
NEW BRUNSWICK, N.J. , Jan. 25, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2017 CAGNY Conference on Wednesday, Feb. 22 , at The Boca Raton Resort, Boca Raton , FL. Jorge Mesquita , Executive Vice President, Worldwide Chairman, Consumer will represe
Read more →JNJJohnson & Johnson Reports 2016 Fourth-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $18.1 billion for the fourth quarter of 2016, an increase of 1.7% as compared to the fourth...
NEW BRUNSWICK, N.J. , Jan. 24, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $18.1 billion for the fourth quarter of 2016, an increase of 1.7% as compared to the fourth quarter of 2015. Operational sales results increased 2.3% and the negative impac
Read more →JNJThe ECHELON FLEX™ GST System Will Now Feature A 45mm Endocutter With Exclusive Gripping Surface Technology Reloads Building on the success of the ECHELON FLEX™ 60mm Powered Plus Stapler with Gripping Surface Technology (GST), Ethicon*, a leading global provider of ...
CINCINNATI , Jan. 23, 2017 /PRNewswire/ -- Building on the success of the ECHELON FLEX™ 60mm Powered Plus Stapler with Gripping Surface Technology (GST), Ethicon*, a leading global provider of medical devices, today announced that the ECHELON FLEX™ GST System 1 (45mm) has receive
Read more →JNJJohnson & Johnson to Participate in the Leerink Partners 6th Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, Feb. 16, at Lotte New...
NEW BRUNSWICK, N.J. , Jan. 23, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, Feb. 16 , at Lotte New York Palace, NY. Joaquin Duato , Executive Vice President, Worldwide Chairman, P
Read more →JNJEthicon Announces Acquisition of Megadyne Medical Products, Inc. Ethicon Endo-Surgery, Inc. announced today that it has acquired Megadyne Medical Products, Inc., a privately held medical device company that...
"We are committed to meeting the evolving needs of surgeons and hospital systems, and the addition of Megadyne's state-of-the-art portfolio gives us a comprehensive suite of energy devices to improve patient care in surgeries across all specialties," said Michael del Prado , Comp
Read more →JNJDr. Paul Janssen Award for Biomedical Research Issues 2017 Call for Nominations The Dr. Paul Janssen Award for Biomedical Research today opens its 2017 call for nominations. This prestigious award recognizes individuals whose...
NEW BRUNSWICK, N.J. , Jan. 10, 2017 /PRNewswire/ -- The Dr. Paul Janssen Award for Biomedical Research today opens its 2017 call for nominations. This prestigious award recognizes individuals whose basic or clinical discoveries have made, or have the potential to make, significan
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for First Quarter 2017 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2017 of $0.80 per...
NEW BRUNSWICK, N.J. , Jan. 3, 2017 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2017 of $0.80 per share on the company's common stock. The dividend is payable on March 14, 2017 to
Read more →JNJJohnson & Johnson to Participate in 35th Annual JP Morgan Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 35th Annual JP Morgan Health Care Conference on Monday, Jan. 9, at the Westin St. Francis in...
NEW BRUNSWICK, N.J. , Dec. 27, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 35 th Annual JP Morgan Health Care Conference on Monday, Jan. 9 , at the Westin St. Francis in San Francisco. Alex Gorsky , Chairman of the Board of Directors and Chief Exec
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Fourth-Quarter/Full-Year 2016 Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 24th, to review fourth-quarter...
NEW BRUNSWICK, N.J. , Dec. 27, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 24 th , to review fourth-quarter and full-year results. Alex Gorsky , Chairman and Chief Executive Officer; Do
Read more →JNJJohnson & Johnson Confirms Exclusive Negotiations with Actelion Johnson & Johnson (NYSE: JNJ) today confirmed it has entered into exclusive negotiations with Actelion Ltd. (SIX: ATLN) regarding a potential...
NEW BRUNSWICK, N.J. , Dec. 21, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today confirmed it has entered into exclusive negotiations with Actelion Ltd. (SIX: ATLN) regarding a potential transaction. There can be no assurance any transaction will result from these discus
Read more →JNJJohnson & Johnson Announces it has Ended Discussions with Actelion Johnson & Johnson (NYSE: JNJ) today confirmed it has ended discussions with Actelion Pharmaceuticals Ltd. (SIX: ATLN) regarding a potential...
NEW BRUNSWICK, N.J. , Dec. 13, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today confirmed it has ended discussions with Actelion Pharmaceuticals Ltd. (SIX: ATLN) regarding a potential transaction. Johnson & Johnson was not able to reach an agreement that it believed woul
Read more →JNJJohnson & Johnson Confirms Discussions with Actelion Regarding Potential Transaction Johnson & Johnson (NYSE:JNJ) today confirmed it is engaged in preliminary discussions with Actelion Pharmaceuticals Ltd. (SIX: ATLN) regarding a...
NEW BRUNSWICK, N.J. , Nov. 25, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today confirmed it is engaged in preliminary discussions with Actelion Pharmaceuticals Ltd. (SIX: ATLN) regarding a potential transaction. There can be no assurance any transaction will result fro
Read more →JNJJohnson & Johnson Establishes Susan Lindquist Chair for Women in Science Johnson & Johnson (NYSE: JNJ) today announced the establishment of the Susan Lindquist Chair for Women in Science to honor the life and legacy of...
NEW BRUNSWICK, N.J. , Nov. 16, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the establishment of the Susan Lindquist Chair for Women in Science to honor the life and legacy of Susan L. Lindquist , Ph.D., a globally renowned scientist whose intellectually co
Read more →JNJJohnson & Johnson annonce le lancement de l'Africa Innovation Challenge qui vise à soutenir les entrepreneurs du continent et la mise au point de solutions locales pour la santé des consommateurs Attachée de longue date à l'Afrique, Johnson & Johnson (NYSE : JNJ) a annoncé aujourd'hui le lancement de l'Africa Innovation Challenge, une...
Le Challenge s'inscrit dans la stratégie globale de l'entreprise qui tend à promouvoir la santé et l'innovation sur le continent CAPE TOWN , Afrique du Sud, 1 novembre 2016 /PRNewswire/ -- Attachée de longue date à l'Afrique, Johnson & Johnson (NYSE : JNJ ) a annoncé aujourd'hui
Read more →JNJJohnson & Johnson Mourns the Loss of Susan Lindquist, Biomedical Research Pioneer and Member of the Johnson & Johnson Board of Directors Susan Lee Lindquist, Ph.D., member of the Johnson & Johnson (NYSE: JNJ) board of directors and world-renowned biomedical innovator, today lost her...
NEW BRUNSWICK, N.J. , Oct. 28, 2016 /PRNewswire/ -- Susan Lee Lindquist, Ph.D., member of the Johnson & Johnson (NYSE: JNJ ) board of directors and world-renowned biomedical innovator, today lost her battle with cancer. An insightful leader with an incomparable perspective on th
Read more →JNJJohnson & Johnson to Participate in the 25th Annual Credit Suisse Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 25th Annual Credit Suisse Health Care Conference on Tuesday, Nov. 8, at The Phoenician in...
NEW BRUNSWICK, N.J. , Oct. 26, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 25th Annual Credit Suisse Health Care Conference on Tuesday, Nov. 8 , at The Phoenician in Scottsdale, AZ. Sandi Peterson , Group Worldwide Chairman will represent the Compa
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2016 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2016 of $0.80 per...
NEW BRUNSWICK, N.J. , Oct. 20, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2016 of $0.80 per share on the company's common stock. The dividend is payable on December 6, 2016
Read more →JNJJohnson & Johnson Opens New Global Services Center In Tampa, Florida Today Johnson & Johnson (NYSE: JNJ) officially opened the doors of the new Johnson & Johnson Global Services delivery center in Tampa, Florida,...
TAMPA, Fla. , Oct. 19, 2016 /PRNewswire/ -- Today Johnson & Johnson (NYSE: JNJ ) officially opened the doors of the new Johnson & Johnson Global Services delivery center in Tampa, Florida , fulfilling the commitment the company announced in August 2015 to establish their best-in-
Read more →JNJJohnson & Johnson Reports 2016 Third-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $17.8 billion for the third quarter of 2016, an increase of 4.2% as compared to the third...
NEW BRUNSWICK, N.J. , Oct. 18, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $17.8 billion for the third quarter of 2016, an increase of 4.2% as compared to the third quarter of 2015. Operational sales results increased 4.3% and the negative impact
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Third-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 18th, to review third-quarter ...
NEW BRUNSWICK, N.J. , Sept. 20, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 18 th , to review third-quarter results. Dominic Caruso , Executive Vice President, Chief Financial Office
Read more →JNJJohnson & Johnson Advances Commitment to Improve Global Health and Well-Being Johnson & Johnson (NYSE: JNJ) announced a new five-year commitment to help advance the United Nations Sustainable Development Goals to help improve...
NEW BRUNSWICK, N.J. , Sept. 20, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced a new five-year commitment to help advance the United Nations Sustainable Development Goals to help improve the health and well-being of men, women and children around the world. Johnson
Read more →JNJJohnson & Johnson Announces Agreement to Acquire Abbott Medical Optics Johnson & Johnson (NYSE: JNJ) today announced a definitive agreement to acquire Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott...
NEW BRUNSWICK, N.J. , Sept. 16, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced a definitive agreement to acquire Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott Laboratories, for $4.325 billion in cash. AMO reported sales of $1.1 billion for
Read more →JNJJohnson & Johnson Announces World Health Organization will Review Ebola Vaccine Regimen for Emergency Use Assessment and Listing (EUAL) Johnson & Johnson (NYSE: JNJ) announced today that Janssen Vaccines & Prevention B.V. (Janssen) has completed a submission to the World Health...
ANTWERP, Belgium , Sept. 12, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today that Janssen Vaccines & Prevention B.V. (Janssen) has completed a submission to the World Health Organization (WHO) for Emergency Use Assessment and Listing (EUAL) for its investigati
Read more →JNJJohnson & Johnson Partners with Global Citizen to Improve the Trajectory of Human Health Around the World Johnson & Johnson is partnering with social action platform Global Citizen to help give every man, woman and child around the globe the opportunity...
NEW BRUNSWICK, N.J. , Sept. 7, 2016 /PRNewswire/ -- Johnson & Johnson is partnering with social action platform Global Citizen to help give every man, woman and child around the globe the opportunity for a healthier future. The partnership aims to create large-scale change for he
Read more →JNJJohnson & Johnson to Participate in 2016 Morgan Stanley Global Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2016 Morgan Stanley Global Health Care Conference on Wednesday, Sept. 14, at The Grand Hyatt...
NEW BRUNSWICK, N.J. , Aug. 31, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2016 Morgan Stanley Global Health Care Conference on Wednesday, Sept. 14, at The Grand Hyatt Hotel in New York. Alex Gorsky, Chairman and Chief Executive Officer and Dominic
Read more →JNJJohnson & Johnson to Participate in the 2016 Wells Fargo 11th Annual Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2016 Wells Fargo 11th Annual Healthcare Conference on Thursday, Sept. 8, at The Westin Boston...
NEW BRUNSWICK, N.J. , Aug. 25, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2016 Wells Fargo 11 th Annual Healthcare Conference on Thursday, Sept. 8 , at The Westin Boston Waterfront in Boston, MA. Dominic Caruso, Executive Vice President, Chief Fin
Read more →JNJJohnson & Johnson Announces Ruling Related to REMICADE® in the District of Massachusetts Federal Court Hearing Johnson & Johnson (NYSE: JNJ) today announced that the District of Massachusetts Federal Court has issued a ruling on a summary judgment motion filed ...
NEW BRUNSWICK, N.J. , Aug. 17, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that the District of Massachusetts Federal Court has issued a ruling on a summary judgment motion filed by Celltrion Healthcare Co. Ltd. and Celltrion Inc. (together, Celltrion) and
Read more →JNJJohnson & Johnson Reports 2016 Second-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $18.5 billion for the second quarter of 2016, an increase of 3.9% as compared to the second...
NEW BRUNSWICK, N.J. , July 19, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $18.5 billion for the second quarter of 2016, an increase of 3.9% as compared to the second quarter of 2015. Operational sales results increased 5.3% and the negative impac
Read more →JNJJohnson & Johnson Announces Completion Of Acquisition Of Vogue International LLC Johnson & Johnson (NYSE: JNJ) today announced that Johnson & Johnson Consumer Inc. has successfully completed the acquisition of Vogue International...
NEW BRUNSWICK, N.J. , July 18, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that Johnson & Johnson Consumer Inc. has successfully completed the acquisition of Vogue International LLC, a privately-held company focused on the marketing, development and distri
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2016 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2016 of $0.80 per...
NEW BRUNSWICK, N.J. , July 18, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2016 of $0.80 per share on the company's common stock. The dividend is payable on September 6, 2016
Read more →JNJJanssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 data for DARZALEX® (daratumumab) and the Janssen Immuno-oncology Strategy and Portfolio Janssen Research & Development, LLC and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast focused on Phase 3 data recently presented...
NEW BRUNSWICK, N.J. , July 7, 2016 /PRNewswire/ -- Janssen Research & Development, LLC and Johnson & Johnson (NYSE: JNJ ) will provide a pre-recorded webcast focused on Phase 3 data recently presented for DARZALEX ® (daratumumab) as well as the company's immuno-oncology strategy
Read more →JNJJohnson & Johnson Announces Retirement of Louise Mehrotra and Appointment of Joseph Wolk as Vice President of Investor Relations Johnson & Johnson (NYSE: JNJ) today announced that Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson, will retire in...
NEW BRUNSWICK, N.J. , June 22, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that Louise Mehrotra , Vice President of Investor Relations for Johnson & Johnson, will retire in January 2017 , after a transition period with her successor. Louise first joined th
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 19th, to review second-quarter...
NEW BRUNSWICK, N.J. , June 21, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 19 th , to review second-quarter results. Alex Gorsky , Chairman and Chief Executive Officer, Dominic Caruso ,
Read more →JNJYoshinori Ohsumi, Ph.D., Wins 2016 Dr. Paul Janssen Award for Biomedical Research As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept...
SAN FRANCISCO , June 8, 2016 /PRNewswire/ -- As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi , Ph.
Read more →JNJJohnson & Johnson Partners with Leading Organizations to Advance Education of Young Women and Girls in Science, Technology, Engineering, Math, Manufacturing and Design (STEM2D) Johnson & Johnson (NYSE:JNJ) is partnering with leading non-profit organizations FHI 360 and JA (Junior Achievement) Worldwide to advance the...
NEW BRUNSWICK, N.J. , June 6, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) is partnering with leading non-profit organizations FHI 360 and JA (Junior Achievement) Worldwide to advance the education of young women and girls in Science, Technology, Engineering, Math, Manufac
Read more →JNJJohnson & Johnson Announces Agreement to Acquire Vogue International Johnson & Johnson (NYSE: JNJ) today announced that Johnson & Johnson Consumer Inc. has entered into a definitive agreement to acquire Vogue...
NEW BRUNSWICK, N.J. , June 2, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that Johnson & Johnson Consumer Inc. has entered into a definitive agreement to acquire Vogue International, a privately held company focused on the marketing, development and distri
Read more →JNJJohnson & Johnson to Participate in the Goldman Sachs 37th Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, at the Terranea in ...
NEW BRUNSWICK, N.J. , May 25, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8 , at the Terranea in Rancho Palos Verdes, CA. Dominic Caruso, Executive Vice President, Chief Fina
Read more →JNJJohnson & Johnson Showcasing its Broad Innovation and Technology Strategies in Consumer and Medical Device Businesses At a meeting today with the investment community, senior leaders from the Johnson & Johnson Family of Companies (NYSE: JNJ) will review strategies...
NEW BRUNSWICK, N.J. , May 18, 2016 /PRNewswire/ -- At a meeting today with the investment community, senior leaders from the Johnson & Johnson Family of Companies (NYSE: JNJ ) will review strategies and opportunities for growth in the Consumer and Medical Device segments. The com
Read more →JNJJohnson & Johnson Announces Collaboration with HP Inc. Subsidiary to Create Personalized Health Care Solutions with 3D Printing Technologies Johnson & Johnson (NYSE: JNJ) today announced a collaboration between Johnson & Johnson Services, Inc. and a subsidiary of HP Inc. The collaboration...
NEW BRUNSWICK, N.J. , May 17, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced a collaboration between Johnson & Johnson Services, Inc. and a subsidiary of HP Inc. The collaboration is focused on using 3D printing technologies to create better health care outco
Read more →JNJJohnson & Johnson to Participate in the 2016 UBS Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2016 UBS Global Healthcare Conference on Monday, May 23, at the Grand Hyatt New York. Sandi...
NEW BRUNSWICK, N.J. , May 9, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2016 UBS Global Healthcare Conference on Monday, May 23 , at the Grand Hyatt New York. Sandi Peterson, Executive Vice President, Group Worldwide Chairman will represent the Co
Read more →JNJJohnson & Johnson Announces Dividend Increase of 6.7% Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 6.7% increase in the quarterly dividend rate, from $0.75 per ...
NEW BRUNSWICK, N.J. , April 28, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a 6.7% increase in the quarterly dividend rate, from $0.75 per share to $0.80 per share. The increase was announced this morning at the Ann
Read more →JNJJohnson & Johnson Consumer Inc. to Acquire NeoStrata Company, Inc., a Leader in Dermocosmetics Johnson & Johnson Consumer Inc. (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire NeoStrata Company, Inc., a...
SKILLMAN, N.J. , April 26, 2016 /PRNewswire/ -- Johnson & Johnson Consumer Inc. (NYSE: JNJ ) announced today that it has entered into a definitive agreement to acquire NeoStrata Company, Inc., a global leader in dermocosmetics. The acquisition will include NeoStrata's affiliates
Read more →JNJJohnson & Johnson to Participate in the 2016 Deutsche Bank 41st Annual Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2016 Deutsche Bank 41st Annual Health Care Conference on Thursday, May 5, at The...
NEW BRUNSWICK, N.J. , April 21, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2016 Deutsche Bank 41 st Annual Health Care Conference on Thursday, May 5 , at The InterContinental Boston. Dr. William Hait , MD. PhD, Global Head Janssen Research & Devel
Read more →JNJJohnson & Johnson Reports 2016 First-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $17.5 billion for the first quarter of 2016, an increase of 0.6% as compared to the first...
NEW BRUNSWICK, N.J. , April 19, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $17.5 billion for the first quarter of 2016, an increase of 0.6% as compared to the first quarter of 2015. Operational sales results increased 3.9% and the negative impact
Read more →JNJJohnson & Johnson Announces Launch of New Global Public Health Strategy at Opening of New Operations in Africa Johnson & Johnson (NYSE: JNJ) today announced the official launch of its global public health strategy at the opening of its companies' on-the-ground ...
NEW BRUNSWICK, N.J. , April 5, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the official launch of its global public health strategy at the opening of its companies' on-the-ground global public health operations in Cape Town, South Africa . Through this gl
Read more →JNJJohnson & Johnson to Webcast Annual Meeting of Shareholders Johnson & Johnson (NYSE: JNJ) will webcast its Annual Meeting of Shareholders at 10:00 a.m. (EDT) on Thursday, April 28, 2016, from the State Theatre ...
NEW BRUNSWICK, N.J. , March 28, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will webcast its Annual Meeting of Shareholders at 10:00 a.m. (EDT) on Thursday, April 28, 2016 , from the State Theatre in New Brunswick, N.J. Investors and other interested parties may access a
Read more →JNJJohnson & Johnson to Host Investor Conference Call on First-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 19th, to review first-quarter...
NEW BRUNSWICK, N.J. , March 15, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 19 th , to review first-quarter results. Dominic Caruso , Vice President, Finance and Chief Financial Office
Read more →JNJJohnson & Johnson to Participate in Barclays Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Healthcare Conference on Thursday, Mar. 17, at the Loews Miami Beach Hotel,...
NEW BRUNSWICK, N.J. , March 3, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Barclays Global Healthcare Conference on Thursday, Mar. 17 , at the Loews Miami Beach Hotel, Miami , FL. Dominic Caruso , Vice President, Finance & Chief Financial Officer a
Read more →JNJJohnson & Johnson sucht innovative Ideen, um HIV-Infektionen in Subsahara-Afrika zu senken Johnson & Johnson (NYSE: JNJ) verlautbarte heute einen Aufruf zur Einreichung innovativer Ideen im Rahmen des Innovationswettbewerbs DREAMS...
DREAMS-Initiative startet Innovationswettbewerb mit Preisgeld-Summe i. H. v. 85 Mio. USD für Lösungen, die weiblichen Teenagern und jungen Frauen helfen NEW BRUNSWICK, New Jersey , 18. Februar 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) verlautbarte heute einen Aufruf zu
Read more →JNJJohnson & Johnson hace una petición de ideas innovadoras para reducir las infecciones por VIH en el África sub-sahariana Johnson & Johnson (NYSE: JNJ) ha hecho una petición para ideas innovadoras como parte del Reto de Innovación DREAMS, que está apoyado por el...
DREAMS Partners anuncia un reto de innovación de 85 millones de dólares centrado en soluciones para las adolescentes y mujeres jóvenes NEW BRUNSWICK , Nueva Jersey , 18 de febrero de 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) ha hecho una petición para ideas innovadoras
Read more →JNJJohnson & Johnson lance un appel aux idées innovantes afin de réduire les infections au VIH en Afrique subsaharienne Aujourd'hui, Johnson & Johnson (NYSE : JNJ) a lancé un appel pour des idées innovantes dans le cadre du défi de l'innovation DREAMS qui est soutenu...
Les partenaires DREAMS annoncent un défi de l'innovation de 85 millions $ axé sur les solutions pour les adolescentes et les jeunes femmes NEW BRUNSWICK, New Jersey , le 18 février 2016 /PRNewswire/ -- Aujourd'hui, Johnson & Johnson (NYSE : JNJ ) a lancé un appel pour des idées
Read more →JNJJohnson & Johnson Issues Call for Innovative Ideas to Reduce HIV Infections in Sub-Saharan Africa Johnson & Johnson (NYSE: JNJ) today issued a call for innovative ideas as part of the DREAMS Innovation Challenge, which is supported by the U.S....
DREAMS Partners Announce $85 Million Innovation Challenge Focused on Solutions for Adolescent Girls and Young Women NEW BRUNSWICK, N.J. , Feb. 17, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today issued a call for innovative ideas as part of the DREAMS Innovation Challe
Read more →JNJJohnson & Johnson lança apelo em busca de ideias inovadoras para reduzir a infecção do vírus HIV na África Subsaariana A Johnson & Johnson (NYSE: JNJ) lançou um apelo hoje solicitando ideias inovadoras para o Desafio em Busca de Inovação DREAMS, apoiado pelo Plano de...
NEW BRUNSWICK , Nova Jersey , 17 de fevereiro de 2016 /PRNewswire/ -- A Johnson & Johnson (NYSE: JNJ ) lançou um apelo hoje solicitando ideias inovadoras para o Desafio em Busca de Inovação DREAMS, apoiado pelo Plano de Emergência do Presidente dos EUA para o Combate à AIDS (PEPF
Read more →JNJJohnson & Johnson lanza una convocatoria para ideas innovadoras para reducir las infecciones por VIH en el África subsahariana Johnson & Johnson (NYSE: JNJ) lanzó una convocatoria hoy para la presentación de ideas innovadoras como parte del DREAMS Innovation Challenge...
NEW BRUNSWICK , Nueva Jersey , 17 de febrero de 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) lanzó una convocatoria hoy para la presentación de ideas innovadoras como parte del DREAMS Innovation Challenge (Desafío por la Innovación DREAMS), que está respaldado por el Plan
Read more →JNJJohnson & Johnson to Participate in RBC Capital Markets Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the RBC Capital Markets Global Healthcare Conference on Tuesday, Feb. 23, at the New York Palace in ...
NEW BRUNSWICK, N.J. , Feb. 9, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the RBC Capital Markets Global Healthcare Conference on Tuesday, Feb. 23 , at the New York Palace in New York City. Dominic Caruso , Vice President, Finance & Chief Financial Off
Read more →JNJJohnson & Johnson Reports 2015 Fourth-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $17.8 billion for the fourth quarter of 2015, a decrease of 2.4% as compared to the fourth...
NEW BRUNSWICK, N.J. , Jan. 26, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $17.8 billion for the fourth quarter of 2015, a decrease of 2.4% as compared to the fourth quarter of 2014. Operational sales results increased 4.4% and the negative impact
Read more →JNJJohnson & Johnson Joins First Industry-wide Call for New Collective Action to Address Antimicrobial Resistance Johnson & Johnson (NYSE: JNJ) today announced it has joined more than 80 companies and organizations in signing the Declaration on Combating...
NEW BRUNSWICK, N.J. , Jan. 20, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced it has joined more than 80 companies and organizations in signing the Declaration on Combating Antimicrobial Resistance (AMR) , an industry-wide call to action announced at the Worl
Read more →JNJJohnson & Johnson Announces Actions To Strengthen Medical Devices Leadership Position In Evolving Healthcare Marketplace Johnson & Johnson (NYSE: JNJ) today announced restructuring actions in its Medical Devices businesses to better serve the needs of customers and...
NEW BRUNSWICK, N.J. , Jan. 19, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced restructuring actions in its Medical Devices businesses to better serve the needs of customers and patients in today's evolving healthcare marketplace. The company is undertaking ac
Read more →JNJJanssen and Johnson & Johnson to Provide Webcast Presentation on the Janssen Oncology Hematologic Malignancy Portfolio Janssen Research & Development, LLC (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast focused on data from the Janssen...
NEW BRUNSWICK, N.J. , Jan. 15, 2016 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and Johnson & Johnson (NYSE: JNJ ) will provide a pre-recorded webcast focused on data from the Janssen Oncology hematologic malignancy portfolio for investors and other interested p
Read more →JNJDr. Paul Janssen Award for Biomedical Research lanza su llamada a la participación para 2016 El Dr. Paul Janssen Award for Biomedical Research abre hoy su plazo de participación para 2016. Este prestigioso premio reconoce a las personas cuyos ...
NEW BRUNSWICK , Nueva Jersey , 6 de enero de 2016 /PRNewswire/ -- El Dr. Paul Janssen Award for Biomedical Research abre hoy su plazo de participación para 2016. Este prestigioso premio reconoce a las personas cuyos descubrimientos básicos o clínicos han hecho, o tienen el potenc
Read more →JNJJohnson & Johnson Partners with Leading Universities to Advance Women's Education in Science, Technology, Engineering, Math, Manufacturing and Design (STEM2D) Johnson & Johnson (NYSE: JNJ) today announced it has entered into 10 partnerships around the world to help increase the number of undergraduate women ...
NEW BRUNSWICK, N.J. , Jan. 6, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced it has entered into 10 partnerships around the world to help increase the number of undergraduate women enrolling in and declaring majors in the fields of Science, Technology, Engine
Read more →JNJDr. Paul Janssen Award for Biomedical Research Issues 2016 Call for Nominations The Dr. Paul Janssen Award for Biomedical Research today opens its 2016 call for nominations. This prestigious award recognizes individuals whose...
NEW BRUNSWICK, N.J. , Jan. 5, 2016 /PRNewswire/ -- The Dr. Paul Janssen Award for Biomedical Research today opens its 2016 call for nominations. This prestigious award recognizes individuals whose basic or clinical discoveries have made, or have the potential to make, significant
Read more →JNJLe Dr. Paul Janssen Award for Biomedical Research lance son appel à nominations 2016 Le Dr. Paul Janssen Award for Biomedical Research lance aujourd'hui son appel à nominations 2016. Ce prix prestigieux récompense des personnes dont...
NEW BRUNSWICK, New Jersey , 5 janvier 2016 /PRNewswire/ -- Le Dr. Paul Janssen Award for Biomedical Research lance aujourd'hui son appel à nominations 2016. Ce prix prestigieux récompense des personnes dont les découvertes élémentaires ou cliniques ont apporté ou peuvent apporter
Read more →JNJDr. Paul Janssen Award for Biomedical Research ruft zur Kandidatennominierung 2016 auf Der Dr. Paul Janssen Award for Biomedical Research startet heute seinen Aufruf zur Nominierung von Kandidaten für 2016. Die angesehene Auszeichnung...
NEW BRUNSWICK, New Jersey , 5. Januar 2016 /PRNewswire/ -- Der Dr. Paul Janssen Award for Biomedical Research startet heute seinen Aufruf zur Nominierung von Kandidaten für 2016. Die angesehene Auszeichnung wird an Personen verliehen, deren wissenschaftliche Forschung einen wicht
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for First Quarter 2016 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2016 of $0.75 per...
NEW BRUNSWICK, N.J. , Jan. 4, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2016 of $0.75 per share on the company's common stock. The dividend is payable on March 8, 2016 to s
Read more →JNJJohnson & Johnson to Participate in the 34th Annual JP Morgan Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 34th Annual JP Morgan Health Care Conference on Monday, Jan. 11, at the Westin St. Francis in...
NEW BRUNSWICK, N.J. , Dec. 28, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 34 th Annual JP Morgan Health Care Conference on Monday, Jan. 11 , at the Westin St. Francis in San Francisco. Alex Gorsky , Chairman of the Board of Directors and Chief Exe
Read more →JNJJohnson & Johnson to Host Fourth-Quarter/Full-Year 2015 Investor Conference Call on Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 26th, to review fourth-quarter...
NEW BRUNSWICK, N.J. , Dec. 22, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 26 th , to review fourth-quarter results. Alex Gorsky , Chairman and Chief Executive Officer; Dominic Caruso ,
Read more →JNJJohnson & Johnson Announces Formation Of Verb Surgical Inc., In Collaboration With Verily Johnson & Johnson (NYSE: JNJ) today announced the formation of Verb Surgical Inc., an independent surgical solutions company, in collaboration with...
NEW BRUNSWICK, N.J. , Dec. 10, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the formation of Verb Surgical Inc., an independent surgical solutions company, in collaboration with Verily Life Sciences LLC ( formerly Google Life Sciences ). This new company wa
Read more →JNJJohnson & Johnson Announces Completion Of Novira Therapeutics, Inc. Acquisition Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Novira Therapeutics, Inc., a privately held, clinical-stage...
NEW BRUNSWICK, N.J. , Dec. 4, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the completion of the acquisition of Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing innovative therapies for curative treatment of c
Read more →JNJJohnson & Johnson Marks World AIDS Day with Major New Global Commitments to End HIV Infection in Adolescent Girls and Women Building on its 25-year legacy in the fight against HIV/AIDS, Johnson & Johnson (NYSE: JNJ) today announced four new public-private partnerships...
NEW BRUNSWICK, N.J. , Dec. 1, 2015 /PRNewswire/ -- Building on its 25-year legacy in the fight against HIV/AIDS, Johnson & Johnson (NYSE: JNJ ) today announced four new public-private partnerships through its Janssen Pharmaceutical Companies to significantly reduce the burden of
Read more →JNJShare A Photo, Give Back In A Snap Today in Times Square, thousands of visitors joined actor and Operation Smile Ambassador Zachary Levi; celebrity photographer and USO Ambassador...
NEW YORK , Nov. 24, 2015 /PRNewswire/ -- Today in Times Square, thousands of visitors joined actor and Operation Smile Ambassador Zachary Levi ; celebrity photographer and USO Ambassador Nigel Barker ; actress and United Nations Foundation's Girl Up Ambassador Katherine McNamara
Read more →JNJJohnson & Johnson Announces $1.75 Million Donation to Save the Children to Support Syrian Humanitarian Refugee Crisis Johnson & Johnson (NYSE: JNJ) today announced an expanded partnership with Save the Children to support children impacted by the Syrian refugee...
NEW BRUNSWICK, N.J. , Nov. 17, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced an expanded partnership with Save the Children to support children impacted by the Syrian refugee crisis and strengthen long-term resiliency in their communities. The $1.75 million
Read more →JNJJohnson & Johnson Announces Agreement To Acquire Novira Therapeutics, Inc. Johnson & Johnson (NYSE: JNJ) today announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage...
NEW BRUNSWICK, N.J. , Nov. 4, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic h
Read more →JNJJohnson & Johnson to Participate in the 24th Annual Credit Suisse Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 24th Annual Credit Suisse Health Care Conference on Tuesday, Nov. 10, at The Phoenician in...
NEW BRUNSWICK, N.J. , Oct. 27, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 24th Annual Credit Suisse Health Care Conference on Tuesday, Nov. 10 , at The Phoenician in Scottsdale, AZ. Dominic Caruso , Vice President, Finance & Chief Financial Office
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2015 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2015 of $0.75 per...
NEW BRUNSWICK, N.J. , Oct. 22, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2015 of $0.75 per share on the company's common stock. The dividend is payable on December 8, 2015
Read more →JNJLeitender Neurowissenschaftler bei Janssen in den Wissenschaftlichen Beirat des globalen Dementia Discovery Fund bestellt Johnson & Johnson (NYSE:JNJ) meldete heute, dass Husseini K. Manji, MD, FRCPC, globaler therapeutischer Leiter für Neurowissenschaften bei Janssen...
Johnson & Johnsons Investition in Höhe von 10 Millionen US-Dollar unterstützt den unter Führung der britischen Regierung aufgelegten Fonds, der Industrie, Regierung und gemeinnützige Organisationen im gemeinsamen Streben nach neuartigen Therapien zusammenbringt LONDON , 21. Okto
Read more →JNJLe neuroscientifique en chef de Janssen a été nommé au conseil consultatif scientifique du Dementia Discovery Fund mondial Johnson & Johnson (NYSE : JNJ) a annoncé aujourd'hui que Husseini K. Manji, MD, FRCPC, directeur de la recherche thérapeutique mondiale pour les...
Un investissement de 10 millions USD de Johnson & Johnson appuie le fonds dirigé par le gouvernement du Royaume-Uni, qui rassemble des organisations sectorielles, gouvernementales et à but non lucratif dans la poursuite de nouvelles thérapies LONDRES, 22 octobre 2015 /PRNewswire
Read more →JNJHead Janssen Neuroscientist Appointed to Scientific Advisory Board of Global Dementia Discovery Fund Johnson & Johnson (NYSE:JNJ) announced today that Husseini K. Manji, MD, FRCPC, Global Therapeutic Head for Neuroscience at Janssen Research &...
LONDON , Oct. 21, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today that Husseini K. Manji , MD, FRCPC, Global Therapeutic Head for Neuroscience at Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has been ap
Read more →JNJEl jefe de Neurociencias de Janssen asesorará al Fondo para el Descubrimiento de la Demencia Johnson & Johnson (NYSE:JNJ) ha anunciado hoy que Husseini K. Manji, MD, FRCPC, jefe terapéutico global de Neurociencias en Janssen Research &...
- El jefe de Neurociencias de Janssen nombrado para el Comité de Asesoramiento Científico del Fondo para el Descubrimiento de la Demencia (FDD) La inversión de 10 millones de dólares de Johnson & Johnson respalda el fondo gubernamental británico que une a la industria, el gobier
Read more →JNJJohnson & Johnson Reports 2015 Third-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $17.1 billion for the third quarter of 2015, a decrease of 7.4% as compared to the third...
NEW BRUNSWICK, N.J. , Oct. 13, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $17.1 billion for the third quarter of 2015, a decrease of 7.4% as compared to the third quarter of 2014. Operational sales results increased 0.8% and the negative impact o
Read more →JNJJohnson & Johnson Announces $10 Billion Share Repurchase Program Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has approved the repurchase of up to $10 billion of the company's common...
NEW BRUNSWICK, N.J. , Oct. 13, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has approved the repurchase of up to $10 billion of the company's common stock. "We are pleased that Johnson & Johnson's strong balance sheet and cash f
Read more →JNJJohnson & Johnson Announces Start of Clinical Trial of Ebola Vaccine Regimen in Sierra Leone Johnson & Johnson (NYSE: JNJ) today announced the start of a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine...
Johnson & Johnson Announces Start of Clinical Trial of Ebola Vaccine Regimen in Sierra Leone Accessibility Statement Skip Navigation --> -->
Read more →JNJJohnson & Johnson Announces Completion of Cordis Divestiture to Cardinal Health Johnson & Johnson (NYSE: JNJ) today announced the completion of the divestiture of its Cordis business to Cardinal Health for an approximate value of ...
NEW BRUNSWICK, N.J. , Oct. 4, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the completion of the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion , subject to customary adjustments. The Cordis business is a globa
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Third-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, Oct. 13th, to review third-quarter...
NEW BRUNSWICK, N.J. , Sept. 15, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, Oct. 13 th , to review third-quarter results. Gary Pruden , Worldwide Chairman, Medical Devices; Dominic Caruso ,
Read more →JNJJohnson & Johnson to Participate in the 2015 Morgan Stanley Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2015 Morgan Stanley Healthcare Conference on Thursday, Sept. 17, at the Grand Hyatt New York....
NEW BRUNSWICK, N.J. , Sept. 3, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2015 Morgan Stanley Healthcare Conference on Thursday, Sept. 17 , at the Grand Hyatt New York. Dominic Caruso , Vice President, Finance & Chief Financial Officer will repres
Read more →JNJJohnson & Johnson to Participate in the 2015 Wells Fargo 10th Annual Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2015 Wells Fargo 10th Annual Healthcare Conference on Thursday, Sept. 10, at The Hyatt Regency...
NEW BRUNSWICK, N.J. , Aug. 27, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2015 Wells Fargo 10 th Annual Healthcare Conference on Thursday, Sept. 10 , at The Hyatt Regency Boston. Alex Gorsky, Chairman of the Board of Directors and Chief Executive
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2015 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2015 of $0.75 per...
NEW BRUNSWICK, N.J. , July 20, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2015 of $0.75 per share on the company's common stock. The dividend is payable on September 8, 2015
Read more →JNJJohnson & Johnson Reports 2015 Second-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $17.8 billion for the second quarter of 2015, a decrease of 8.8% as compared to the second...
NEW BRUNSWICK, N.J. , July 14, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $17.8 billion for the second quarter of 2015, a decrease of 8.8% as compared to the second quarter of 2014. Operational results decreased 0.9% and the negative impact of cu
Read more →JNJBert Vogelstein, M.D., Wins 2015 Dr. Paul Janssen Award for Biomedical Research Johnson & Johnson (NYSE: JNJ) today named Dr. Bert Vogelstein of Johns Hopkins University, Johns Hopkins Kimmel Cancer Center and the Howard Hughes...
PHILADELPHIA , June 17, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today named Dr. Bert Vogelstein of Johns Hopkins University , Johns Hopkins Kimmel Cancer Center and the Howard Hughes Medical Institute, the winner of the 2015 Dr. Paul Janssen Award for Biomedical Resea
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 14th, to review second-quarter...
NEW BRUNSWICK, N.J. , June 16, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 14 th , to review second-quarter results. Alex Gorsky , Chairman of the Board of Directors and Chief Executive
Read more →JNJCEO and Director of Huntsman Cancer Institute Dr. Mary Beckerle Joins Johnson & Johnson Board of Directors Johnson & Johnson (NYSE: JNJ) announced today that its Board of Directors has appointed Mary Beckerle, Ph.D., Chief Executive Officer and Director of ...
NEW BRUNSWICK, N.J. , June 9, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today that its Board of Directors has appointed Mary Beckerle , Ph.D., Chief Executive Officer and Director of Huntsman Cancer Institute at the University of Utah , as a Director of Johnso
Read more →JNJJohnson & Johnson Announces Open Translational Science Project in Schizophrenia Johnson & Johnson announced today that Janssen Research & Development, LLC (Janssen), a Janssen Pharmaceutical Company of Johnson & Johnson, and a...
TITUSVILLE, N.J. , June 9, 2015 /PRNewswire/ -- Johnson & Johnson announced today that Janssen Research & Development, LLC (Janssen), a Janssen Pharmaceutical Company of Johnson & Johnson, and a group of leading research organizations are launching the OPTICS Project -- Open Tran
Read more →JNJJohnson & Johnson Announces Acceptance of Binding Offer From Cardinal Health To Acquire Cordis Johnson & Johnson (NYSE: JNJ) today announced the acceptance of the March 1, 2015 binding offer from Cardinal Health to acquire its Cordis business...
NEW BRUNSWICK, N.J. , May 28, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the acceptance of the March 1, 2015 binding offer from Cardinal Health to acquire its Cordis business for an approximate value of $2 billion . The offer was accepted after consultati
Read more →JNJJohnson & Johnson to Participate in the Goldman Sachs 36th Annual Global Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 36th Annual Global Healthcare Conference on Thursday, June 11, at the Terranea in ...
NEW BRUNSWICK, N.J. , May 27, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Goldman Sachs 36th Annual Global Healthcare Conference on Thursday, June 11 , at the Terranea in Rancho Palos Verdes, CA. Sandi Peterson, Group Worldwide Chairman will repres
Read more →JNJJohnson & Johnson Pharmaceutical Segment to Continue Driving Above-Industry Growth with Plans to File More than 10 New Products by 2019, Each with Potential to Exceed $1 Billion in Revenue At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) will announce...
NEW BRUNSWICK, N.J. , May 20, 2015 /PRNewswire/ -- At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) will announce plans to file for regulatory approval of more than 10 new products between 2015 and
Read more →JNJJohnson & Johnson Expands IP Policy to Create Broad Access in 128 Countries for Development of New and Optimized HIV Medicine Formulations for Children Living with HIV Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have furthered their commitment to improve the health of children living...
-- Expanded Policy will Increase Access for Darunavir Pediatric Formulations in 128 Resource-Limited Countries -- Trinidad and Tobago , Antigua , Aruba , Bahamas , Barbados and Jamaica are some of the countries that would benefit with this policy PANAMA CITY, May 14, 2015 /PRNe
Read more →JNJJohnson & Johnson amplía política de PI para ampliar el acceso a niños de 128 países que viven con VIH al desarrollo de nuevas y optimizadas fórmulas de medicamentos para el VIH Johnson & Johnson anunció hoy que sus compañías farmacéuticas Janssen han dado un paso más en su compromiso con la tarea de mejorar la salud de los...
CIUDAD DE PANAMÁ, 14 de mayo de 2015 /PRNewswire-HISPANIC PR WIRE/ -- Johnson & Johnson anunció hoy que sus compañías farmacéuticas Janssen han dado un paso más en su compromiso con la tarea de mejorar la salud de los niños que viven con VIH mediante una política ampliada que bus
Read more →JNJJohnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines Johnson & Johnson (NYSE: JNJ) today announced a first-of-its-kind partnership that enlists a third party to review requests made to the Janssen...
NEW BRUNSWICK, N.J. , May 7, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced a first-of-its-kind partnership that enlists a third party to review requests made to the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) for compassionate use of its
Read more →JNJJohnson & Johnson to Participate in the 2015 Deutsche Bank 40th Annual Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2015 Deutsche Bank 40th Annual Health Care Conference on Thursday, May 7, at The...
NEW BRUNSWICK, N.J. , April 30, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2015 Deutsche Bank 40th Annual Health Care Conference on Thursday, May 7 , at The InterContinental Boston. Dominic Caruso, Vice President, Finance & Chief Financial Officer
Read more →JNJJohnson & Johnson Announces Further Patent and Trademark Office Action Related to REMICADE® Johnson & Johnson (NYSE: JNJ) today announced receipt of a further action from the United States Patent and Trademark Office (PTO) regarding the...
NEW BRUNSWICK, N.J. , April 29, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced receipt of a further action from the United States Patent and Trademark Office (PTO) regarding the reexamination of U.S. Patent No. 6,284,471 ('471) relating to REMICADE® (inflixim
Read more →JNJJohnson & Johnson Announces Dividend Increase of 7.1% Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate, from $0.70 per ...
NEW BRUNSWICK, N.J. , April 23, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a 7.1% increase in the quarterly dividend rate, from $0.70 per share to $0.75 per share. The increase was announced this morning at the Ann
Read more →JNJJohnson & Johnson to Host Pharmaceutical Business Review Johnson & Johnson (NYSE: JNJ) will host a review of its Pharmaceutical business for the investment community beginning at 8:30 a.m. (Eastern Time) on ...
NEW BRUNSWICK, N.J. , April 20, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a review of its Pharmaceutical business for the investment community beginning at 8:30 a.m. (Eastern Time) on Wednesday, May 20, 2015 at the Hyatt Regency Hotel in New Brunswick, New Jer
Read more →JNJJohnson & Johnson Reports 2015 First-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $17.4 billion for the first quarter of 2015, a decrease of 4.1% as compared to the first...
NEW BRUNSWICK, N.J. , April 14, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $17.4 billion for the first quarter of 2015, a decrease of 4.1% as compared to the first quarter of 2014. Operational results increased 3.1% and the negative impact of cur
Read more →JNJJohnson & Johnson to Webcast Annual Meeting of Shareholders Johnson & Johnson (NYSE: JNJ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 23, 2015, from the State...
NEW BRUNSWICK, N.J. , March 27, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 23, 2015 , from the State Theatre in New Brunswick, N.J. Investors and other interested parties may ac
Read more →JNJJohnson & Johnson Announces Strategic Investment Alliance to Combat Dementia Globally Johnson & Johnson (NYSE:JNJ) today announced that its Janssen Pharmaceutical Companies will invest $10 million in a new UK government-led global...
NEW BRUNSWICK, N.J. , March 17, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Janssen Pharmaceutical Companies will invest $10 million in a new UK government-led global dementia discovery fund that will support innovative research to help find new w
Read more →JNJJohnson & Johnson to Host Investor Conference Call on First-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th, to review first-quarter...
NEW BRUNSWICK, N.J. , March 17, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14 th , to review first-quarter results. Dominic Caruso , Vice President, Finance and Chief Financial Office
Read more →JNJJohnson & Johnson Announces Binding Offer from Cardinal Health to Acquire Cordis Johnson & Johnson (NYSE:JNJ) today announced a binding offer from Cardinal Health to acquire its Cordis business for an aggregate value of $1.99...
NEW BRUNSWICK, N.J. , March 2, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced a binding offer from Cardinal Health to acquire its Cordis business for an aggregate value of $1.99 billion , consisting of $1.944 billion of cash proceeds from Cardinal Health plus
Read more →JNJJohnson & Johnson Announces Formation of New Health and Wellness Platform Designed to Transform Health Care Delivery and Improve the Patient Experience Johnson & Johnson (NYSE: JNJ) today announced the formation of a new health and wellness platform that leverages the breadth of capabilities across...
NEW BRUNSWICK, N.J. , Feb. 26, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the formation of a new health and wellness platform that leverages the breadth of capabilities across its businesses. Johnson & Johnson Health and Wellness Solutions, Inc. will faci
Read more →JNJJohnson & Johnson Announces Patent and Trademark Office Action Related to REMICADE® Johnson & Johnson (NYSE: JNJ) today announced receipt of a further action from the Patent and Trademark Office regarding the re-examination of U.S....
NEW BRUNSWICK, N.J. , Feb. 12, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced receipt of a further action from the Patent and Trademark Office regarding the re-examination of U.S. Patent No. 6,284,471 ('471) relating to REMICADE ® issuing a final rejection of
Read more →JNJEl Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 El Dr. Paul Janssen Award for Biomedical Research abre hoy su llamada a nominaciones para 2015. Este prestigioso premio reconoce a las personas cuya...
NEW BRUNSWICK , Nueva Jersey , 22 de enero de 2015 /PRNewswire/ -- El Dr. Paul Janssen Award for Biomedical Research abre hoy su llamada a nominaciones para 2015. Este prestigioso premio reconoce a las personas cuya investigación científica ha hecho, o tiene el potencial para hac
Read more →JNJDr. Paul Janssen Award for Biomedical Research ruft zur Kandidatennominierung 2015 auf Ab heute werden Nominierungen für den Dr. Paul Janssen Award for Biomedical Research 2015 entgegengenommen. Die angesehene Auszeichnung wird an...
NEW BRUNSWICK, New Jersey , 21. Januar 2015 /PRNewswire/ -- Ab heute werden Nominierungen für den Dr. Paul Janssen Award for Biomedical Research 2015 entgegengenommen. Die angesehene Auszeichnung wird an Personen verliehen, deren wissenschaftliche Forschung einen wichtigen Beitra
Read more →JNJLe prix 2015 du Dr Paul Janssen pour les questions de recherche biomédicale fait appel à des candidatures Le prix du Dr Paul Janssen en recherche biomédicale ouvre aujourd'hui son appel à candidatures pour 2015. Ce prix prestigieux récompense les...
NEW BRUNSWICK, New Jersey , 21 janvier 2015 /PRNewswire/ -- Le prix du Dr Paul Janssen en recherche biomédicale ouvre aujourd'hui son appel à candidatures pour 2015. Ce prix prestigieux récompense les personnes dont la recherche scientifique a apporté ou a le potentiel d'apporter
Read more →JNJDr. Paul Janssen Award for Biomedical Research Issues 2015 Call for Nominations The Dr. Paul Janssen Award for Biomedical Research today opens its 2015 call for nominations. This prestigious award recognizes individuals whose...
NEW BRUNSWICK, N.J. , Jan. 21, 2015 /PRNewswire/ -- The Dr. Paul Janssen Award for Biomedical Research today opens its 2015 call for nominations. This prestigious award recognizes individuals whose scientific research has made, or has the potential to make, significant contributi
Read more →JNJJohnson & Johnson Reports 2014 Fourth-Quarter and Full-Year Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth...
NEW BRUNSWICK, N.J., Jan. 20, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of cur
Read more →JNJJohnson & Johnson annonce la création d'un consortium de développement d'un vaccin contre Ebola, et l'obtention d'un financement de la part de l'Initiative pour les médicaments innovants Johnson & Johnson (NYSE : JNJ) est ravie d'annoncer la création d'un consortium composé d'institutions et d'organisations non-gouvernementales de...
- Un consortium fondé au travers du programme Ebola+ de l'IMI et soutenu par la Commission européenne - Un consortium formé de London School of Hygiene and Tropical Medicine, l'INSERM, l'Université d'Oxford, La Centre Muraz, Bavarian Nordic A/S, Vibalogics, la Grameen Foundation
Read more →JNJJohnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative Johnson & Johnson (NYSE: JNJ) is pleased to announce the formation of consortia with leading global research institutions and non-government...
NEW BRUNSWICK, N.J. , Jan. 16, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) is pleased to announce the formation of consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical Companies to accelera
Read more →JNJJohnson & Johnson kondigt de start aan van fase 1 klinisch onderzoek van een vaccinregime tegen ebola Johnson & Johnson (NYSE: JNJ) maakte vandaag de start bekend van een fase 1 klinisch onderzoek van een preventief ebola-vaccin, dat voor het eerst...
- Het bedrijf heeft meer dan 400.000 vaccin regimes geproduceerd voor gebruik in grootschalig klinische onderzoeken in april 2015 NEW BRUNSWICK, New Jersey , 6 januari 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) maakte vandaag de start bekend van een fase 1 klinisch onde
Read more →JNJJohnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen Johnson & Johnson (NYSE: JNJ) today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at...
NEW BRUNSWICK, N.J. , Jan. 6, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vacci
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for First Quarter 2015 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2015 of $0.70 per...
NEW BRUNSWICK, N.J. , Jan. 5, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2015 of $0.70 per share on the company's common stock. The dividend is payable on March 10, 2015 to
Read more →JNJJohnson & Johnson to Participate in 33rd Annual JP Morgan Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 33rd Annual JP Morgan Health Care Conference on Monday, Jan. 12, at the Westin St. Francis in...
NEW BRUNSWICK, N.J. , Dec. 30, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 33 rd Annual JP Morgan Health Care Conference on Monday, Jan. 12 , at the Westin St. Francis in San Francisco. Alex Gorsky, Chairman of the Board of Directors and Chief Exec
Read more →JNJJohnson & Johnson to Host Fourth-Quarter/Full-Year 2014 Investor Conference Call on Results Johnson & Johnson (NYSE: JNJ) will host a conference call at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 20, to discuss fourth-quarter and full-year...
NEW BRUNSWICK, N.J. , Dec. 17, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 20 , to discuss fourth-quarter and full-year 2014 financial results. Alex Gorsky , Chairman of the Board of Directors and Ch
Read more →JNJJohnson & Johnson Announces Collaboration between Janssen and USAID to Expand Access to Anti-Multidrug-Resistant Tuberculosis (MDR-TB) Compound Johnson & Johnson today announced that its affiliate Janssen Therapeutics, Division of Janssen Products, LP (Janssen), has signed a Memorandum of...
NEW BRUNSWICK, N.J. , Dec. 11, 2014 /PRNewswire/ -- Johnson & Johnson today announced that its affiliate Janssen Therapeutics, Division of Janssen Products, LP (Janssen), has signed a Memorandum of Understanding (MOU) representing the intention of the Company along with the Unite
Read more →JNJJohnson & Johnson Partners with Save the Children to Help Millions of Children over the Next Three Years Johnson & Johnson (NYSE: JNJ) announced today a global partnership with Save the Children that has the potential to help millions of children over...
NEW BRUNSWICK, N.J. , Nov. 19, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today a global partnership with Save the Children that has the potential to help millions of children over the next three years. The $10 million commitment was announced in New York City
Read more →JNJJohnson & Johnson Announces Completion Of Alios BioPharma Acquisition Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage...
NEW BRUNSWICK, N.J. , Nov. 7, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total
Read more →JNJJohnson & Johnson Innovation Launches Asia Pacific Innovation Center and Announces New Alliances Johnson & Johnson Innovation today announced the opening of the Asia Pacific Innovation Center, located in Shanghai with satellites in Singapore,...
QUEENSLAND, Australia , Oct. 29, 2014 /PRNewswire/ -- Johnson & Johnson Innovation today announced the opening of the Asia Pacific Innovation Center, located in Shanghai with satellites in Singapore , Australia and Japan . The Asia Pacific Innovation Center extends the network of
Read more →JNJJohnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production Johnson & Johnson (NYSE: JNJ) today announced that it has made a commitment of up to $200 million to accelerate and significantly expand the...
NEW BRUNSWICK, N.J. , Oct. 22, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Co
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2014 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2014 of $0.70 per...
NEW BRUNSWICK, N.J. , Oct. 16, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2014 of $0.70 per share on the company's common stock. The dividend is payable on December 9, 2014
Read more →JNJJohnson & Johnson Family of Consumer Companies Turns Brands Purple in Support of Spirit Day Johnson & Johnson Family of Consumer Companies will turn more than 20 brand logos purple in support of Spirit Day, a national day devoted to standing ...
NEW BRUNSWICK, N.J. , Oct. 15, 2014 /PRNewswire/ -- Johnson & Johnson Family of Consumer Companies will turn more than 20 brand logos purple in support of Spirit Day, a national day devoted to standing up against bullying and showing love and support for lesbian, gay, bisexual an
Read more →JNJJohnson & Johnson Reports 2014 Third-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third...
NEW BRUNSWICK, N.J. , Oct. 14, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of cur
Read more →JNJJohnson & Johnson Announces Agreement To Acquire Alios BioPharma Johnson & Johnson (NYSE: JNJ) today announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage...
NEW BRUNSWICK, N.J. , Sept. 30, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approxima
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Third-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, Oct. 14, 2014, to review...
NEW BRUNSWICK, N.J. , Sept. 23, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, Oct. 14, 2014 , to review third-quarter results. Dominic Caruso , Vice President, Finance and Chief Financial Offi
Read more →JNJPioneering Gene Editing Research Celebrated This Week During 2014 Dr. Paul Janssen Award for Biomedical Research Events This week, Johnson & Johnson will host events to celebrate the work of the winners of the 2014 Dr. Paul Janssen Award for Biomedical Research. Drs....
NEW YORK , Sept. 9, 2014 /PRNewswire/ -- This week, Johnson & Johnson will host events to celebrate the work of the winners of the 2014 Dr. Paul Janssen Award for Biomedical Research . Drs. Emmanuelle Charpentier and Jennifer Doudna will be honored for their breakthrough discover
Read more →JNJJohnson & Johnson Responds to Ebola Crisis With Commitment to Accelerate Vaccine Program in Collaboration With the US National Institutes of Health (NIH) and Provide Humanitarian Relief Aid Johnson & Johnson (NYSE: JNJ) today announced it will fast-track the development of a promising new combination vaccine regimen against Ebola and...
NEW BRUNSWICK, N.J. , Sept. 4, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced it will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly collaborate with its partners in global health to deliver immediate relie
Read more →JNJJohnson & Johnson to Participate in 2014 Morgan Stanley Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2014 Morgan Stanley Health Care Conference on Wednesday, Sept. 10, at the Grand Hyatt New York. ...
NEW BRUNSWICK, N.J. , Sept. 3, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2014 Morgan Stanley Health Care Conference on Wednesday, Sept. 10 , at the Grand Hyatt New York. Dominic Caruso , Vice President, Finance & Chief Financial Officer will repr
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2014 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2014 of $0.70 per...
NEW BRUNSWICK, N.J. , July 21, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2014 of $0.70 per share on the company's common stock. The dividend is payable on September 9, 2014
Read more →JNJJohnson & Johnson Announces $5 Billion Share Repurchase Program Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has approved the repurchase of up to $5 billion of the company's common...
NEW BRUNSWICK, N.J. , July 21, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has approved the repurchase of up to $5 billion of the company's common stock. Repurchases may be made at management's discretion from time to time on th
Read more →JNJJohnson & Johnson Reports 2014 Second-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second...
NEW BRUNSWICK, N.J. , July 15, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of c
Read more →JNJCARE WITH PRIDE™ On Target To Deliver More Than $500K to LGBT Charities Johnson & Johnson's corporate-wide anti-bullying and LGBT equality initiative is expanding as it kicks off its third year in June. Since 2012,...
NEW BRUNSWICK, N.J. , June 25, 2014 /PRNewswire/ -- Johnson & Johnson's corporate-wide anti-bullying and LGBT equality initiative is expanding as it kicks off its third year in June. Since 2012, donations raised through CARE WITH PRIDE™ have supported PFLAG's anti-bullying effort
Read more →JNJJennifer Doudna, Ph.D., and Emmanuelle Charpentier, Ph.D., Win 2014 Dr. Paul Janssen Award for Biomedical Research Johnson & Johnson today named Dr. Jennifer Doudna of the University of California at Berkeley and the Howard Hughes Medical Institute, and Dr....
SAN DIEGO , June 24, 2014 /PRNewswire/ -- Johnson & Johnson today named Dr. Jennifer Doudna of the University of California at Berkeley and the Howard Hughes Medical Institute, and Dr. Emmanuelle Charpentier , of the Hannover Medical School and Helmholtz Centre for Infection Rese
Read more →JNJCEO and Chairman of UPS, D. Scott Davis, Joins Johnson & Johnson Board of Directors Johnson & Johnson (NYSE: JNJ) announced today that its Board of Directors has appointed D. Scott Davis, Chief Executive Officer (CEO) and Chairman of ...
NEW BRUNSWICK, N.J. , June 19, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today that its Board of Directors has appointed D. Scott Davis , Chief Executive Officer (CEO) and Chairman of United Parcel Service, Inc. (NYSE: UPS ), as a Director of Johnson & Johnson
Read more →JNJJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 15th, to review second-quarter...
NEW BRUNSWICK, N.J. , June 17, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 15 th , to review second-quarter results. Alex Gorsky , Chairman of the Board of Directors and Chief Executive
Read more →JNJIl marchio LISTERINE® celebra il torneo della FIFA World Cup™ con la sua maggiore azione mondiale sui social media Il marchio LISTERINE® lancia la sua maggiore azione mondiale di marketing tramite social media con POWER TO YOUR MOUTH™ per la FIFA World Cup™. Il...
MORRIS PLAINS, New Jersey , 5 giugno 2014 /PRNewswire/ -- Il marchio LISTERINE® lancia la sua maggiore azione mondiale di marketing tramite social media con "POWER TO YOUR MOUTH™" per la FIFA World Cup™. Il marchio LISTERINE® comincerà dalla campagna pubblicitaria precedente il t
Read more →JNJLa marca LISTERINE® celebra el torneo de la Copa Mundial FIFA™ a través de su mayor activación mundial en medios sociales La marca LISTERINE® lanza su mayor activación mundial de marketing social, PODER A TU BOCA™ , para la Copa Mundial FIFA™. A partir del desarrollo...
MORRIS PLAINS , Nueva Jersey , 5 de junio de 2014 /PRNewswire/ -- La marca LISTERINE® lanza su mayor activación mundial de marketing social, "PODER A TU BOCA™", para la Copa Mundial FIFA™. A partir del desarrollo previo al torneo y hasta el pitazo final, la marca LISTERINE® reacc
Read more →JNJLISTERINE® Brand Celebrates the FIFA World Cup™ Tournament through its Largest Global Social Media Activation The LISTERINE® Brand launches its largest global marketing social activation, POWER TO YOUR MOUTH™, for the FIFA World Cup™. From the...
MORRIS PLAINS, N.J. , June 5, 2014 /PRNewswire/ -- The LISTERINE® Brand launches its largest global marketing social activation, "POWER TO YOUR MOUTH™," for the FIFA World Cup™. From the pre-tournament build up, through the final whistle, the LISTERINE® Brand will react to the ne
Read more →JNJLa marca LISTERINE® celebra el torneo de la FIFA World Cup™ a través de los medios sociales La marca LISTERINE® lanza su mayor activación mundial de marketing social, POWER TO YOUR MOUTH™, para la FIFA World Cup™. Desde la construcción de...
- La marca LISTERINE® celebra el torneo de la FIFA World Cup™ a través de su mayor activación mundial de los medios sociales MORRIS PLAINS, Nueva Jersey , 5 de junio de 2014 /PRNewswire/ -- La marca LISTERINE® lanza su mayor activación mundial de marketing social, "POWER TO YOUR
Read more →JNJJohnson & Johnson anuncia a la ganadora del programa Campeones del Cariño en EEUU, como parte de su patrocinio a la Copa Mundial de la FIFA Brasil 2014™ Johnson & Johnson, el Patrocinador Oficial de cuidados de la salud para la Copa Mundial de la FIFA Brasil 2014™, anunció hoy a la ganadora del...
NEW BRUNSWICK , Nueva Jersey , 5 de junio de 2014 /PRNewswire-HISPANIC PR WIRE/ -- Johnson & Johnson, el Patrocinador Oficial de cuidados de la salud para la Copa Mundial de la FIFA Brasil 2014™, anunció hoy a la ganadora del programa Campeones del Cariño en Estados Unidos: María
Read more →JNJJohnson & Johnson Reinforces Importance of Children Learning the Value of Care from their Parents as Part of CARE INSPIRES CARE™ Program What does it take for parents to raise a caring child? How can parents inspire their children to care? A recent Johnson & Johnson survey shows that...
NEW BRUNSWICK, N.J. , June 4, 2014 /PRNewswire/ -- What does it take for parents to raise a caring child? How can parents inspire their children to care? A recent Johnson & Johnson survey shows that parents have a tremendous impact when it comes to instilling caring values in the
Read more →JNJJohnson & Johnson Medical Devices & Diagnostics Businesses Expanding Market Leadership with Innovative Products and Customer-Focused Solutions At a meeting today with members of the investment community, senior leaders from the Medical Devices and Diagnostics (MD&D) segment of Johnson &...
NEW BRUNSWICK, N.J. , May 22, 2014 /PRNewswire/ -- At a meeting today with members of the investment community, senior leaders from the Medical Devices and Diagnostics (MD&D) segment of Johnson & Johnson (NYSE: JNJ ) will outline plans to improve patient outcomes and expand their
Read more →JNJSabine Dandiguian Honoured as HBA Luminary by the Healthcare Businesswomen's Association (HBA) Sabine Dandiguian, Company Group Chairman, Johnson & Johnson, Global Surgery Europe Middle East and Africa (EMEA), was honoured with an HBA Luminary ...
HAMBURG, Germany , May 13, 2014 /PRNewswire/ -- Sabine Dandiguian, Company Group Chairman, Johnson & Johnson, Global Surgery Europe Middle East and Africa (EMEA), was honoured with an "HBA Luminary Award" assigned by the Healthcare Businesswomen's Association (HBA) at its 25th a
Read more →JNJJohnson & Johnson and American College of Sports Medicine Form Global Alliance to Advance Human Health and Performance Johnson & Johnson announced, in partnership with the American College of Sports Medicine (ACSM), the creation of the Global Alliance for Health and...
NEW YORK , April 30, 2014 /PRNewswire/ -- Johnson & Johnson announced, in partnership with the American College of Sports Medicine (ACSM), the creation of the Global Alliance for Health and Performance (the Global Alliance). The Global Alliance will work to educate and promote th
Read more →JNJJohnson & Johnson Announces Dividend Increase of 6.1% Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 6.1% increase in the quarterly dividend rate, from $0.66 per ...
NEW BRUNSWICK, N.J. , April 24, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a 6.1% increase in the quarterly dividend rate, from $0.66 per share to $0.70 per share. The increase was announced this morning at the Ann
Read more →JNJJohnson & Johnson to Host Medical Devices & Diagnostics Business Review Johnson & Johnson (NYSE: JNJ) will host a review of its Medical Devices & Diagnostics business for the investment community beginning at 9:30 a.m....
NEW BRUNSWICK, N.J. , April 23, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a review of its Medical Devices & Diagnostics business for the investment community beginning at 9:30 a.m. (Eastern Time) on Thursday, May 22, 2014 at the Hyatt Regency Hotel in New Brun
Read more →JNJJohnson & Johnson Reports 2014 First-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first...
NEW BRUNSWICK, N.J. , April 15, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of cu
Read more →JNJJohnson & Johnson Enters Agreement to be Official Healthcare Partner of the USO Johnson & Johnson (NYSE: JNJ) announced it has entered a multi-year agreement to be the Official Healthcare Partner of the USO. The announcement was...
BETHESDA, Md. , April 1, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced it has entered a multi-year agreement to be the Official Healthcare Partner of the USO. The announcement was made today during a ceremony to mark the opening of the USO's Warrior and Family Cen
Read more →JNJJohnson & Johnson Announces Acceptance Of Binding Offer From The Carlyle Group To Acquire Ortho-Clinical Diagnostics Johnson & Johnson (NYSE: JNJ) today announced that it has accepted the binding offer from The Carlyle Group, which was received and announced on...
NEW BRUNSWICK, N.J. , March 31, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that it has accepted the binding offer from The Carlyle Group, which was received and announced on January 16, 2014 , to acquire its Ortho-Clinical Diagnostics business for approxi
Read more →JNJJohnson & Johnson to Webcast Annual Meeting of Shareholders Johnson & Johnson (NYSE: JNJ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 24, 2014, from the Hyatt...
NEW BRUNSWICK, N.J. , March 21, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 24, 2014 , from the Hyatt Regency Hotel in New Brunswick, N.J. Investors and other interested parties
Read more →JNJThe LISTERINE® Brand Supports the FDI World Dental Federation In 2014 Global Oral Health Initiative LISTERINE® Brand Mouthwash, part of the Johnson & Johnson Family of Consumer Companies, today announces its support of the 2014 World Oral Health...
MORRIS PLAINS, N.J. , March 19, 2014 /PRNewswire/ -- LISTERINE ® Brand Mouthwash, part of the Johnson & Johnson Family of Consumer Companies, today announces its support of the 2014 World Oral Health Day, to be held March 20 with celebrations expected across the world from dental
Read more →JNJJohnson & Johnson to Host Analyst Conference Call on First-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 15th, to review first-quarter...
NEW BRUNSWICK, N.J. , March 11, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 15 th , to review first-quarter results. Dominic Caruso, Vice President, Finance and Chief Financial Officer
Read more →JNJJohnson & Johnson lanza Campeones del Cariño en los Estados Unidos como parte de su patrocinio de la Copa Mundial de la FIFA 2014™ Johnson & Johnson, Patrocinador Oficial de Cuidados de Salud de la Copa Mundial de la FIFA 2014™, anunció hoy el lanzamiento del programa Campeones...
NEW BRUNSWICK , Nueva Jersey y MIAMI , 6 de marzo de 2014 /PRNewswire-HISPANIC PR WIRE/ -- Johnson & Johnson, Patrocinador Oficial de Cuidados de Salud de la Copa Mundial de la FIFA 2014™, anunció hoy el lanzamiento del programa Campeones del Cariño en los Estados Unidos para des
Read more →JNJJohnson & Johnson Launches Champions of Care Program in the U.S as Part of 2014 FIFA World Cup™ Sponsorship Johnson & Johnson, the Official Healthcare Sponsor of the 2014 FIFA World Cup™, announced today the launch of the Champions of Care program in the...
NEW BRUNSWICK, N.J. and MIAMI , March 6, 2014 /PRNewswire/ -- Johnson & Johnson, the Official Healthcare Sponsor of the 2014 FIFA World Cup™, announced today the launch of the Champions of Care program in the United States to shine a spotlight on people who go above and beyond to
Read more →JNJJohnson & Johnson to Participate in 2014 Cowen 34th Annual Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2014 Cowen 34th Annual Health Care Conference on Tuesday, Mar. 4, at The Boston Marriott Copley ...
NEW BRUNSWICK, N.J. , Feb. 25, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2014 Cowen 34 th Annual Health Care Conference on Tuesday, Mar. 4 , at The Boston Marriott Copley Place. Dominic Caruso , Vice President, Finance & Chief Financial Officer w
Read more →JNJJohnson & Johnson to Participate in 2014 Citi Global Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2014 Citi Global Health Care Conference on Monday, Feb. 24, at the Hilton New York Hotel in New ...
NEW BRUNSWICK, N.J. , Feb. 14, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2014 Citi Global Health Care Conference on Monday, Feb. 24 , at the Hilton New York Hotel in New York , NY. Joaquin Duato , Worldwide Chairman, Pharmaceuticals, will represe
Read more →JNJJohnson & Johnson and Scientists Without Borders Announce Winners of Mental Health Awareness Challenge Johnson & Johnson, in collaboration with Scientists Without Borders, today announced the winners of a $10,000 open innovation challenge that called...
NEW YORK , Feb. 11, 2014 /PRNewswire/ -- Johnson & Johnson, in collaboration with Scientists Without Borders, today announced the winners of a $10,000 open innovation challenge that called for ideas to increase awareness and utilization of mental health services for depression an
Read more →JNJJohnson & Johnson Issues Dr. Paul Janssen Award for Biomedical Research Call for Nominations The Dr. Paul Janssen Award for Biomedical Research opens its 2014 call for nominations today. This prestigious award recognizes individuals whose...
NEW BRUNSWICK, N.J. , Feb. 3, 2014 /PRNewswire/ -- The Dr. Paul Janssen Award for Biomedical Research opens its 2014 call for nominations today. This prestigious award recognizes individuals whose scientific research has made, or has the potential to make, significant transformat
Read more →JNJJohnson & Johnson Announces Clinical Trial Data Sharing Agreement With Yale School of Medicine Johnson & Johnson today announced that its subsidiary, Janssen Research and Development, LLC, has entered into a novel agreement with Yale School of...
In addition to Janssen's sharing of data from pharmaceutical product clinical trials through the agreement with YODA, Johnson & Johnson is also committed to the sharing of data from clinical trials of the medical device and consumer products of the Johnson & Johnson family of com
Read more →JNJJohnson & Johnson Reports 2013 Fourth-Quarter and Full-Year Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $18.4 billion for the fourth quarter of 2013, an increase of 4.5% as compared to the fourth...
NEW BRUNSWICK, N.J. , Jan. 21, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $18.4 billion for the fourth quarter of 2013, an increase of 4.5% as compared to the fourth quarter of 2012. Operational results increased 6.3% and the negative impact of c
Read more →JNJJohnson & Johnson Announces Binding Offer From The Carlyle Group To Acquire Ortho-Clinical Diagnostics Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from The Carlyle Group to acquire its Ortho-Clinical Diagnostics...
NEW BRUNSWICK, N.J. , Jan. 16, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that it has received a binding offer from The Carlyle Group to acquire its Ortho-Clinical Diagnostics business for $4.15 Billion . "Ortho-Clinical Diagnostics plays an important ro
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for First Quarter 2014 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2014 of $0.66 per...
NEW BRUNSWICK, N.J. , Jan. 2, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2014 of $0.66 per share on the company's common stock. The dividend is payable on March 11, 2014 to
Read more →JNJJohnson & Johnson to Host Fourth-Quarter/Full-Year 2013 Earnings Meeting Johnson & Johnson (NYSE: JNJ) will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 21, to discuss fourth-quarter and full-year...
NEW BRUNSWICK, N.J. , Dec. 18, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 21 , to discuss fourth-quarter and full-year 2013 financial results. Alex Gorsky , Chairman of the Board of Directors and C
Read more →JNJJohnson & Johnson to Participate in Credit Suisse 2013 Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 2013 Health Care Conference on Tuesday, Nov. 12th, at The Phoenician, 6000 East...
NEW BRUNSWICK, N.J. , Nov. 5, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Credit Suisse 2013 Health Care Conference on Tuesday, Nov. 12 th , at The Phoenician, 6000 East Camelback Road, Scottsdale, AZ. Dominic J. Caruso , Vice President, Finance &
Read more →JNJJohnson & Johnson and its Subsidiaries, Janssen Pharmaceuticals, Inc. and Scios Inc., Conclude Previously Disclosed Settlement Agreements with U.S. Department of Justice and 45 States Johnson & Johnson (NYSE: JNJ) and its subsidiaries, Janssen Pharmaceuticals, Inc. and Scios Inc., today announced they have finalized previously...
NEW BRUNSWICK, N.J. , Nov. 4, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) and its subsidiaries, Janssen Pharmaceuticals, Inc. and Scios Inc., today announced they have finalized previously disclosed settlement agreements with the U.S. Department of Justice (DOJ) and 45 st
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2013 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2013 of $0.66 per...
NEW BRUNSWICK, N.J. , Oct. 17, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2013 of $0.66 per share on the company's common stock. The dividend is payable on December 10, 201
Read more →JNJJohnson & Johnson Reports 2013 Third-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $17.6 billion for the third quarter of 2013, an increase of 3.1% as compared to the third...
NEW BRUNSWICK, N.J. , Oct. 15, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $17.6 billion for the third quarter of 2013, an increase of 3.1% as compared to the third quarter of 2012. Operational results increased 4.7% and the negative impact of cur
Read more →JNJFormer FDA Commissioner, Dr. Mark B. McClellan, to Join Johnson & Johnson Board of Directors Johnson & Johnson (NYSE: JNJ) announced today that Mark B. McClellan, M.D., Ph.D., Senior Fellow in Economic Studies, and Director of the Initiative...
NEW BRUNSWICK, N.J. , Oct. 14, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today that Mark B. McClellan , M.D., Ph.D., Senior Fellow in Economic Studies, and Director of the Initiative on Value and Innovation in Health Care, Brookings Institution , will join the
Read more →JNJFuture of Innovation Dependent on Funding, Collaboration and Idea Exchange Investment in basic research, convergence across disciplines and better engagement between academia and industry are key to the future of innovation, ...
NEW YORK , Sept. 19, 2013 /PRNewswire/ -- Investment in basic research, convergence across disciplines and better engagement between academia and industry are key to the future of innovation, according to a panel of renowned thought leaders speaking at the celebration of the 2013
Read more →JNJJohnson & Johnson to Host Conference Call on Third-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 15th, to review third-quarter ...
NEW BRUNSWICK, N.J. , Sept. 17, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 15 th , to review third-quarter results. Michel Orsinger , Worldwide Chairman of DePuy Synthes Companies,
Read more →JNJJohnson & Johnson to Participate in Morgan Stanley Global Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley Global Health Care Conference on Wednesday, Sept. 11th, at the Grand Hyatt New...
NEW BRUNSWICK, N.J. , Sept. 4, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Morgan Stanley Global Health Care Conference on Wednesday, Sept. 11 th , at the Grand Hyatt New York, 109 East 42 nd Street at Grand Central, New York , NY. Dominic Caruso ,
Read more →JNJJohnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc. Johnson & Johnson (NYSE: JNJ) today announced it has successfully completed its acquisition of Aragon Pharmaceuticals, Inc., a privately-held...
NEW BRUNSWICK, N.J. , Aug. 19, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced it has successfully completed its acquisition of Aragon Pharmaceuticals, Inc., a privately-held pharmaceutical discovery and development company focused on drugs to treat hormonally
Read more →JNJJohnson & Johnson Reports 2013 Second-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $17.9 billion for the second quarter of 2013, an increase of 8.5% as compared to the second...
NEW BRUNSWICK, N.J. , July 16, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $17.9 billion for the second quarter of 2013, an increase of 8.5% as compared to the second quarter of 2012. Operational results increased 10.0% and the negative impact of
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2013 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2013 of $0.66 per...
NEW BRUNSWICK, N.J. , July 15, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2013 of $0.66 per share on the company's common stock. The dividend is payable on September 10, 201
Read more →JNJJohnson & Johnson Announces Opening of Boston Innovation Center Johnson & Johnson today announced the opening of the Johnson & Johnson Innovation center in Boston, the third of four regional hubs being established ...
CAMBRIDGE, Mass. , June 27, 2013 /PRNewswire/ -- Johnson & Johnson today announced the opening of the Johnson & Johnson Innovation center in Boston , the third of four regional hubs being established in the world's leading life science hotspots. A part of Johnson & Johnson Innova
Read more →JNJJohnson & Johnson to Host Conference Call on Second-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 16th, to review second-quarter...
NEW BRUNSWICK, N.J. , June 25, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 16 th , to review second-quarter results. Alex Gorsky, Chairman of the Board and Chief Executive Officer, Sand
Read more →JNJJohnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc. Johnson & Johnson (NYSE: JNJ) announced today a definitive agreement to acquire Aragon Pharmaceuticals, Inc., a privately-held, pharmaceutical...
NEW BRUNSWICK, N.J. , June 17, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) announced today a definitive agreement to acquire Aragon Pharmaceuticals, Inc., a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancer
Read more →JNJDavid Julius Wins 2013 Dr. Paul Janssen Award for Biomedical Research Johnson & Johnson today named David Julius, PhD, chair of the Department of Physiology at the University of California, San Francisco (UCSF), the...
SAN FRANCISCO , June 12, 2013 /PRNewswire/ -- Johnson & Johnson today named David Julius , PhD, chair of the Department of Physiology at the University of California, San Francisco (UCSF), the winner of the 2013 Dr. Paul Janssen Award for Biomedical Research. Dr. Julius was chose
Read more →JNJJohnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth with More than 10 Potential New Product Filings by 2017 At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced they...
NEW BRUNSWICK, N.J. , May 23, 2013 /PRNewswire/ -- At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced they anticipate submitting more than 10 new product filings and more than 25 significant
Read more →JNJJanssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL) Janssen R&D Ireland (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on...
NEW BRUNSWICK, N.J. , May 2, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) and Johnson & Johnson (NYSE: JNJ ) will provide a pre-recorded webcast for investors and other interested parties on Friday, May 3 , at approximately 8:30 a.m., Eastern Time , to discuss simeprevir ph
Read more →JNJJohnson & Johnson Announces Dividend Increase of 8.2% Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared an 8.2% increase in the quarterly dividend rate, from $0.61...
NEW BRUNSWICK, N.J. , April 25, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared an 8.2% increase in the quarterly dividend rate, from $0.61 per share to $0.66 per share. The increase was announced this morning at the An
Read more →JNJJohnson & Johnson to Host Pharmaceuticals Business Review Johnson & Johnson (NYSE: JNJ) will host a review of its Pharmaceuticals business for the Investment Community beginning at 8:30 a.m. (Eastern Time)...
NEW BRUNSWICK, N.J. , April 23, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a review of its Pharmaceuticals business for the Investment Community beginning at 8:30 a.m. (Eastern Time) on Thursday, May 23, 2013 at the Hyatt Regency Hotel in New Brunswick, New Jer
Read more →JNJJohnson & Johnson Announces Sale of Elan American Depositary Shares to Elan Johnson & Johnson (NYSE: JNJ) today announced the sale to Elan Corporation, plc of approximately 82 million American Depositary Shares (ADS) of Elan...
NEW BRUNSWICK, N.J. , April 18, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced the sale to Elan Corporation, plc of approximately 82 million American Depositary Shares (ADS) of Elan held by Janssen Pharmaceutical (Janssen), an affiliate of Johnson & Johnson.
Read more →JNJJohnson & Johnson Reports 2013 First-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $17.5 billion for the first quarter of 2013, an increase of 8.5% as compared to the first...
NEW BRUNSWICK, N.J. , April 16, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $17.5 billion for the first quarter of 2013, an increase of 8.5% as compared to the first quarter of 2012. Operational results increased 9.8% and the negative impact of cu
Read more →JNJJohnson & Johnson to Webcast Annual Meeting of Shareholders Johnson & Johnson (NYSE: JNJ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 25, 2013, from the Hyatt...
NEW BRUNSWICK, N.J. , April 11, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 25, 2013 , from the Hyatt Regency Hotel in New Brunswick, N.J. Investors and other interested parties
Read more →JNJJohnson & Johnson to Host Analyst Conference Call on First-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16th, to review first-quarter...
NEW BRUNSWICK, N.J. , March 19, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16 th , to review first-quarter results. Dominic Caruso , Vice President, Finance and Chief Financial Office
Read more →JNJJohnson & Johnson anuncia la apertura del Centro de Innovación de Londres Johnson & Johnson ha anunciado hoy la apertura del centro de innovación de Johnson & Johnson en Londres, uno de los cuatro ejes regionales...
-- El centro servirá como eje europeo para acelerar la innovación en el paisaje del cuidado de la salud -- El director científico de Johnson & Johnson celebra la apertura en el discurso de la exposición de Londres LONDRES, 13 de marzo de 2013 /PRNewswire/ -- Johnson & Johnson h
Read more →JNJJohnson & Johnson gibt Eröffnung des Innovationszentrums in London bekannt Johnson & Johnson gab heute die Eröffnung des Johnson & Johnson Innovationszentrums in London bekannt, eines der vier regionalen Zentren, die dieses...
- Zentrum als europäischer Hub zum Vorantreiben von Innovationen in der Gesundheitsbranche - Der Chief Scientific Officer von Johnson & Johnson feiert die Eröffnung im Rahmen der Keynote auf der London Expo LONDON , 13. März 2013 /PRNewswire/ -- Johnson & Johnson gab heute die
Read more →JNJJohnson & Johnson annonce l'ouverture d'un centre d'innovation à Londres Johnson & Johnson a annoncé aujourd'hui l'inauguration du centre londonien de Johnson & Johnson Innovation, soit l'un des quatre pôles régionaux mis...
-- Ce centre servira de pôle européen visant à accélérer l'innovation dans le secteur de la santé -- Le directeur scientifique de Johnson & Johnson marque cette inauguration avec un discours d'ouverture au London Expo LONDRES, 14 mars 2013 /PRNewswire/ -- Johnson & Johnson a an
Read more →JNJJohnson & Johnson Announces Opening of London Innovation Centre Johnson & Johnson today announced the opening of the Johnson & Johnson Innovation centre in London, one of four regional hubs being established this...
LONDON , March 12, 2013 /PRNewswire/ -- Johnson & Johnson today announced the opening of the Johnson & Johnson Innovation centre in London , one of four regional hubs being established this year in the world's leading innovation hotspots. A part of Johnson & Johnson Innovation, t
Read more →JNJJohnson & Johnson Comments on Venezuelan Currency Devaluation Johnson & Johnson (NYSE: JNJ) today announced that based on its preliminary assessment of the impact of the Venezuelan government's decision to...
About Johnson & Johnson Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,600 em
Read more →JNJJohnson & Johnson to Participate in 2013 Citi Global Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2013 Citi Global Health Care Conference on Monday, Feb. 25, at the Hilton New York Hotel in New ...
NEW BRUNSWICK, N.J. , Feb. 20, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2013 Citi Global Health Care Conference on Monday, Feb. 25 , at the Hilton New York Hotel in New York, NY . Alex Gorsky, Chairman of the Board of Directors and Chief Executi
Read more →JNJJohnson & Johnson to Participate in 2013 Leerink Swann Global Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2013 Leerink Swann Global Health Care Conference on Wednesday, Feb. 13, at The Waldorf Astoria...
NEW BRUNSWICK, N.J. , Feb. 6, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2013 Leerink Swann Global Health Care Conference on Wednesday, Feb. 13 , at The Waldorf Astoria in New York , NY. Joaquin Duato , Worldwide Chairman, Pharmaceuticals will rep
Read more →JNJJohnson & Johnson Presents Growth Strategies for Medical Devices & Diagnostics Segment Johnson & Johnson (NYSE: JNJ) will present its Medical Devices & Diagnostics (MD&D) business strategy for accelerating growth during its annual...
NEW YORK , Jan. 22, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will present its Medical Devices & Diagnostics (MD&D) business strategy for accelerating growth during its annual Business Review today. The presentations will focus on its market leading products, plans for
Read more →JNJJohnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $17.6 billion for the fourth quarter of 2012, an increase of 8.0% as compared to the fourth...
NEW BRUNSWICK, N.J. , Jan. 22, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $17.6 billion for the fourth quarter of 2012, an increase of 8.0% as compared to the fourth quarter of 2011. Operational results increased 9.3% and the negative impact of c
Read more →JNJJohnson & Johnson Issues Dr. Paul Janssen Award for Biomedical Research Call for Nominations The Dr. Paul Janssen Award for Biomedical Research today opens its 2013 call for nominations. This prestigious award recognizes individuals whose...
NEW BRUNSWICK, N.J. , Jan. 10, 2013 /PRNewswire/ -- The Dr. Paul Janssen Award for Biomedical Research today opens its 2013 call for nominations. This prestigious award recognizes individuals whose scientific research has made, or has the potential to make, significant transforma
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for First Quarter 2013 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2013 of $0.61 per...
NEW BRUNSWICK, N.J. , Jan. 2, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2013 of $0.61 per share on the company's common stock. The dividend is payable on March 12, 2013 , t
Read more →JNJJohnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter/Full-Year 2012 Financial Results and Medical Devices and Diagnostics Review Johnson & Johnson (NYSE: JNJ) will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 22, to discuss fourth-quarter and full-year...
NEW BRUNSWICK, N.J. , Dec. 21, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 22 , to discuss fourth-quarter and full-year 2012 financial results. The meeting will be hosted by Alex Gorsky , Chairman E
Read more →JNJCEO Alex Gorsky Elected Chairman of Johnson & Johnson; Bill Weldon To Step Down After 41-year Career at Johnson & Johnson Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has elected Alex Gorsky Chairman, Board of Directors of Johnson & Johnson....
NEW BRUNSWICK, N.J. , Nov. 30, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has elected Alex Gorsky Chairman, Board of Directors of Johnson & Johnson. Mr. Gorsky will assume the Chairman title and additional leadership responsibi
Read more →JNJHealth Care Executive, Scholar and Vice Chancellor from UCLA, Dr. A. Eugene Washington, Appointed to Johnson & Johnson Board of Directors Dr. A. Eugene Washington, M.D., M.Sc., who holds several prominent health care executive positions affiliated with the University of California, Los...
NEW BRUNSWICK, N.J. , Nov. 9, 2012 /PRNewswire/ -- Dr. A. Eugene Washington , M.D., M.Sc., who holds several prominent health care executive positions affiliated with the University of California, Los Angeles ( UCLA ), has been appointed to the Board of Directors of Johnson & Joh
Read more →JNJJohnson & Johnson to Participate in Credit Suisse 2012 Healthcare Conference Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 2012 Healthcare Conference Wednesday, Nov. 14th, at the Arizona Biltmore Hotel,...
NEW BRUNSWICK, N.J. , Nov. 7, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Credit Suisse 2012 Healthcare Conference Wednesday, Nov. 14 th , at the Arizona Biltmore Hotel, 2400 E. Missouri Avenue, Phoenix , AZ. Dominic Caruso , Vice President, Financ
Read more →JNJJanssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting Janssen and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, November 10, at ...
NEW BRUNSWICK, N.J. , Nov. 2, 2012 /PRNewswire/ -- Janssen and Johnson & Johnson (NYSE: JNJ ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, November 10 , at approximately 5:00 p.m., Eastern Time , to coincide with the American College
Read more →JNJJohnson & Johnson Postpones Medical Devices & Diagnostics Review Given the state of emergency in New Jersey due to Hurricane Sandy, Johnson & Johnson (NYSE: JNJ) announced that it will postpone the company's...
About Johnson & Johnson Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 129,000 em
Read more →JNJJohnson & Johnson to Host Medical Devices & Diagnostics Review Johnson & Johnson (NYSE: JNJ) will host a Medical Devices & Diagnostics business review for the investment community beginning at 8:30 a.m. (Eastern...
NEW BRUNSWICK, N.J. , Oct. 25, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a Medical Devices & Diagnostics business review for the investment community beginning at 8:30 a.m. (Eastern Time) on Thursday, November 1 st at the Hyatt Regency Hotel in New Brunswick,
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2012 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2012 of $0.61 per...
NEW BRUNSWICK, N.J. , Oct. 17, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2012 of $0.61 per share on the company's common stock. The dividend is payable on December 11, 201
Read more →JNJJohnson & Johnson Reports 2012 Third-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $17.1 billion for the third quarter of 2012, an increase of 6.5% as compared to the third...
NEW BRUNSWICK, N.J. , Oct. 16, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $17.1 billion for the third quarter of 2012, an increase of 6.5% as compared to the third quarter of 2011. Operational results increased 10.8% and the negative impact of cu
Read more →JNJJames E. Burke, Former Chairman and CEO of Johnson & Johnson, Dies at 87 Former Johnson & Johnson (NYSE: JNJ) Chairman and Chief Executive Officer James E. Burke, whose extraordinary career in the private and public...
NEW BRUNSWICK, N.J. , Oct. 1, 2012 /PRNewswire-FirstCall/ -- Former Johnson & Johnson (NYSE: JNJ ) Chairman and Chief Executive Officer James E. Burke , whose extraordinary career in the private and public sectors earned him the prestigious Presidential Medal of Freedom, died lat
Read more →JNJJanssen and Johnson & Johnson to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients with Type 2 Diabetes Janssen Research & Development, LLC and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties...
NEW BRUNSWICK, N.J. , Sept. 26, 2012 /PRNewswire-FirstCall/ -- Janssen Research & Development, LLC and Johnson & Johnson (NYSE: JNJ ) will provide a pre-recorded webcast for investors and other interested parties on Tuesday, October 2 , at approximately 12:00 p.m., Eastern Time ,
Read more →JNJJohnson & Johnson Provides Notice Of Adjournment Of Final Settlement Hearing To October 18, 2012, And Notice Of Revised Settlement Objection Deadline Of October 5, 2012 For Shareholders Who Received Mailed Notice After September 1, 2012 The following statement is being issued by Johnson & Johnson (NYSE: JNJ): UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY IN RE JOHNSON & JOHNSON ...
NEW BRUNSWICK, N.J. , Sept. 25, 2012 /PRNewswire/ -- The following statement is being issued by Johnson & Johnson (NYSE: JNJ ): UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY NOTICE OF ADJOURNMENT OF FINAL SETTLEMENT HEARING TO OCTOBER 18, 2012 , AND NOTICE OF REVISED SETT
Read more →JNJJohnson & Johnson Announces Plans to Establish Innovation Centers Johnson & Johnson today announced plans to establish four regional innovation centers in major life sciences communities in the world as part of a...
NEW BRUNSWICK, N.J. , Sept. 18, 2012 /PRNewswire/ -- Johnson & Johnson today announced plans to establish four regional innovation centers in major life sciences communities in the world as part of a novel approach to accelerate early innovation and enhance opportunities for coll
Read more →JNJJohnson & Johnson to Host Analyst Conference Call on Third-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 16th, to review third-quarter ...
NEW BRUNSWICK, N.J. , Sept. 18, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 16 th , to review third-quarter results. Dominic Caruso, Vice President, Finance and Chief Finan
Read more →JNJJohnson & Johnson Launches Be Vital Challenge to Reward College Student Organizations Making a Difference in their Communities Johnson & Johnson (NYSE: JNJ) is launching a challenge to reward college student organizations for their effort in taking care of the world we share. ...
NEW BRUNSWICK, N.J. , Sept. 18, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) is launching a challenge to reward college student organizations for their effort in taking care of the world we share. Johnson & Johnson is proud to present the Be Vital Challenge for student org
Read more →JNJSandra E. Peterson to Join Johnson & Johnson as Group Worldwide Chairman and Member of the Executive Committee Sandra E. Peterson will join Johnson & Johnson (NYSE: JNJ) on December 1, 2012, as Group Worldwide Chairman and member of the Company's Executive...
NEW BRUNSWICK, N.J. , Sept. 13, 2012 /PRNewswire-FirstCall/ -- Sandra E. Peterson will join Johnson & Johnson (NYSE: JNJ ) on December 1, 2012 , as Group Worldwide Chairman and member of the Company's Executive Committee. She will have responsibility for the Consumer Group of Com
Read more →JNJSandra E. Peterson wird Group Worldwide Chairman und Mitglied des Exekutivausschusses bei Johnson & Johnson Sandra E. Peterson wird bei Johnson & Johnson (NYSE: JNJ) ab dem 1. Dezember 2012 als Group Worldwide Chairman und Mitglied des Exekutivausschusses...
NEW BRUNSWICK, New Jersey , 13. September 2012 /PRNewswire/ -- Sandra E. Peterson wird bei Johnson & Johnson (NYSE: JNJ ) ab dem 1 . Dezember 2012 als Group Worldwide Chairman und Mitglied des Exekutivausschusses tätig sein. Sie wird für die Verbrauchergruppen der Unternehmen, di
Read more →JNJSandra E. Peterson sur le point de rejoindre Johnson & Johnson en tant que Présidente générale du groupe et membre du Comité de direction Sandra E. Peterson va rejoindre Johnson & Johnson (NYSE : JNJ) le 1er décembre 2012 en tant que Présidente générale du groupe et membre du Comité de...
NEW BRUNSWICK, New Jersey , 13 septembre 2012 /PRNewswire/ -- Sandra E. Peterson va rejoindre Johnson & Johnson (NYSE : JNJ ) le 1er décembre 2012 en tant que Présidente générale du groupe et membre du Comité de direction de la société. Elle aura en charge le Groupe d'entreprises
Read more →JNJSandra E. Peterson se une a Johnson & Johnson como presidenta internacional del grupo y miembro de su comité ejecutivo Sandra E. Peterson formará parte de Johnson & Johnson (NYSE: JNJ) a partir del 1 de diciembre de 2012 como presidenta internacional del grupo y...
NEW BRUNSWICK , Nueva Jersey , 13 de septiembre de 2012 /PRNewswire/ -- Sandra E. Peterson formará parte de Johnson & Johnson (NYSE: JNJ ) a partir del 1 de diciembre de 2012 como presidenta internacional del grupo y miembro del comité ejecutivo de la empresa. Tendrá a su cargo e
Read more →JNJSandra E. Peterson se Juntará à Johnson & Johnson como Presidente Global do Grupo e Membro do Comitê Executivo Sandra E. Peterson se juntará à Johnson & Johnson (NYSE: JNJ) em 1 de dezembro de 2012 como Presidente Global do Grupo e membro do Comitê Executivo...
NEW BRUNSWICK , Nova Jersey , 13 de setembro de 2012 /PRNewswire/ -- Sandra E. Peterson se juntará à Johnson & Johnson (NYSE: JNJ ) em 1 de dezembro de 2012 como Presidente Global do Grupo e membro do Comitê Executivo da Companhia. Ela será responsável pelas Companhias dos Grupos
Read more →JNJJohnson & Johnson Symposium Honors 2012 Recipients of the Dr. Paul Janssen Award for Biomedical Research Johnson & Johnson today honors the winners of the 2012 Dr. Paul Janssen Award for Biomedical Research in a ceremony and scientific symposium at the...
NEW YORK , Sept. 7, 2012 /PRNewswire/ -- Johnson & Johnson today honors the winners of the 2012 Dr. Paul Janssen Award for Biomedical Research in a ceremony and scientific symposium at the New York Academy of Sciences in New York , NY. Victor Ambros , Ph.D., of the University of
Read more →JNJJohnson & Johnson to Participate in Morgan Stanley Global Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley Global Health Care Conference Monday, September 10th, at the Grand Hyatt New...
NEW BRUNSWICK, N.J. , Sept. 5, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Morgan Stanley Global Health Care Conference Monday, September 10 th , at the Grand Hyatt New York, 109 East 42 nd Street at Grand Central, New York , NY. Gary Pru
Read more →JNJJohnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimer's Disease Johnson & Johnson (NYSE: JNJ) today announced that phase 3 clinical development of bapineuzumab intravenous (IV) in mild-to-moderate Alzheimer's...
NEW BRUNSWICK, N.J. , Aug. 6, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) today announced that phase 3 clinical development of bapineuzumab intravenous (IV) in mild-to-moderate Alzheimer's disease is being discontinued. Janssen Alzheimer Immunotherapy (Janssen
Read more →JNJJohnson & Johnson Provides Notice Of Proposed Settlement Of Shareholder Derivative Actions, Final Settlement Hearing, And Right To Appear The following statement is being issued by Johnson & Johnson (NYSE: JNJ): UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY IN RE JOHNSON & JOHNSON ...
NEW BRUNSWICK, N.J. , July 19, 2012 /PRNewswire/ -- The following statement is being issued by Johnson & Johnson (NYSE: JNJ ): UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY SUMMARY NOTICE OF PROPOSED SETTLEMENT OF JOHNSON & JOHNSON SHAREHOLDER DERIVATIVE ACTIONS, FINAL SE
Read more →JNJJohnson & Johnson Reports 2012 Second-Quarter Results: Sales of $16.5 Billion decreased 0.7% Versus 2011 Second Quarter; Second-Quarter EPS was $0.50 Excluding Special Items, 2012 Second-Quarter EPS of $1.30 increased 1.6%* Johnson & Johnson today announced sales of $16.5 billion for the second quarter of 2012, a decrease of 0.7% as compared to the second quarter of 2011....
NEW BRUNSWICK, N.J. , July 17, 2012 /PRNewswire/ -- Johnson & Johnson today announced sales of $16.5 billion for the second quarter of 2012, a decrease of 0.7% as compared to the second quarter of 2011. Operational results increased 3.5% and the negative impact of currency was 4.
Read more →JNJJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2012 Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2012 of $0.61 per...
NEW BRUNSWICK, N.J. , July 16, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2012 of $0.61 per share on the company's common stock. The dividend is payable on September 11, 201
Read more →JNJDr. Victor Ambros and Dr. Gary Ruvkun Win 2012 Dr. Paul Janssen Award for Biomedical Research for Discovery of MicroRNAs Johnson & Johnson today named Dr. Victor Ambros and Dr. Gary Ruvkun the winners of the 2012 Dr. Paul Janssen Award for Biomedical Research during an...
BOSTON , June 19, 2012 /PRNewswire/ -- Johnson & Johnson today named Dr. Victor Ambros and Dr. Gary Ruvkun the winners of the 2012 Dr. Paul Janssen Award for Biomedical Research during an event at the Biotechnology Industry Organization International Convention in Boston . Drs. A
Read more →JNJJohnson & Johnson to Host Analyst Conference Call on Second-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 17th, to review second-quarter...
NEW BRUNSWICK, N.J. , June 18, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 17th , to review second-quarter results. Alex Gorsky , Chief Executive Officer, Dominic Caruso , Vic
Read more →JNJJohnson & Johnson Announces Completion of Synthes Acquisition Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Synthes, Inc. for a total purchase price of $19.7 billion in cash...
NEW BRUNSWICK, N.J. , June 14, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) today announced the completion of the acquisition of Synthes, Inc. for a total purchase price of $19.7 billion in cash and stock. Synthes will now be integrated with the DePuy franchise t
Read more →JNJJohnson & Johnson Receives U.S. Regulatory Clearance for Synthes Acquisition; Closing Date for Transaction Set Johnson & Johnson (NYSE: JNJ) today announced that it has received U.S. regulatory clearance for its proposed acquisition of Synthes, Inc. This...
NEW BRUNSWICK, N.J. , June 12, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that it has received U.S. regulatory clearance for its proposed acquisition of Synthes, Inc. This completes all regulatory approvals required to close the transaction. Johnson & Joh
Read more →JNJJohnson & Johnson Expects to Incur Special Charge in Second Quarter for Previously Disclosed Legal Matters Johnson & Johnson (NYSE: JNJ) today announced it expects to incur a special charge in the second quarter of 2012 of approximately $600 million to...
NEW BRUNSWICK, N.J. , June 8, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) today announced it expects to incur a special charge in the second quarter of 2012 of approximately $600 million to increase its accrual for the potential settlement of previously disclose
Read more →JNJJanssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes Janssen and Johnson & Johnson (NYSE: JNJ) will provide investors and other interested parties an overview presentation of results from five pivotal...
NEW BRUNSWICK, N.J. , June 5, 2012 /PRNewswire/ -- Janssen and Johnson & Johnson (NYSE: JNJ ) will provide investors and other interested parties an overview presentation of results from five pivotal Phase 3 studies evaluating investigational canagliflozin for the treatment of Ty
Read more →JNJJanssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA® (abiraterone acetate) Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, June 2 at approximately...
NEW BRUNSWICK, N.J. , May 25, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, June 2 at approximately 10:00 a.m., Eastern Time , to coincide with the American Society of Clinical Oncol
Read more →JNJJohnson & Johnson to Participate in 2012 Deutsche Bank Securities, Inc. 37th Annual Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2012 Deutsche Bank Securities, Inc. 37th Annual Health Care Conference on Wednesday, May 9, at...
NEW BRUNSWICK, N.J. , May 2, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2012 Deutsche Bank Securities, Inc. 37th Annual Health Care Conference on Wednesday, May 9 , at The InterContinental Boston in Boston , MA. Dominic Caruso , Vice President, Fi
Read more →JNJJohnson & Johnson Holds 2012 Annual Meeting of Shareholders After 10 years presiding over Johnson & Johnson (NYSE: JNJ) during a period of extraordinary change in the health care industry, Chairman and Chief...
NEW BRUNSWICK, N.J. , April 26, 2012 /PRNewswire/ -- After 10 years presiding over Johnson & Johnson (NYSE: JNJ ) during a period of extraordinary change in the health care industry, Chairman and Chief Executive Officer Bill Weldon officially transferred responsibilities for runn
Read more →JNJJohnson & Johnson Announces Dividend Increase of 7.0% Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 7.0% increase in the quarterly dividend rate, from $0.57 per ...
NEW BRUNSWICK, N.J. , April 26, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a 7.0% increase in the quarterly dividend rate, from $0.57 per share to $0.61 per share. The increase was announced this morning at the Ann
Read more →JNJJohnson & Johnson to Webcast Annual Meeting of Shareholders Johnson & Johnson (NYSE: JNJ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 26, 2012, from the Hyatt...
NEW BRUNSWICK, N.J. , April 19, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 26, 2012 , from the Hyatt Regency Hotel in New Brunswick, N.J. Investors and other intereste
Read more →JNJJohnson & Johnson Reports 2012 First-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $16.1 billion for the first quarter of 2012, a decrease of 0.2% as compared to the first...
NEW BRUNSWICK, N.J. , April 17, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $16.1 billion for the first quarter of 2012, a decrease of 0.2% as compared to the first quarter of 2011. Operational results increased 1.0% and the negative imp
Read more →JNJJohnson & Johnson to Host Analyst Conference Call on First-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, April 17th, to review...
NEW BRUNSWICK, N.J. , April 10, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, April 17th , to review first-quarter results. Dominic Caruso , Vice President, Finance and Chief Financia
Read more →JNJJohnson & Johnson Announces Resignation of Sheri S. McCoy Johnson & Johnson (NYSE: JNJ) said today that Sheri S. McCoy, Vice Chairman of the Executive Committee, has resigned from the Company effective April ...
NEW BRUNSWICK, N.J. , April 9, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) said today that Sheri S. McCoy , Vice Chairman of the Executive Committee, has resigned from the Company effective April 18 to join another publicly traded company as CEO. Ms. McCoy joined Johnson
Read more →JNJJohnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiology's Annual Scientific Sessions Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Monday, March 26th at approximately...
NEW BRUNSWICK, N.J. , March 19, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will provide a pre-recorded webcast for investors and other interested parties on Monday, March 26th at approximately 10:30 a.m., Eastern Time , to coincide with the American College of Cardiology
Read more →JNJJohnson & Johnson to Participate in Cowen and Company 32nd Annual Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the Cowen and Company 32nd Annual Health Care Conference on Tuesday, Mar. 6, at The Boston Marriott ...
NEW BRUNSWICK, N.J. , Feb. 28, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Cowen and Company 32nd Annual Health Care Conference on Tuesday, Mar. 6 , at The Boston Marriott Copley Place. Dominic Caruso , Vice President, Finance & Chief Financial Off
Read more →JNJAlex Gorsky to Succeed Bill Weldon as CEO of Johnson & Johnson Johnson & Johnson today announced that its Board of Directors has named Alex Gorsky Chief Executive Officer (CEO) of Johnson & Johnson effective...
NEW BRUNSWICK, N.J. , Feb. 21, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson today announced that its Board of Directors has named Alex Gorsky Chief Executive Officer (CEO) of Johnson & Johnson effective April 26, 2012 , the date of the Company's Annual Meeting of Shareholders
Read more →JNJJohnson & Johnson to Participate in 2012 Leerink Swann Global Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2012 Leerink Swann Global Health Care Conference on Thursday, Feb. 16, at The Waldorf Astoria...
NEW BRUNSWICK, N.J. , Feb. 9, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2012 Leerink Swann Global Health Care Conference on Thursday, Feb. 16 , at The Waldorf Astoria in New York , N.Y. Sheri McCoy , Vice Chairman of the Executive Committee, will
Read more →JNJJohnson & Johnson Joins Public and Private Partners in the Largest Coordinated Action to Date to Eliminate or Control Neglected Tropical Diseases Today Johnson & Johnson joined the World Health Organization (WHO), 12 other pharmaceutical companies, the Bill & Melinda Gates Foundation, the U.S....
LONDON , Jan. 30 2012 /PRNewswire/ -- Today Johnson & Johnson joined the World Health Organization (WHO), 12 other pharmaceutical companies, the Bill & Melinda Gates Foundation, the U.S. and U.K. governments, the World Bank, and officials from endemic countries in a new, coordina
Read more →JNJJohnson & Johnson Reports 2011 Fourth-Quarter and Full-Year Results: Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of...
NEW BRUNSWICK, N.J. , Jan. 24, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of curren
Read more →JNJJohnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter and Full-Year 2011 Financial Results Johnson & Johnson (NYSE: JNJ) will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 24, to discuss fourth-quarter and full-year...
NEW BRUNSWICK, N.J. , Jan. 17, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 24 , to discuss fourth-quarter and full-year 2011 financial results. The meeting will be hosted by William C. Wel
Read more →JNJJohnson & Johnson Announces First-Quarter 2012 Quarterly Dividend Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first-quarter of 2012 of $0.57 per...
NEW BRUNSWICK, N.J. , Jan. 3, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the first-quarter of 2012 of $0.57 per share on the company's common stock. The dividend is payable on March 13, 2012 , t
Read more →JNJDr. Paul Janssen Award for Biomedical Research Issues Call for Nominations The Dr. Paul Janssen Award for Biomedical Research today opens its 2012 call for nominations. This prestigious award recognizes individuals whose...
NEW BRUNSWICK, N.J. , Dec. 9, 2011 /PRNewswire/ -- The Dr. Paul Janssen Award for Biomedical Research today opens its 2012 call for nominations. This prestigious award recognizes individuals whose scientific research has made, or has the potential to make, significant transformat
Read more →JNJJohnson & Johnson to Participate in the Piper Jaffray 23rd Annual Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the Piper Jaffray 23rd Annual Health Care Conference on Tuesday, Nov. 29th at The New York Palace,...
NEW BRUNSWICK, N.J. , Nov. 28, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Piper Jaffray 23 rd Annual Health Care Conference on Tuesday, Nov. 29 th at The New York Palace, New York , NY. Gary Pruden , Company Group Chairman, Ethicon will
Read more →JNJLandmark Study Shows that Adding Rivaroxaban to Standard Antiplatelet Therapy Significantly Reduced Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that adding oral rivaroxaban to standard antiplatelet therapy...
ORLANDO, Fla. , Nov. 13, 2011 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that adding oral rivaroxaban to standard antiplatelet therapy significantly reduced the composite primary efficacy endpoint of cardiovascular-related deat
Read more →JNJJohnson & Johnson Reports 2011 Third-Quarter Results Johnson & Johnson (NYSE: JNJ) today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third...
NEW BRUNSWICK, N.J. , Oct. 18, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive imp
Read more →JNJJohnson & Johnson to Host Analyst Conference Call on Third-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, October 18, 2011, to review...
NEW BRUNSWICK, N.J. , Oct. 11, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, October 18, 2011 , to review third-quarter results. Dominic Caruso, Vice President, Finance and
Read more →JNJJohnson & Johnson Makes Strong Progress in First Year of Initiative to Improve Health of Millions of Women and Children in the Developing World Johnson & Johnson (NYSE: JNJ) today announced important progress made in the inaugural year of the Company's comprehensive effort designed to improve ...
NEW BRUNSWICK, N.J. , Sept. 20, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced important progress made in the inaugural year of the Company's comprehensive effort designed to improve the health of as many as 120 million women and children each year in develop
Read more →JNJJohnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research Napoleone Ferrara, M.D., will receive the Johnson & Johnson Dr. Paul Janssen Award for Biomedical Research, including a $100,000 prize, this week...
NEW YORK , Sept. 14, 2011 /PRNewswire/ -- Napoleone Ferrara , M.D., will receive the Johnson & Johnson Dr. Paul Janssen Award for Biomedical Research, including a $100,000 prize, this week during a series of events that celebrate his central role in the discovery of vascular endo
Read more →JNJJohnson & Johnson to Participate in Morgan Stanley Global Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley Global Health Care Conference Tuesday, September 13th, at the Grand Hyatt New...
NEW BRUNSWICK, N.J. , Sept. 6, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Morgan Stanley Global Health Care Conference Tuesday, September 13 th , at the Grand Hyatt New York, 109 East 42 nd Street at Grand Central, New York, NY . Dominic Caruso, V
Read more →JNJThe Amazing Nurses Contest: Celebrating America's Caregivers The Johnson & Johnson Campaign for Nursing's Future, as part of its ongoing campaign to support nurses and nursing education, is honored to sponsor...
NEW BRUNSWICK, N.J. , July 26, 2011 /PRNewswire/ -- The Johnson & Johnson Campaign for Nursing's Future, as part of its ongoing campaign to support nurses and nursing education, is honored to sponsor the "Amazing Nurses" national contest to celebrate and reward the important role
Read more →JNJJohnson & Johnson Reports 2011 Second-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $16.6 billion for the second quarter of 2011, an increase of 8.3% as compared to the second...
NEW BRUNSWICK, N.J. , July 19, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $16.6 billion for the second quarter of 2011, an increase of 8.3% as compared to the second quarter of 2010. Operational results increased 2.6% and the positive i
Read more →JNJJohnson & Johnson Announces Third-Quarter 2011 Quarterly Dividend Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2011 of $0.57 per...
NEW BRUNSWICK, N.J. , July 18, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2011 of $0.57 per share on the company's common stock. The dividend is payable on Sept. 13, 2011 ,
Read more →JNJJohnson & Johnson Launches Healthy Future 2015, Its Citizenship and Sustainability Goals As 2011 marks the 125th year of Johnson & Johnson (NYSE: JNJ), today the company announced the launch of Healthy Future 2015, a five-year strategic...
NEW BRUNSWICK, N.J. , July 14, 2011 /PRNewswire-FirstCall/ -- As 2011 marks the 125th year of Johnson & Johnson (NYSE: JNJ ), today the company announced the launch of Healthy Future 2015 , a five-year strategic roadmap for its citizenship and sustainability priorities. Healthy F
Read more →JNJJohnson & Johnson to Host Analyst Conference Call on Second-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, July 19, 2011, to review...
NEW BRUNSWICK, N.J. , July 12, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, July 19, 2011 , to review second-quarter results. Dominic Caruso, Vice President, Finance and Ch
Read more →JNJJohnson & Johnson Announces Global Sponsorship of the 2014 FIFA World Cup Brazil™ Johnson & Johnson (NYSE: JNJ) today announced that the company has entered into an agreement to become a global sponsor of the 2014 FIFA World Cup...
SAO PAULO and NEW BRUNSWICK, N.J. , July 7, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that the company has entered into an agreement to become a global sponsor of the 2014 FIFA World Cup Brazil™, becoming the eighth and final FIFA World Cup™ Sponsor. Wi
Read more →JNJDr. Napoleone Ferrara Wins 2011 Dr. Paul Janssen Award for Biomedical Research Johnson & Johnson today announced the winner of the 2011 Dr. Paul Janssen Award for Biomedical Research during the BIO International Convention (BIO) ...
WASHINGTON , June 28, 2011 /PRNewswire/ -- Johnson & Johnson today announced the winner of the 2011 Dr. Paul Janssen Award for Biomedical Research during the BIO International Convention (BIO) in Washington D.C. Napoleone Ferrara, M.D., is the seventh leading scientist to win the
Read more →JNJJohnson & Johnson Announces Special Charge Related to Restructuring Plans for Cordis Corporation Subsidiary Johnson & Johnson (NYSE: JNJ) today announced that it expects to record an after-tax restructuring charge in the range of $500-$600 million in the...
NEW BRUNSWICK, N.J. , June 15, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) today announced that it expects to record an after-tax restructuring charge in the range of $500-$600 million in the second quarter of 2011 as a result of restructuring plans announced by
Read more →JNJFormer Chairman and CEO of Aetna Inc., Ronald Williams, Appointed to Johnson & Johnson Board of Directors Ronald A. Williams, former chairman and chief executive officer (CEO) of Aetna Inc., has been appointed to the Board of Directors of Johnson &...
NEW BRUNSWICK, N.J. , June 14, 2011 /PRNewswire/ -- Ronald A. Williams , former chairman and chief executive officer (CEO) of Aetna Inc., has been appointed to the Board of Directors of Johnson & Johnson (NYSE: JNJ ), the world's most comprehensive and broadly based health care p
Read more →JNJJohnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches Johnson & Johnson (NYSE: JNJ) will review growth strategies for its Pharmaceuticals business at a meeting with the investment community today. Senior ...
NEW BRUNSWICK, N.J. , May 26, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will review growth strategies for its Pharmaceuticals business at a meeting with the investment community today. Senior leaders from the company's executive committee and pharmaceuticals s
Read more →JNJJohnson & Johnson to Host Pharmaceuticals Business Review Johnson & Johnson (NYSE: JNJ) will host a review of its Pharmaceuticals business for the investment community beginning at 9:00 a.m. (Eastern Time)...
NEW BRUNSWICK, N.J. , May 19, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host a review of its Pharmaceuticals business for the investment community beginning at 9:00 a.m. (Eastern Time) on Thursday, May 26, 2011 at The Heldrich Hotel, in New Brunswick, N.J. ending a
Read more →JNJJohnson & Johnson to Participate in Bank of America Merrill Lynch 2011 Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the Bank of America Merrill Lynch 2011 Health Care Conference on Tuesday, May 10th, at the Encore...
NEW BRUNSWICK, N.J. , May 4, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Bank of America Merrill Lynch 2011 Health Care Conference on Tuesday, May 10th , at the Encore at Wynn, 3121 Las Vegas Blvd. South. Las Vegas, NV. Alex Gorsky, Vice Chairman E
Read more →JNJJohnson & Johnson Holds 2011 Annual Meeting of Shareholders At Johnson & Johnson's Annual Meeting of Shareholders today, Chairman and CEO Bill Weldon provided an in-depth look at the steps being taken to...
NEW BRUNSWICK, N.J. , April 28, 2011 /PRNewswire-FirstCall/ -- At Johnson & Johnson's Annual Meeting of Shareholders today, Chairman and CEO Bill Weldon provided an in-depth look at the steps being taken to address recent quality issues, to restore confidence and trust in the com
Read more →JNJJohnson & Johnson Announces Dividend Increase of 5.6% Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 5.6% increase in the quarterly dividend rate, from $0.54 per ...
NEW BRUNSWICK, N.J. , April 28, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced that its Board of Directors has declared a 5.6% increase in the quarterly dividend rate, from $0.54 per share to $0.57 per share. The increase was announced this morning at the Ann
Read more →JNJJohnson & Johnson and Synthes Announce Definitive Merger Agreement to Create World's Most Innovative and Comprehensive Orthopaedics Business Johnson & Johnson (NYSE: JNJ), the world's most comprehensive and broadly-based manufacturer of health care products, and Synthes, Inc....
NEW BRUNSWICK, N.J. and WEST CHESTER, Pa. , April 27, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ), the world's most comprehensive and broadly-based manufacturer of health care products, and Synthes, Inc. (SWX:SYST.VX), a premier global manufacturer of orthopaedic devices,
Read more →JNJJohnson & Johnson to Participate in Deutsche Bank 36th Annual Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the Deutsche Bank 36th Annual Health Care Conference on Tuesday, May 3rd, at the InterContinental...
NEW BRUNSWICK, N.J. , April 26, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Deutsche Bank 36th Annual Health Care Conference on Tuesday, May 3rd , at the InterContinental Boston hotel in Boston, MA. Dominic Caruso, Vice President, Finance
Read more →JNJJohnson & Johnson to Webcast Annual Meeting of Shareholders Johnson & Johnson (NYSE: JNJ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 28, 2011, from the Hyatt...
NEW BRUNSWICK, N.J. , April 20, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 28, 2011 , from the Hyatt Regency Hotel in New Brunswick, N.J. Investors and other intereste
Read more →JNJJohnson & Johnson Reports 2011 First-Quarter Results Johnson & Johnson (NYSE: JNJ) today announced sales of $16.2 billion for the first quarter of 2011, an increase of 3.5% as compared to the first...
NEW BRUNSWICK, N.J. , April 19, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $16.2 billion for the first quarter of 2011, an increase of 3.5% as compared to the first quarter of 2010. Operational results increased 1.8% and the positive im
Read more →JNJJohnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck Johnson & Johnson (NYSE: JNJ) provided additional information today on its amended agreement with Merck regarding distribution rights for REMICADE®...
NEW BRUNSWICK, N.J. , April 15, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) provided additional information today on its amended agreement with Merck regarding distribution rights for REMICADE® (infliximab) and SIMPONI® (golimumab) in markets outside the United States . T
Read more →JNJJohnson & Johnson to Host Analyst Conference Call on First-Quarter Results Johnson & Johnson (NYSE: JNJ) will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, April 19, 2011, to review...
NEW BRUNSWICK, N.J. , April 12, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, April 19, 2011 , to review first-quarter results. Dominic Caruso, Vice President, Finance and C
Read more →JNJJohnson & Johnson Announces Settlement With U.S. Department of Justice and U.S. Securities and Exchange Commission Johnson & Johnson (NYSE: JNJ) announced today it will pay $70,006,316 in fines, disgorgement and interest, an amount previously reserved for, in a...
NEW BRUNSWICK, N.J. , April 8, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) announced today it will pay $70,006,316 in fines, disgorgement and interest, an amount previously reserved for, in a settlement related to publicly disclosed Foreign Corrupt Practices Act
Read more →JNJJohnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that following the end of the...
NEW BRUNSWICK, N.J. , and LEIDEN, Netherlands , March 8, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) today announced that following the end of the subsequent offering period ( na-aanmeldingstermijn, Subs
Read more →JNJJohnson & Johnson to Participate in 2011 RBC Capital Markets' Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2011 RBC Capital Markets' Health Care Conference on Wednesday, March 2, at the New York Palace...
NEW BRUNSWICK, N.J. , Feb. 23, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2011 RBC Capital Markets' Health Care Conference on Wednesday, March 2 , at the New York Palace Hotel in New York, N.Y. Michael Mahoney, Worldwide Chairman, Medical Devices
Read more →JNJJohnson & Johnson to Participate in 2011 Citi Global Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the 2011 Citi Global Health Care Conference on Tuesday, March 1, at the Hilton New York Hotel in...
NEW BRUNSWICK, N.J. , Feb. 22, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the 2011 Citi Global Health Care Conference on Tuesday, March 1 , at the Hilton New York Hotel in New York, N.Y. Joaquin Duato, Worldwide Chairman, Pharmaceuticals, will represe
Read more →JNJJohnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announce that Johnson & Johnson has completed ...
NEW BRUNSWICK, N.J. and LEIDEN, Netherlands , Feb. 22, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) today announce that Johnson & Johnson has completed the tender offer for Crucell N.V. (Crucell) and has
Read more →JNJMinimum Acceptance Condition Satisfied Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that the minimum acceptance...
NEW BRUNSWICK, N.J. , and LEIDEN, Netherlands , Feb. 17, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) today announced that the minimum acceptance condition of Johnson & Johnson's Offer to acquire Crucell
Read more →JNJJohnson & Johnson Receives Approval from European Commission Johnson & Johnson and Crucell today announced that the European Commission has granted approval for Johnson & Johnson's proposed acquisition of...
NEW BRUNSWICK, N.J. and LEIDEN, Netherlands , Jan. 28, 2011 /PRNewswire/ -- Johnson & Johnson and Crucell today announced that the European Commission has granted approval for Johnson & Johnson's proposed acquisition of Crucell. Reference is made to the joint press release of Jo
Read more →JNJJohnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results Johnson & Johnson (NYSE: JNJ) today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth...
NEW BRUNSWICK, N.J. , Jan. 25, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impac
Read more →JNJJohnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter and Full-Year 2010 Financial Results Johnson & Johnson (NYSE: JNJ) will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 25, to discuss fourth-quarter and full-year...
NEW BRUNSWICK, N.J. , Jan. 18, 2011 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 25 , to discuss fourth-quarter and full-year 2010 financial results. The meeting will be hosted by William C. Weldon , Chai
Read more →JNJJohnson & Johnson Provides Update on McNeil Consumer Healthcare Remediation; Announces Completion of Internal Assessment Phase of Comprehensive Action Plan McNeil Consumer Healthcare Division of McNeil-PPC, Inc., a Johnson & Johnson (NYSE: JNJ) company, in July 2010 submitted to the FDA a Comprehensive...
NEW BRUNSWICK, N.J. , Jan. 14, 2011 /PRNewswire/ -- McNeil Consumer Healthcare Division of McNeil-PPC, Inc., a Johnson & Johnson (NYSE: JNJ ) company, in July 2010 submitted to the FDA a Comprehensive Action Plan on quality improvement, and made a commitment to restore its operat
Read more →JNJJohnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee Johnson & Johnson (NYSE: JNJ) today announced that Alex Gorsky, currently Worldwide Chairman, Medical Devices & Diagnostics (MD&D) and Sheri McCoy,...
NEW BRUNSWICK, N.J. , Dec. 15, 2010 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) today announced that Alex Gorsky , currently Worldwide Chairman, Medical Devices & Diagnostics (MD&D) and Sheri McCoy , currently Worldwide Chairman, Pharmaceuticals, have been appointed
Read more →JNJDr. Paul Janssen Award for Biomedical Research Issues Call for Nominations The Dr. Paul Janssen Award for Biomedical Research today opens its 2011 call for nominations. This prestigious award recognizes individuals whose...
NEW BRUNSWICK, N.J. , Dec. 14, 2010 /PRNewswire/ -- The Dr. Paul Janssen Award for Biomedical Research today opens its 2011 call for nominations. This prestigious award recognizes individuals whose scientific research has made, or has the potential to make, significant transforma
Read more →JNJJohnson & Johnson Launches Recommended Public Offer to Acquire Crucell Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that Johnson & Johnson, through its ...
NEW BRUNSWICK, N.J. and LEIDEN, Netherlands , Dec. 8, 2010 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) today announced that Johnson & Johnson, through its newly formed indirect wholly owned subsidia
Read more →JNJJohnson & Johnson and Crucell Progress Update: Expect to Commence Public Offer Prior to 10 December 2010 Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) provide the following joint update on the...
NEW BRUNSWICK, N.J. and LEIDEN, the Netherlands , Nov. 30, 2010 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) provide the following joint update on the preparations for the intended public offer by JJ
Read more →JNJJohnson & Johnson to Participate in the Piper Jaffray 22nd Annual Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the Piper Jaffray 22nd Annual Health Care Conference on Wednesday, Dec. 1st at The New York Palace, ...
NEW BRUNSWICK, N.J. , Nov. 24, 2010 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Piper Jaffray 22nd Annual Health Care Conference on Wednesday, Dec. 1st at The New York Palace, New York, NY . Michael Mahoney, Company Group Chairman for the DePu
Read more →JNJJohnson & Johnson to Participate in Credit Suisse 19th Annual Health Care Conference Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 19th Annual Health Care Conference on Thursday, Nov. 11, at the Arizona Biltmore...
NEW BRUNSWICK, N.J. , Nov. 4, 2010 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Credit Suisse 19th Annual Health Care Conference on Thursday, Nov. 11 , at the Arizona Biltmore Hotel. Alex Gorsky, Worldwide Chairman of the Medical Devices & Diag
Read more →JNJJohnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer Pursuant to the provisions of Section 7 paragraph 1(a) of the Dutch Decree on Public Takeover Bids (Besluit Openbare Biedingen Wft) requiring a...
NEW BRUNSWICK, N.J. and LEIDEN, Netherlands , Oct. 29 /PRNewswire-FirstCall/ -- Pursuant to the provisions of Section 7 paragraph 1(a) of the Dutch Decree on Public Takeover Bids (Besluit Openbare Biedingen Wft) requiring a public announcement within four weeks following the anno
Read more →JNJJohnson & Johnson Reports 2010 Third-Quarter Results: Johnson & Johnson (NYSE: JNJ) today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third...
NEW BRUNSWICK, N.J. , Oct. 19 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of
Read more →JNJJohnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Pharmaceutical Business Johnson & Johnson (NYSE: JNJ) will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Oct. 19, 2010, to discuss third-quarter financial...
NEW BRUNSWICK, N.J. , Oct. 11 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Oct. 19, 2010 , to discuss third-quarter financial results and review its Pharmaceutical business. The meeting will be hoste
Read more →JNJJohnson & Johnson and Crucell Reach Agreement on Intended Public Offer of Euro 24.75 per Ordinary Share of Crucell Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced an agreement whereby Johnson &...
NEW BRUNSWICK, N.J. and LEIDEN, Netherlands , Oct. 6 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) today announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outst
Read more →JNJJohnson & Johnson Completes Acquisition of Micrus Endovascular Johnson & Johnson (NYSE: JNJ) today announced that it has completed the acquisition of Micrus Endovascular, a global developer and manufacturer of...
NEW BRUNSWICK, N.J. , Sept. 27 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) today announced that it has completed the acquisition of Micrus Endovascular, a global developer and manufacturer of minimally invasive devices for hemorrhagic and ischemic stroke. Johnson & J
Read more →JNJJohnson & Johnson and Crucell In Advanced Negotiations for an All Cash Public Offer of Euro 24.75 Per Ordinary Share of Crucell Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that they are in advanced...
NEW BRUNSWICK, N.J. and LEIDEN, Netherlands , Sept. 17 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) today announced that they are in advanced negotiations for a potential public offer by Johnson & Jo
Read more →JNJColleen Goggins, Worldwide Chairman, Consumer Group Plans Retirement From Johnson & Johnson in Early 2011 Johnson & Johnson (NYSE: JNJ) said today that Colleen Goggins, 56, Worldwide Chairman, Consumer Group, has announced her retirement from the Company...
NEW BRUNSWICK, N.J. , Sept. 16 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) said today that Colleen Goggins , 56, Worldwide Chairman, Consumer Group, has announced her retirement from the Company effective March 1, 2011 , after a successful and distinguished career sp
Read more →JNJJohnson & Johnson Aims to Help Up to 120 Million Women and Children Each Year Through Five-Year Commitment to U.N. Millennium Development Goals Johnson & Johnson today announced the launch of Every Mother, Every Child, a comprehensive, five-year, private-sector effort to improve the health of ...
NEW BRUNSWICK, N.J. , Sept. 8 /PRNewswire/ -- Johnson & Johnson today announced the launch of Every Mother, Every Child , a comprehensive, five-year, private-sector effort to improve the health of women and children in developing countries. The initiative supports the United Nati
Read more →JNJJohnson & Johnson of Charleston Named One of the 50 Best Employers to Work for in America Johnson & Johnson (J&J), a locally owned Wholesale Insurance Agent, has been recognized as the 8th Best Small Company to Work for in America by Great ...
CHARLESTON, S.C. , Sept. 8 /PRNewswire/ -- Johnson & Johnson (J&J), a locally owned Wholesale Insurance Agent, has been recognized as the 8th Best Small Company to Work for in America by Great Place to Work Institute, Inc. (GPTW) for the 2nd year in a row. GPTW have revealed the
Read more →JNJDrs. Erik De Clercq and Anthony S. Fauci Win 2010 Dr. Paul Janssen Award for Biomedical Research Johnson & Johnson today announced that Erik De Clercq, M.D., Professor Emeritus, Rega Institute for Medical Research, Leuven, Belgium, and Anthony S. ...
WASHINGTON , Sept. 8 /PRNewswire/ -- Johnson & Johnson today announced that Erik De Clercq , M.D., Professor Emeritus, Rega Institute for Medical Research, Leuven, Belgium , and Anthony S. Fauci , M.D., Director of the National Institute of Allergy and Infectious Diseases, the Na
Read more →Competitive Position
How JNJ ranks across every disease it competes inCompetitive Position is a premium feature
See how JNJ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial